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Psoriasis is een chronische huidziekte, waaraan  
ongeveer 350.000 mensen in Nederland lijden.  
Hoewel psoriasis geen levensbedreigende ziekte is, 
heeft de ziekte wel een grote impact op de kwaliteit 
van leven van patiënten. 
Patiënten worden elke dag met hun ziekte  
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de immunopathogenese en het identificeren van 
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groep van psoriasis patiënten zal uiteindelijk  
leiden tot betere behandelingen voor de patiënt. 
Dit proefschrift richt zich op verschillende  
facetten van psoriasis waaronder:
• de invloed van het zenuwstelsel  
en neuropeptides
• het werkingsmechanisme van fumaarzuur
• de werking van de biologic ustekinumab  
en het identificeren van responders en  
non-responders op ustekinumab op basis  
van cytokine profielen en
• het anti-inflammatoire mechanisme  
van interleukine-4 bij psoriasis
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GENERAL INTRODUCTION
Although psoriasis is not a life-threatening disease, it does have a large impact on the 
life of patients. Patients are confronted with their disease every day and unfamiliar-
ity and the mistaken fear for contagiousness in the general population makes it even 
harder to cope with this disease. Research is important to better dene the character-
istics and immunopathogenesis of psoriasis because this leads to improved and new 
treatments. Due to improved treatment, coping with psoriasis will become somewhat 
easier. Despite extensive research and great advances in our knowledge of the patho-
genesis of psoriasis over the years, the exact cause is still unknown. Whether psoriasis 
is an autoimmune disease, an autoinammatory disease, a neurogenic inammatory 
disease or is triggered by environmental factors in genetically predisposed individuals: 
the answer will likely cover all these possibilities, as evidence for each of the possibili-
ties is available. The current concept is that psoriasis is a multifactorial disease in which 
genetic, (neuro)immunological and environmental factors interact and cause a vicious 
cycle of inammation that is insuciently controlled by regulatory systems. The aim of 
this thesis was to further elucidate the molecular pathways that take part in this vicious 
cycle of inammation by intervening clinically and experimentally in psoriasis. In this 
introduction an overview of the historical and current view on psoriasis is summarized 
including an overview of the usually underexposed role of neuroimmunological factors. 
In addition, current treatment modalities and their molecular targets are discussed.
Clinical presentations of psoriasis
Psoriasis is a common chronic inammatory skin disease with a prevalence of 2 to 3% 
in the Western population (1, 2). The incidence shows two peaks, one between 15 and 
30 years of age and another peak between 50 to 60 years (3). There are several phe-
notypes of psoriasis, including plaque, guttate, inverse, arthropathic, pustular, annular, 
erythroderm, verrucous and rupoides psoriasis. The most common form (90%) and most 
investigated phenotype is plaque type psoriasis or psoriasis vulgaris. Psoriasis vulgaris 
patients suer from red indurated lesions, covered with silvery scales. Lesions are classi-
cally located on the elbows and the knees, but can also cover the whole body (Figure 1). 
When removing the scales, small bleeding spots may become visible, called the Auspitz 
sign. Psoriatic skin lesions can cause itch, however there is a large variety between 
individual patients (4, 5). Nail disease is common presenting as nail pitting, onycholysis, 
subungual hyperkeratosis and discoloration of the nails. Eventually, 6-42% of patients 
eventually will develop psoriatic arthritis (6). The quality of life of patients with psoriasis 
is strongly reduced and comparable with the quality of life experienced by patients with 
diabetes, coronary artery disease or cancer (7) and patients may suer from depressive 
symptoms and suicidal ideation (8). Unexpectedly, the quality of life of psoriasis patients 
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is not dependent on the extent of the disease or PASI score nor the anatomical location 
of the skin lesions (9, 10). However, in clinical dermatology practice and in clinical trials, 
treatment outcome and success of treatment is mainly based on the clearing of the le-
sions. It is very important in clinical (trial) practice not to only evaluate the skin, but also 
the patient as a whole, including quality of life. As patients cope with the disease for 
years, many quality adjusted life years are lost. In addition there are large economic con-
sequences because of the high cost of care. In the United States the direct costs of 1.4 
million individuals with clinically signicant disease are estimated at 650 million dollars, 
this includes hospitalizations, visits to the outpatient clinic, drugs and photo chemo-
therapy costs (11). In addition there is a large economic consequence because patients 
often miss working days or are even unemployed because of their psoriasis. Patients 
with severe psoriasis have almost twofold higher odds to be unemployed compared to 
patients with mild psoriasis (12). The burden of psoriasis reaches further than the skin, 
nails, joints and a reduced quality of life. Comorbidities including cardiovascular disease 
are very common in psoriatic patients. In addition, psoriasis is an independent risk factor 
for diabetes, metabolic syndrome, Crohn’s disease, colitis ulcerosa, celiac disease and 
non-alcoholic fatty liver disease (13-18). Considering the comorbidities associated with 
psoriasis, patients will likely benet from early detection and treatment which may limit 
and prevent future complications (19, 20).
Figure 1. Clinical presentation of psoriasis.
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Psoriatic lesion structure
Clinical thickening of the psoriatic skin is at the microscopic level characterized by 
hyperkeratosis and parakeratosis caused by the premature keratinocyte maturation 
(Figure 2). The granular layer is minimal in size or even absent, and the epidermis shows 
acanthosis with elongation of the rete ridges. In the epidermis collections of neutrophils 
can be seen, called Munro abscesses. Migration of cytotoxic CD8+ T cells into the epi-
dermis is typical for psoriatic lesions. These cells are positive for cutaneous lymphocyte-
associated antigen (CLA), a marker for skin homing T cells (3). High in the dermis there is 
an accumulation of elongated, tortuous small blood vessels. In the dermis the inamma-
tory inltrate consists of CLA+ CD4+ T cells and neutrophilic granulocytes. In addition, 
dendritic cells (DC) are present in the inammatory inltrate. In the dermis these are 
mainly factor XIIIa-positive DC and plasmacytoid DC. In the epidermis Langerhans cells 
(LC) are present that upon antigenic stimulation migrate to the lymph nodes for antigen 
presentation to T cells (21). The number and the morphology of LC in uninvolved psori-
atic skin does not seem to dier from healthy controls, but LC migration upon cytokine 
stimulation is impaired in uninvolved psoriatic skin (22). The inuence of this impaired 
LC mobilization might be important in psoriasis pathogenesis.
Views on psoriasis pathogenesis over time
Infectious cause
The Greek physician Galen (about 200-133 before Christ) was the rst to use the term 
‘psoriasis’ (‘psora’ meaning itch in Greek) (23) and it was Willan who described psoriasis 
as we know the disease today (Willan R. On cutaneous diseases Vol. I. J. London: Johnson, 
Figure 2. Histopathology of psoriasis. 1) hyperkeratosis and parakeratosis 2) acanthosis 3) elongation of 
rete ridges 4) elongated tortuous blood vessels 5) leucocyte inltrate.
14 CHAPTER 1
1808). In 1841 the Austrian dermatologist Hebra described the dierence between pso-
riasis and lepra and thus identied psoriasis as a separate disease. In the 1920’s the cause 
of psoriasis was assumed to be an unknown infectious organism (24). In addition, it was 
believed that an antigen was the cause of psoriasis, however until now no self-antigens 
have been unequivocally identied. Recently, Lande et al showed that two-thirds of the 
patients with moderate-to-severe psoriasis have T cells specic for LL-37, also known 
as cathelicidin. LL-37 is an antimicrobial peptide that is overexpressed in psoriatic skin, 
that can form complexes with self-DNA and self-RNA that activate plasmacytoid DC 
to produce IFN-α which activates dermal DC. The frequency of LL-37 specic T helper 
cells correlates with disease activity. These ndings suggest a contribution of LL-37 to 
psoriasis disease pathogenesis as a bona de autoantigen (25).
Disease of the epidermis
After the 1920’s, psoriasis was regarded to be a disease of abnormal keratinocyte pro-
liferation. In the 1960’s more attention was directed to a possible immunological cause 
of the disease (26, 27). Aswaq et al. showed in guinea pigs that intradermal injection 
with serum of psoriatic patients leads to skin inammation in contrast to injection with 
control serum (26).
T cell mediated disease
In the 1970’s the benecial eect of cyclosporine, a broad immune suppressant that 
inhibits calcineurin-NFAT signaling and that inhibits T cell proliferation, in psoriasis 
was demonstrated in a randomized controlled trial. This pointed towards an immune-
mediated mechanism involving the T lymphocytes (28). In the 1990’s it was shown that 
T cells in psoriatic plaques consisted of CD4 (74%), CD8 (25%) and CD4-/CD8- (1%) cells 
and that these T cells produced mainly IFN-γ belonging to the Th1 subset (29). Psoriasis 
was hence regarded as a T cell mediated disease in which the Th1/Th2 balance was 
disturbed favouring a Th1 phenotype in contrast to atopic dermatitis, which was con-
sidered a Th2 mediated disease. T cells in psoriatic skin are mostly found in the dermis, 
but characteristically CLA+ CD8+ T cells are found in the epidermis. The migration of T 
cells from the dermis into the epidermis is a key event in psoriasis. It is controlled by the 
interaction of α1β1 integrin (also known as very late antigen 1, VLA-1) on T cells with 
collagen IV in the basement membrane of the psoriatic epidermis. Blocking this inter-
action inhibits the development of psoriasis in clinically relevant models (30). In 2004 
Boyman et al. showed that transplanted uninvolved skin from patients with psoriasis on 
immunodecient AGR mice (interferon alpha and gamma receptor decient) developed 
psoriasis-like skin lesions. The development of psoriasis in the previously normal looking 
‘uninvolved’ psoriasis donor skin is possibly due to resident/memory skin-homing CLA+ 
T cells (31). Later it was shown that T regulatory cells (T reg) of psoriatic patients have 
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a defect in their suppressive activity and this was suggested as a cause for the vicious 
inammatory cascade in psoriasis (32-34). Recently novel functional T cell subsets were 
discovered, adding Th17 and Th22 cells to the model of psoriasis pathogenesis (35-37). 
T cell related cytokines such as IL-17A and IL-22 were shown to induce the keratinocyte 
activation and proliferation in psoriasis (2). In addition, IL-23 induces epidermal hyper-
plasia indirectly via IL-19 and IL-24 (38).
Genetics
Many patients with psoriasis have a relative with psoriasis and the lifetime disease 
concordance in monozygotic twins is 35-73% and in dizygotic twins 12-20% (3). These 
ndings illustrate the genetic predisposition in psoriasis. In 44 susceptibility loci for 
psoriasis, around 13 independently replicated polymorphisms increase the risk for 
developing psoriasis (3, 39, 40). The most important genetic determinant is HLA-Cw6 
and this HLA-I gene variant lies in the PSOR1 region on chromosome 6 (41). Psoriasis 
patients can be divided in two subgroups according to HLA-Cw6 status (type I and type 
II). Type I patients are HLA-Cw6 positive (65% of patients) and in these patients psoriasis 
usually develops at a younger age (below 20 years) and there is often a positive fam-
ily history of psoriasis, in contrast to type II psoriasis patients (42). The PSOR4 region 
is another important locus of susceptibility associated with psoriasis (3). This region 
is responsible for epidermal dierentiation pathways and contains variations in copy 
numbers of late cornied envelope complex (LCE) genes and S100 genes and human 
beta-defensin genes (43, 44). Furthermore, a role for bacterial peptidoglycan (PG) in 
psoriasis pathogenesis has been proposed and polymorphisms in PG recognition pro-
teins have been found in the PSOR4 region (45, 46). The hypothesis is that a breakdown 
of immune tolerance to the microbiota of the skin leads to chronic inammation (47). 
Interestingly, in psoriatic skin macrophages are present in the dermal papillae close to 
PG-specic CD4+ T cells. In culture streptococcal specic T cell lines respond to group 
A streptococcal PG by the production of IFN-γ and staphylococcal specic T cell lines 
respond only to staphylococcal PG by IFN-γ production (48). Most of the identied 
psoriasis risk variants are involved in the immune system including IL12B coding for 
IL-12/IL-23p40, IL-23A coding for the IL-23p19 subunit, IL-23R coding for the IL-23 recep-
tor subunit, IL-4/ IL-13 coding for the cytokines involved in Th2 cell dierentiation, and 
TNFAIP3 coding for tumor necrosis factor alpha-induced protein 3. IL-23 and its receptor 
complex are important in Th17 subset dierentiation and TNFAIP3 plays a regulating 
role in the NF-κB signaling cascade. Genetic variation in these genes could inuence the 
balance between a controlled and an exaggerated immune response. IL-12 and IL-23 
are increased in psoriatic lesions and crucial cytokines driving the dierentiation of Th1 
and Th17 subsets. In addition, a region harboring LCE3B and LCE3C genes, that code 
for epidermal barrier proteins, is deleted in European psoriatic patients compared with 
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controls (49). The current hypothesis is that SNP’s and deletions lead to dysfunctional 
gene signaling and as a consequence an aberrant innate or adaptive immune response 
and that this eventually promotes psoriasis (3).
Current view on psoriasis pathogenesis
The current view on psoriasis (Figure 3 and 4) includes the role of antimicrobial pep-
tides (AMP). Psoriatic keratinocytes are a rich source of AMP, including LL-37, hBD-2 
(β-defensin) and S100A7 (psoriasin) and their production in psoriatic skin is increased 
(50). In addition to their antimicrobial activity, AMP can have a chemotactic function and 
shape immune cell function, including that of DC and T cells (51). In 2007 it was shown 
that the antimicrobial peptide LL-37 is able to bind self DNA and self RNA and that these 
complexes activate plasmacytoid DC that subsequently activate Th1 and Th17 cells in 
the lymph nodes. Activation of these cells can occur through binding of the AMP LL-37 
in complexes with host DNA with endosomally expressed TLR9 (52). In addition, recently 
LL-37 specic T cells have been demonstrated and the presence of these specic T cells 
correlates with disease activity (25). The current view on psoriasis is that in genetically 
predisposed individuals the epidermal cells are triggered by diverse environmental fac-
tors such as mechanical trauma or certain drugs (antimalarials, lithium, β-adrenergic 
Figure 3. Overview T cell subsets pathogenesis of psoriasis.
Figure adapted from Perera et al. Ann Rev Pathol 2012.
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antagonists, systemic corticosteroids, indomethacin). This results in the production of 
a large amount of AMP that form complexes with self DNA or RNA. These complexes 
activate the plasmacytoid DC, that produce type I IFN-α, IL-12 and IL-23. These cytokines 
activate the dierentiation of CLA+ Th1/Th17 cells in the lymph nodes, that migrate to 
the skin. Recently innate lymphoid cells (ILC) that can produce IL-22, known to be a key 
driver of epidermal thickening, have been found to be increased in psoriatic lesional 
skin (53). In addition Villanova et al. determined the presence of ILC3 that produce IL17A 
and IL-22 in psoriatic skin (J Invest Dermatol 2014). γδ T cell numbers are increased in 
psoriatic skin and these cells produce IL-17A (38). However, other groups were not able 
to show the presence of this cell type in psoriasis. In the skin these ILC, possibly the γδ 
T cells, Th1, Th17 and likely the LL-37 specic T cells and their cytokines cause activa-
tion and proliferation of the keratinocytes. The interplay between these cells and the 
proinammatory environment results in the production of more proinammatoryme-
diators and more antimicrobial peptides that are not only produced by T cells, but also 
by macrophages, neutrophils and broblasts. Eventually, this causes a vicious cycle of 
inammation that leads to thickening and scaling of the skin.
Figure 4. Current vieuw on (neuro)immunopathogenesis of psoriasis.
Parts of this gure were provided by E.M. Baerveldt.
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Neurogenic inammation in the pathogenesis of psoriasis
The current prevailing view on the pathogenesis of psoriasis, presented in the previous 
paragraph, does not put emphasis on the role of neurogenic inammation, which is 
often underexposed in psoriasis review articles. Involvement of neuroimmunological 
factors in the pathogenesis of psoriasis is supported by the following sets of observa-
tions:
 - clearance of psoriatic lesions after inadvertent denervation
 - symmetry of psoriasis lesions
 - psoriasis exacerbation by psychological stress
 - increase in nerves and neuropeptides in lesional skin
In 1986 Farber et al. introduced the concept of a role for cutaneous nerves and their neu-
ropeptides in the pathogenesis of psoriasis (54). In the following years several observa-
tions were made supporting this hypothesis. For example a patient was described with 
clearance of a large psoriatic lesion on her left knee following reconstructive surgery 
after destruction of the joint due to arthritis (55). This report and other case-reports 
describe the clearance of lesions in areas of denervation after surgical trauma of the 
skin by surgery or other causes (56, 57). In the KC-Tie2 mouse model the skin possesses 
clinical and immunological features of psoriasis by ectopic expression of the angiopoi-
etin receptor Tie2 (58). Denervation in this psoriasis mouse model led to a decrease 
in psoriasis-like skin lesions due to the denervation and decreased DC numbers, IL-23 
production and T cell inltration. Substance P (SP) and calcitonin-gene related peptide 
(CGRP) expression in the skin decreased and upon injection of these neuropeptides in 
the skin, the skin lesions reappeared (58). The fact that psoriasis lesions appear mostly 
symmetrical and that psychological stress including major interpersonal upsets within 
the family group, marital or nancial problems and deaths or hospitalizations of close 
relatives can act as exacerbating factors, suggests involvement of the peripheral ner-
vous system (54, 59, 60). In addition, pathological psychological stress impairs clearance 
of psoriasis in patients treated with photochemotherapy (61). The number of nerve 
bres and some of their products (neuropeptides) also are increased in psoriatic lesions 
compared to healthy control or uninvolved psoriatic skin (62). These ndings indicate 
that signals from the nervous system and neuroimmunological factors sustain psoriasis. 
Targeting the nervous system could be a therapeutic option for instance by blocking 
neuropeptides and their receptors locally. However, the precise role of neurogenic fac-
tors in the pathogenesis of psoriasis remains to be elucidated.
Neuropeptides and neurogenic inammation
Neuropeptides (Table 1) are small proteins, used by neurons to communicate with their 
direct microenvironment. They are released at the peripheral endings of sensory and 
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eerent nerves. In human skin, these nerves often lie in close proximity to immune cell 
types like LC. In psoriatic skin the percentage of contacts between nerve bres and 
LC is signicantly higher than in uninvolved psoriatic skin and healthy controls (63). 
Neuropeptides can also be directly synthesized in the skin from dierent resident cell 
types like keratinocytes and broblasts and mast cells. Many non-neuronal cells express 
neuropeptide receptors including keratinocytes and naive as well as activated T cells 
(64). Nerve growth factor (NGF), vasoactive intestinal peptide (VIP) CGRP and SP are 
neuropeptides that appear to play a role in psoriasis pathogenesis. These neuropep-
tides cause chemotaxis, enhancement of broblast and endothelial cell proliferation, 
degranulation of mast cells and regulation of the release of inammatory mediators 
from macrophages and lymphocytes and T cell activation and KC proliferation. Under 
dierent circumstances neuropeptides can exert proinammatory as well as anti-inam-
matory functions, depending on the micro-environment. Neuropeptides can regulate 
many cell types of the immune system and of epithelia. As mentioned previously, LC 
are in intimate contact with CGRP containing nerve bres, and CGRP can be found at 
the surface of LC (65). This vicinity of CGRP, LC and nerves could point at an important 
role for neuropeptides and DC regulation. In addition, the neuropeptides CGRP and VIP 
inhibit the antigen-presenting function of LC partly by inhibition of NF-κB (65-67).
Table 1. Neuropeptides involved in the pathogenesis of psoriasis.
Neuropeptide Abbreviation Receptor Function
Nerve growth factor NGF TrkA, p75 neutrophil chemotaxis
angiogenesis
lymphocyte activation
sensory neuron survival
Calcitonin gene-related peptide CGRP CGRP1, CGRP2 vasodilation
regulation of Langerhans cells
keratinocyte proliferation
neutrophil chemotaxis
mast cell degranulation
Substance P SP NK-R T cell activation
keratinocyte proliferation
neutrophil chemotaxis
vasodilation
Vasoactive intestinal peptide VIP VPAC1, VPAC2 vasodilation
mast cell degranulation
keratinocyte proliferation
T cell regulation
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In addition to LC there are also indications that mast cells play a role in neurogenic 
inammation by interacting with sensory nerves. Mast cells are frequently localized 
near SP and CGRP expressing nerve bres (68). In addition, neurogenic inammatory 
responses are mediated by the release of neuropeptides from sensory nerves and these 
are often accompanied by mast cell degranulation (69, 70). Mast cells are also capable of 
producing many inammatory cytokines that are important in psoriasis pathophysiol-
ogy such as TNF-α, IL-1β, IL-6 and IL-17A. NGF recruits mast cells and promotes their 
degranulation both of which are early events in a developing lesion of psoriasis (71).
The role of stress in psoriasis
For the purposes of this thesis, stress is dened as the neuroendocrine response of the 
organism to any threat it encounters, which requires an adaptation of the organisms’ 
biopsychosocial function in order to cope with it (72). Patients with psoriasis often 
experience emotional and psychological tension because of their disease in addition to 
regular stress events (73). Psoriasis and psychological stress are related and it is known 
that psoriasis is often triggered for the rst time in a patient by a major stressful life event. 
The incubation time from particular incidents of stress to the development of psoriasis is 
between 2 days and 1 month (59, 60). In addition, patients often experience aggravation 
of the disease in periods of stress. Psychologically distressed patients have less clearance 
of their skin lesions during UV phototherapy treatment than non-distressed patients 
(61). The autonomic nervous system and the hypothalamus-pituitary-adrenal axis are 
activated by stress and this induces the release of (nor)adrenalin and cortisol, which can 
interact with the immune system (74). In the Trier Stress Test subjects perform a public 
speaking task and mental arithmetics in front of a critical audience. This stress test leads 
to a signicantly increased inux of leucocytes including lymphocytes, granulocytes 
and monocytes in the blood of psoriasis patients, but also in controls already after 10 
minutes. However, inux of CD4+ T cells in psoriasis patients is signicantly increased 
compared to controls (75). Skin LC are reduced in number after acute psychological 
stress (Trier Stress Test), which may indicate migration to the lymph nodes (76). Chronic 
psychological stress positively correlates with the number of SP positive inammatory 
cells in noninvolved psoriatic skin (77). In mice, sound stress increases frequency of SP-
containing nerve bres in the skin (78). In psoriasis patients experiencing high levels of 
stress more CGRP and CGRP+ cutaneous nerves are found in the dermis compared to 
patients with low stress levels (79).
 Placebo eect
The placebo eect observed in some randomized controlled trials in psoriasis reached 
levels up to 19% (80). The exact cause of the placebo eect in trials is unknown. One of 
the explanations is the role of expectation as a cognitive mediating variable of placebo 
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eects (81, 82). For example the expectation of pain relief activates µ-opioid receptor 
signaling in the brain which relieves pain (81-83). The expectation can be activated con-
sciously when attention is directed to it. In addition a study showed eects on weight 
and blood pressure by telling room attendants in hotels that their work is a kind of exer-
cise that burns a lot of calories compared to those that were not made aware of this (84). 
Retrospectively no other explanations as more exercise, more work or dietary changes 
were applicable. So the relationship between exercise and health can be moderated by 
mind-set. These ndings are additional arguments for the role of the nervous system in 
psoriasis and a brain skin connection.
Nerve growth factor (NGF)
An important dierence between the skin of psoriasis patients and healthy controls 
is the increased level of NGF and other neuropeptides in the epidermis in the inam-
matory state (85). NGF is a 118 amino acid hormone involved in the development and 
maintenance of sensory and sympathetic nerve bres. Keratinocytes in lesional, but also 
non-lesional psoriatic tissue express high levels of NGF. There is a marked upregulation 
of the two NGF receptors, p75 neurotrophin receptor (p75NTR) and tyrosine kinase A 
(TrkA), in the terminal cutaneous nerves of psoriatic lesions (71, 86). TNF-α enhances the 
secretion of NGF from epidermal keratinocytes (87) and NGF is mitogenic to keratino-
cytes (88, 89). In addition NGF stimulates the release of SP and CGRP (90).
Substance P (SP)
SP is expressed in the brain, spinal cord and dorsal root ganglia of the central nervous 
system (CNS) and by capsaicin sensitive primary sensory neurons in the peripheral 
nervous system (PNS) (91). Studies have shown an increase of SP containing nerve bres 
in psoriatic lesional skin (92-95). In a study of Payan et al. it was demonstrated that SP 
stimulates human T lymphocyte proliferation signicantly in vitro (96).
Calcitonin gene-related peptide (CGRP)
CGRP is a 37-amino acid peptide that is expressed by bres in the human brain stem and 
cerebellum and in neurons of the spinal cord the CNS and peripheral nerve endings of 
the PNS (97). CGRP is a neurotransmitter that causes keratinocyte proliferation in vitro 
and vasodilation in vivo (98, 99). In addition, CGRP acts as a growth factor for Schwann 
cells and endothelial cells. CGRP can act as an immune regulator and this is illustrated 
by the fact that CGRP containing nerves lie in close proximity of LC (65). There are con-
icting reports about the expression of CGRP in psoriatic skin. However, most studies 
nd an increased level of CGRP (62, 100). In patients with high levels of psychological 
stress, based on a life change questionnaire, VIP and CGRP immunoreactive nerves are 
increased in the skin (79).
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Vasoactive intestinal peptide (VIP)
VIP is a small protein composed of 28 amino acids. VIP nerve bers are present in many 
lymphoid organs including the thymus and the spleen (101). VIP can be produced by 
dierent types of leucocytes including T cells, mast cells and macrophages (102). VIP 
has a diverse range of eects such as vasodilation, relaxation of smooth muscles in in-
testinal and pulmonary tissues, and stimulation of electrolyte secretion in the intestine. 
As a consequence, VIP was rst classied as an intestine hormone. Subsequent studies 
demonstrated that VIP is also present in the nervous system. In the CNS, VIP plays an 
important role in the control of circadian rhythms, anxiety, stress, schizophrenia, learn-
ing and memory (103). Furthermore, VIP can enhance Th17 cell dierentiation through 
the VPAC 1 receptor on T cells (102). In vitro studies show that the outcome of VIP signal-
ing depends on the ratio of vasoactive intestinal peptide receptor 1 and 2 (VPAC1/2) 
expressed by on responder cells (104). Stimulation of CD4+ T cells with VIP and TGF-β 
leads to dierentiation into Th17 cells that generate IL-17A but not IL-6 or IL-21. In VPAC2 
knockout mice, the increase in Th17 cells was higher. This suggests that the induction 
of Th17 cells by VIP is mediated by the VPAC1 receptor. Th17 cells induced by VIP and 
IL-6 secreted IL-17 and IL-22, but no IL-21 (104). Interestingly, peptide T is an analogue 
of VIP and when infused into psoriatic lesions this improves disease (105). This stresses 
the importance of VIP in psoriasis, however the precise role of VIP and its receptors in 
psoriasis pathogenesis is currently unknown.
The Koebner phenomenon
The Koebner phenomenon, in which psoriasis patients develop a psoriatic plaque 
after skin injury (for example after extensive scratching, surgery, tattoo placement or 
needle piercing) is seen in approximately 20-25% of the patients (106, 107). The Koebner 
phenomenon can be triggered by tape-stripping of the skin, invoked by applying and 
removing adhesive tape to and from the skin 20 to 40 times in rapid succession. Fol-
lowing injury to the cutaneous nerves, denervated skin is re-innervated by two mecha-
nisms: axonal regeneration and collateral re-innervation (108). NGF has a regulating role 
in both of these processes (109, 110). Interestingly, tape-stripping of the skin causes 
a local increase of NGF (111). In parallel with the increased expression of NGF in the 
keratinocytes, the NGF-receptor expressing nerve bres increased in size and number. 
No CD3+, CD4+ and CD8+ T lymphocytes could be identied in the dermis or epidermis 
of non-lesional psoriatic skin within 24 hours of mechanical traumatisation. In the tape-
stripped skin of the normal controls and psoriasis patients who did not develop Koebner 
lesions, NGF synthesis in the keratinocytes did not increase. These observations suggest 
a possible direct eect of NGF on keratinocyte proliferation in psoriasis (111).
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Neurogenic interventions for psoriasis
The density of blood vessels is increased in psoriatic plaques, but the underlying mecha-
nisms are not known. Dilation of the vessels causes the red colour of psoriatic plaques. 
Neurogenic factors are important for blood ow regulation in psoriatic plaques. Inhi-
bition of local neurogenic mechanisms by surface anesthesia of the plaque evokes a 
marked blood ow reduction. This is compatible with the idea that a local neurogenic 
mechanism (axon-reex) contributes to the high blood ow in the psoriatic plaque 
(112). Resistant psoriatic plaques are sometimes treated with the pulsed dye laser, 
however this is not a therapeutic option for large body areas (113). Topical application 
of capsaicin inhibits SP and CGRP and when applied to pruritic psoriatic lesions, cap-
saicin improves itch scores and the psoriasis severity score (114, 115). Botulinum toxin 
inhibits the release of neurotransmitters from peripheral nerve endings and can be used 
for the treatment of frown lines, hemifacial spasm and hyperhidrosis. Local injection 
of botulinum toxin decreases inltrating lymphocytes and improves acanthosis in the 
KC-Tie2 psoriatic mouse model, suggesting a role for neuropeptides in the maintenance 
of psoriasis (116).
K252a, a NGF receptor blocker
The NGF receptor (TrkA) can be blocked by a high anity receptor blocker from micro-
bial origin called K252a (alkaloid-like material from the culture broth of Nocardiopsis sp.) 
(117). Transplanted psoriatic plaques on SCID mice treated with this receptor blocker 
had signicantly improved clinical, histologic and immunologic features of psoriasis 
following two weeks of treatment (118). This study also investigated the eects of 
anti-NGF-antibodies and a signicant improvement of psoriasis was seen compared to 
plaques treated with placebo. K252a is a potent inhibitor of the receptor tyrosine kinases 
of the Trk family, thereby inhibiting NGF signaling via the Trka receptor (118). Currently 
Phase II trials are running in which the ecacy and safety of a cream with K252a is tested 
in psoriasis vulgaris patients (clinical trials.gov: A randomized, double-Blind, placebo 
controlled Phase II, multi-centre, study of the ecacy and safety of CT 327, a Topical 
Cream Formulation of Pegylated K252a). Taken together, these studies show that altera-
tion of the neurogenic environment improves psoriasis.
Current treatments for psoriasis
For many years psoriasis was mainly treated with coal tar. Fortunately, partly due to 
newer insights, the treatment modalities for psoriasis have increased extensively the 
past 3 decades. Current anti-psoriatic treatment broadly consists of topical therapies, 
phototherapy and systemic interventions. Mild psoriasis can be treated with local 
creams containing corticosteroids, tacrolimus or vitamin D3 derivatives or a combina-
tion of corticosteroids and vitamin D3. For moderate to severe psoriasis UVB or PUVA 
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light therapy or systemic drugs are used, especially when large areas of the body are 
aected. UV light supresses the immune response and narrowband UVB therapy is 
linked to suppression of the IFN and Th17 pathways (119). Systemic drugs frequently 
used in the treatment of psoriasis are methotrexate and cyclosporine. Methotrexate is a 
folic acid antagonist and aects cell proliferation. Cyclosporine, a calcineurin inhibitor, 
has powerful immunosuppressive eects and decreases T cell proliferation. In addition, 
fumaric acid esters (FAE) can be used in the treatment for psoriasis. Despite its successful 
use in psoriasis patients for many years in Germany and other West European countries 
and since 1981 in the Netherlands, FAE are still not registered and not widely used for 
psoriasis. A ≥75% clinical improvement after 16 weeks of treatment is seen in 50-80% of 
FAE treated psoriasis patients (120). In vitro, FAE inhibit DC maturation and keratinocyte 
proliferation (121, 122). In vivo, FAE treatment induces IL-4-producing Th2 cells and gen-
erates type II DC that produce IL-10 instead of IL-12 and IL-23 (123). However the precise 
mechanism in psoriasis improvement is unknown. Data from long-term observational 
studies on treatment of psoriasis patients with FAE indicate a favourable safety prole 
without evidence for an increased risk of infections or malignancies (124-126).
Psoriatic lesions are characterized by a relatively low amount of IL-4, IL-13 and an 
absence of Th2 cells, and by a strong Th1/Th17 signature (37, 127). The prototypic Th2 
cytokine IL-4 is primarily regarded as a master switch essential for Th2 dierentiation 
(128) and IL-4 inhibits the development of Th17 cells from naïve T cells (129, 130). 
Genetic variants found at the IL4/IL13 locus are likely to contribute to the Th1 bias in 
psoriasis (131). Clinical improvement of psoriasis is accompanied by activation of IL-4 
signaling pathways and psoriasis patients treated with recombinant human IL-4 showed 
impressive clinical improvement, up to 68% PASI reduction in 6 weeks (132). This clinical 
improvement is accompanied by reduced expression of IL-23 and reduced numbers of 
Th17 cells (133). However, recombinant IL-4 is currently not used in the treatment of 
psoriasis, likely because of the development of new drugs for psoriasis in the last ten 
years that aect the immune system more specically. These drugs named biologics, 
are produced with recombinant DNA-technology, examples are receptors for cytokines 
and receptor blockers. Examples of these biologics used in the treatment of psoriasis 
are etanercept (anti-TNF-receptor fusion protein), adalimumab (anti-TNF-α), iniximab 
(anti-TNF-α, soluble and transmembrane), ixekizumab (anti-IL17A) and ustekinumab. 
Ustekinumab is a human monoclonal antibody targeting the p40 subunit shared by 
IL-12 and IL-23. IL-12 and IL-23 stimulate DC that subsequently cause dierentiation of 
naïve T cells in Th1 and Th17 cells in the lymph nodes that subsequently migrate to the 
skin. By targeting the p40 shared subunit of IL-12 and IL-23 ustekinumab interferes with 
the production of Th1 cells and cytokines and also the development of Th17 cells and 
cytokines. IL-23 acts downstream not only via IL-17 but also via IL-22 produced by Th17 
cells. IL-22 from Th17 cells is induced by IL-23 or IL-6 and can lead to dermal inamma-
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Table 2. Overview current and pipeline drugs used in psoriasis treatment
Current anti-psoriatic therapies Main mode of action in psoriasis
calcineurin inhibitors inhibition T cells
corticosteroids anti-inammatory
vitamin D analogues inhibition keratinocytes, T cells
coal tar anti-inammatory
Phototherapy  
UVB anti-inammatory
PUVA anti-inammatory
laser reduction of blood vessels
Systemic drugs  
methotrexate folic acid antagonist, limits cell division
cyclosporin inhibition T cells
acitretin inhibition keratinocytes
fumaric acid inhibition T cells, DC
Biologics  
adalimumab inhibition TNF-α (monoclonal antibody)
etanercept Inhibition TNF-α (TNF receptor Fc fusion protein)
iniximab Inhibition TNF- α (monoclonal antibody)
ustekinumab Inhibition IL-12/IL23 (anti-p40 shared subunit)
Pipeline drugs  
Topical drugs  
CT-327 Trk A inhibitor Inhibitor TrkA kinase (inhibits NGF signaling)
Biologics  
secukinumab anti-IL-17A (monoclonal antibody)
ikexuzimab anti-IL-17A (monoclonal antibody)
MK-3222 anti-IL-23p19 (monoclonal antibody)
guselkumab anti-IL-23p19 (monoclonal antibody)
tregalizumab anti-CD4 specic antibody that activates Treg
JAK-inhibitors  
tofacitinib JAK-1/JAK-3 inhibitor
baricitinib JAK-1/JAK-2 inhibitor
ASP-015K JAK-1/JAK-3 inhibitor
Others  
apremilast phosphodiesterase-4 (PDE-4) inhibitor
ponesimod sphingosine-1-phosphate (S1P) receptor modulator
IMO-3100 anti-TLR7/TLR9, limits T cell activation
FP-187 (dimethylfumarate) citric acid cycle, inhibition T cells, DC
sotrastaurin (AEB-071) inhibition protein kinase C pathway
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tion and acanthosis (134). Ustekinumab is an eective treatment for psoriasis and 66% 
of patients reaches ≥PASI-75 improvement after 12 weeks of therapy (135). However, 
it is an expensive treatment that costs about 1.200 euros a month in the Netherlands 
(information provided by the producer). Considering the costs of ustekinumab treat-
ment it would be very ecient to predict the chance of successful treatment before the 
start of therapy, unfortunately this is currently not possible.
Currently, anti-IL-17A (i.e., secukinumab and ixekizumab) and anti-IL-17 receptor 
(i.e., brodalumab) biologics are being studied in Phase III clinical trials to evaluate their 
overall ecacy and safety in psoriasis. The results so far have shown great ecacy and 
underline the pathogenic role of IL-17 in psoriasis (136-139) (Overview current and 
pipeline drugs Table 2).
OUTLINE OF THE THESIS
The aim of this thesis was to further identify molecular mechanisms in the pathogenesis 
of psoriasis through clinical and experimental interventions in the disease process and 
in a novel mouse model (Table 3). Genetic, environmental and immunological factors 
play a role in the pathogenesis of psoriasis. Neurogenic inammation seems to play an 
important role as well, however the exact inuence of neurogenic factors is still unclear. 
The rst part of this thesis focuses on experimental denervation in mice and iatrogenic 
denervation in humans. In Chapter 2 we present a patient suering from iatrogenic 
nerve damage following knee surgery leading to local resolution of his psoriasis. Mo-
lecular analysis of this patient revealed several altered psoriasis-related pathways as 
the result of iatrogenic denervation. To assess whether not only the maintenance of 
psoriasis depends on a intact peripheral nervous system, but also if the initiation of 
psoriasis could be prevented by denervation we analysed underlying molecular mecha-
Table 3. Interventions used in this thesis
Interventions used in this thesis
Denervation
Iatrogenic nerve damage due to surgery
Experimental denervation in the imiquimod mouse model 
Treatment
Fumaric acid ester treatment of psoriatic patients
Ustekinumab treatment of psoriatic patients
IL-4 treatment of psoriatic skin ex vivo and immune cell subsets in vitro
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nisms in the imiquimod-induced psoriasiform mouse model. The results of this study are 
described in Chapter 2.
Since Chapter 2 conrmed that local denervation leads to resolution of psoriatic plaques 
and that the induction of psoriatiform skin inammation is inhibited by denervation, we 
examined the potential role of several neuropeptides in these observations. Neuropep-
tides are the eector molecules of nerves and can be produced by many immune cell 
types. Vasoactive-intestinal-peptide (VIP) is a neuropeptide and its levels are increased 
in psoriatic skin. In vitro studies have shown that the result of VIP signaling depends 
on the ratio between its receptors VPAC1 and VPAC2 on the responder cells, and that 
VPAC1 is important for VIP mediated Th17 dierentiation. In psoriasis there is a chronic 
Th17 mediated inammation in the skin. In Chapter 3 we therefore questioned whether 
the Th17 inammation in psoriasis is dependent on these receptors and assessed the 
expression pattern in psoriatic skin compared to normal skin and during fumaric acid 
ester treatment. Alterations in the expression of the receptor could implicate a role in 
the pathogenesis of psoriasis. In addition we determined whether the VPAC receptor 
expression of PBMC is inuenced by the cytokines that are present in psoriatic skin.
Fumaric acid esters (FAE) are used for the treatment of psoriasis, however they are less 
used than expected on basis of their clinical ecacy and favorable safety prole. This 
could partly be explained by the currently unknown mechanisms of action by which FAE 
improve psoriasis. In Chapter 4 we therefore used a broad microarray analysis to identify 
FAE specic pathways. We made a comparison between FAE and anti-TNF-α treatment 
with etanercept to study regulated genes and pathways in psoriatic skin responsible for 
clinical treatment response by FAE.
Ustekinumab is a highly eective biologic that is used in the treatment of psoriasis. By 
blocking the shared p40 subunit of IL-12 and IL-23, ustekinumab modulates both the 
Th1 and Th17 pathway and is highly eective in the clearance of psoriasis in a large 
proportion of patients with 66% of the patients reaching an improvement of the disease 
of 75% or more (PASI-75) after 12 weeks (135). During treatment with ustekinumab, 
patients observed reduced Koebnerization of the skin. We hypothesized that these clini-
cal observations could be explained by improved psoriasis-related gene expression and 
tape-strip responses in non-involved skin during ustekinumab treatment. We therefore 
analysed skin biopsies of non-lesional and tape-stripped skin of patients before and 
during treatment of which the results are described in Chapter 5.
Ustekinumab is a highly eective treatment, however 34% of patients does not reach 
a PASI improvement of 75%. Treatment is very expensive and therefore only patients 
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with severe disease are treated with ustekinumab. At this moment it is not possible to 
predict which patients will respond to therapy and which patients will not, although this 
would be time- and cost-ecient. In Chapter 6 we aimed to identify cytokine markers 
and cytokine predictive of the response to ustekinumab treatment. We carried out a 
cytokinearray of serum samples taken before and after 12 weeks of treatment in patients 
that responded and not responded to treatment. Results were analyzed by Ingenuity 
Pathway Analysis (IPA) and hierarchical clustering was performed in Partek in order to 
asses treatment response related cytokine proles.
Experimental successful treatment of psoriasis with IL-4 has been described, but the 
current availability of other more specic blocking biologics (anti-TNF-α, anti-IL-12/
IL-23 and more recently anti-IL-17(R) possibly suppressed the enthusiasm for this drug 
with an agonist mode of action. There are several observations that imply a role for 
IL-4 in the pathogenesis of psoriasis including 1) clinical improvement of psoriasis is 
accompanied by activation of IL-4 signaling pathways, 2) the IL4/IL-13 gene is an identi-
ed psoriasis risk variant, 3) the expression of the IL-4 receptor is increased in psoriatic 
epidermal cells, and 4) fumarate treatment induces IL-4-producing Th2 cells in vivo. The 
IL-4 induced improvement was initially attributed to its eects on the Th1/Th2 balance 
in the dermal inltrate. Later it was shown that IL-4 treatment reduces the cutaneous 
expression of IL-23p19 and IL-17, and reduces expression of IL-1β, IL-6 and IL-23 in der-
mal DC. We questioned the role of IL-4 in the epidermal compartment. In Chapter 7 we 
hypothesized that IL-4 induces a shift away from Th1/Th17 inammation by inhibitory 
eects on proinammatory cytokine production in epidermal cells, thereby reversing 
the altered cytokine balance in the epidermal compartment. We assessed the possible 
anti-inammatory eects of IL-4 on proinammatory cytokine production by using 1) 
PP biopsies and healthy skin explants, 2) freshly isolated EC from PP, 3) cultured HaCaT 
cells and normal human keratinocytes, 4) freshly isolated LC from human skin, and 5) 
activated PBMC as a representative of the dermal inltrate.
In Chapter 8 we discuss our ndings in light of recent literature, and provide sugges-
tions for future research both in the clinical and experimental setting.
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ABSTRACT
Background
Fumaric acid esters (FAE) are widely used in Europe for the treatment of psoriasis be-
cause of their clinical ecacy and favourable safety prole. However, the mechanisms 
of action by which FAE improve psoriasis remain largely unknown. The objective was 
to identify pathways and mechanisms aected by FAE treatment and to compare these 
with pathways aected by treatment with the anti-TNF-α biologic etanercept.
Methods
In a prospective cohort study, 50 patients with plaque psoriasis were treated with FAE for 
20 weeks. Nine patients were randomly selected for gene expression proling of plaque 
biopsies from week 0 and week 12. The groups consisted of FAE responders (>PASI-75 
improvement) and non-responders (<PASI-50 improvement). Changes in gene expres-
sion proles were analyzed using Ingenuity Pathway Analysis (IPA) and the outcome was 
compared with gene expression aected by etanercept.
Results
Response to FAE treatment was associated with a >2-fold change (P<0.05) in the ex-
pression of 458 genes. In FAE responders the ‘role of IL17A in psoriasis’ pathway was 
most signicantly activated. Glutathione and Nrf2 pathway molecules were specically 
induced by FAE treatment and not by etanercept treatment, representing a FAE specic 
eect in psoriatic skin. In addition, FAE treatment specically induced the transcription 
factors PTTG1, NR3C1, GATA3 and NFκBIZ in responding patients.
Conclusions
FAE treatment induces glutathione and Nrf2 pathway genes in lesional skin of patients 
with psoriasis. In responders FAE specically regulates the transcription factors PTTG1, 
NR3C1, GATA3 and NFκBIZ, which are important in normal cutaneous development, Th2 
and Th17 pathways, respectively.
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INTRODUCTION
Psoriasis is a common chronic inammatory skin disease, characterized by hyperprolif-
eration of keratinocytes and an increased dermal inltration by immune cells, notably 
neutrophils and Th1/Th17 cells. Most patients with moderate to severe disease require 
long-term systemic treatment to control their psoriasis. Fumaric acid esters (FAE) are 
small molecules used as oral treatment in psoriasis for more than 25 years, mainly in 
Western Europe (1). Fifty to 70% of FAE-treated psoriasis patients show a clinical im-
provement of at least 75% following 16 weeks of treatment (2). This treatment response 
is comparable to the ecacy of rst generation anti-TNF-α biologics, but at a fraction of 
the costs. Data from long-term observational studies on treatment of psoriasis patients 
with FAE indicate a favourable safety prole without evidence for an increased risk of 
infections or malignancies (3-5). In vitro, FAE inhibit dendritic cell maturation and kera-
tinocyte proliferation (6, 7).
Anti-TNF-α biologics including etanercept, are commonly used eective systemic 
treatments for moderate to severe psoriasis (8). In recent years, gene expression proling 
studies provided insights into the mechanisms of action and the signaling pathways by 
which anti-TNF-α biologics improve psoriasis (9, 10). However, the molecular pathways 
by which FAE improve psoriasis remain largely unknown. FAE have not been studied by 
gene expression proling nor have they been compared with anti-TNF-α biologics.
In this study we investigated pathways and mechanisms targeted by FAE treatment, 
and assessed whether successful FAE treatment invoked dierent molecules and path-
ways than etanercept treatment. Gene expression proling was performed on RNA de-
rived from psoriatic plaque biopsies taken before and after 12 weeks of FAE treatment. 
We then compared the molecules and pathways that were dierentially aected by FAE 
treatment, with those aected by etanercept treatment.
MATERIALS AND METHODS
Study design and skin biopsies
In a prospective, single-center clinical study, 50 patients with a psoriasis area and sever-
ity index (PASI) ≥10 were treated with oral FAE for 20 weeks. In the Netherlands, the 
import of Fumaderm tablets from Germany is often not reimbursed by the insurance 
company. We therefore used a Dutch FAE-formulation with enteric coated tablets con-
taining 105 mg FAE (30 mg dimethylfumarate, 75 mg calcium-monoethylfumarate) and 
215 mg FAE (120 mg dimethylfumarate, 95 mg calcium-monoethylfumarate (11). The 
short term ecacy of this FAE formulation is comparable to that of oral methotrexate 
15 mg a week (12).
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Eligible patients were at least 18 years of age, had a diagnosis of plaque psoriasis for 
at least 6 months, and were candidates for phototherapy or systemic therapy. Patients 
were excluded when they had received systemic psoriasis therapy or phototherapy 
within the previous 4 weeks, or had received topical psoriasis treatment within 2 weeks. 
All patients were dosed according to the German S-3 guideline on systemic treatment 
of psoriasis (13) (Supplementary Table 1). Lesional 3 mm skin biopsies were taken at 
baseline from the edge of a well-dened psoriasis plaque on the legs and after 12 weeks, 
from the same plaque, nearby the previous biopsy site at baseline. The interval of 12 
weeks was chosen because subjects by then had reached the maximum daily dosage 
of FAE and after 12 weeks of treatment a clinical meaningful improvement is expected 
in daily clinical practice. Responders were dened as having a PASI-improvement 
>75% at week 12 compared to baseline, while non-responders were dened as having 
a PASI-improvement of <50%, as dened in the European treatment goal consensus 
(14). Patients were randomly selected for gene expression proling based on clinical 
improvement. The intermediate responders (PASI>50<75; n=19) and drop-outs (n=13) 
were not included in the analysis.
The clinical study protocol was approved by the local medical ethical committee (MEC 
2005-105), and all patients gave written informed consent prior to study enrollment. The 
study was conducted according to the principles of the Declaration of Helsinki.
RNA processing and microarray hybridization
From the 10 patients showing a clinical PASI-improvement of more than 75% at week 12 
(PASI>75 response), 4 patients were randomly selected as clinical responders and from 
the 8 patients with a PASI<50 response, 5 patients were randomly selected as clinical 
non-responders for microarray analysis. RNA was extracted from whole skin biopsies 
(epidermis and dermis) of these 9 patients and from 11 additional patients for validation 
of the microarray results by qRT-PCR. RNA was processed as previously described (15). In 
short, 1 μg of total RNA of 4 responding and 5 non-responding patients was hybridized 
to the GeneChip HG-U133 Plus 2.0 arrays (Aymetrix, Santa Clara, CA). Array hybridiza-
tion and scanning was done as previously described (16).
cDNA preparation hybridization
cDNA was made using 1 μg of total RNA template, with SuperScript II reverse transcrip-
tase (Invitrogen, Carlsbad, CA) and oligo(dT). Quantitative RT-PCR was performed using 
the ABI PRISM 7900 sequence-detection system (Applied Biosystems, Foster City, CA) 
(Supplementary Table 2).
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Immunouorescent staining
Cryosections from normal healthy skin and lesional skin biopsies were thaw mounted 
on slides for immunouorescent staining. Slides were xed for 15 min in 4% paraformal-
dehyde in PBS. A rabbit anity puried anti-phospho-STAT3 antibody (Tyr705) (1:100; 
Cell Signaling Technology, Danvers, MA) was used as the primary antibody. Goat anti-
rabbit antibody A488 IgG (1:1600, Invitrogen) was used as secondary antibody. Nuclei 
were stained with DAPI (1:2000). Photomicrographs were taken with an Axio Imager 
uorescence microscope (Carl Zeiss Microimaging GmbH, Jena, Germany).
Statistical analysis
A quality check on the microarray data was performed using the R package “ayQCRe-
port” and analysis was done as previously described (15). A gene was considered dier-
entially expressed when its adjusted P-value was <0.05 and its fold change was >2. We 
utilized IPA (Ingenuity Systems 2012, Redwood City, CA) to identify biological functions 
and pathways aected by FAE in psoriasis lesions and to more thoroughly understand 
the roles of the genes uniquely identied in this study as possible targets of FAE treat-
ment. Clinical data was analysed with SPSS Statistics (version 20) and mRNA data was 
analysed with GraphPad Prism (version 5).
Etanercept comparison data
The gene expression pathways aected by FAE treatment were compared with previ-
ously published data (10) that identied pathways aected by etanercept treatment 
(NCBI Gene Expression Omnibus GSE11903). In this study GeneChip HG-U133A v2 gene 
arrays were used to analyze gene expression in lesional skin biopsies at baseline and at 
week 12 from 11 responders that were treated with etanercept 50 mg twice a week for 12 
weeks. In that study responders were dened as having histological disease resolution 
at week 12 marked by decreased epidermal thickening and normalization of Ki67 and 
K16 expression. For comparison purposes, we selected the 22.277 probe sets present 
both on these microarrays and our HG-U133 Plus 2.0 microarrays and analyzed the data 
using the same methods as used on our full FAE data.
RESULTS
Clinical response to oral FAE treatment
The baseline characteristics of the selected psoriasis patients (6 male and 3 female 
patients) are summarized in Supplementary Table 3. The median PASI reduction after 
12 weeks of FAE treatment in the total group of patients (n=50) was 65.2% (interquartile 
range (IQR): 50.6%-77.8%). The median PASI at baseline was 13.6 (IQR: 11.3-16.4) which 
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decreased to 5.5 (IQR 3.3-7.6) following 12 weeks of FAE treatment (P<0.001). The clini-
cal responders, randomly included for array analysis, had a median decrease in PASI of 
84.3% (IQR 77.5-89.4%) whereas the clinical non-responders had a median PASI decrease 
of 40.4% (IQR 34.8-44.7%). The dierence in PASI reduction was statistically signicant 
(P=0.02) (Supplementary Figure 1).
Dierentially expressed genes in the skin of psoriasis patients treated with FAE
After 12 weeks of FAE treatment, 24 genes were dierentially expressed in the lesional 
skin of psoriasis patients (responders and non-responders). Seven of these were down-
regulated (including psoriasin (S100A7), calgranulin-B (S100A9), pentraxin 3 (PTX3), 
matrix metallopeptidase 1 (MMP1), lipocallin 2 (LCN2), desmocollin 2 (DSC2) and 
5-hydroxytryptamine (serotonin) receptor 3A (HTR3A). Seventeen molecules were up-
regulated including dermcidin (DCD), secretoglobulin (SCGB), prolactin-induced protein 
(PIP), keratins (KRT), and NAD(P)H dehydrogenase (NQO1) (Table 1).
Most of the genes which were dierentially expressed in the skin of psoriasis patients 
are known markers of psoriatic inammation, such as (psoriasin (S100A7), calgranulin-B 
(S100A9), LCN2, DSC2 and PTX3. PIP is an immunosuppressive molecule (17, 18).
Dierentially expressed genes in responders to FAE
We also analyzed gene expression changes separately in the group of responders and 
in the group of non-responders, in order to identify molecules and pathways that might 
be responsible for the clinical improvement of the psoriasis lesions. In responders, 458 
genes were dierentially expressed in lesional skin before treatment versus 12 weeks 
after start of the treatment (166 upregulated, 292 downregulated, ≥2-fold, P<0.05) 
(Supplementary Table 4). In the FAE treated responders several upregulated keratin 
genes were detected, including keratin 15 (K15), which is downregulated in activated 
keratinocytes and in psoriatic skin (19, 20). Thus the upregulation of K15 in FAE-treated 
responding patients was illustrative for the induced transition to normal skin. Similarly, 
the expression of keratin 16 and 17, markers of keratinocyte hyperproliferation that are 
upregulated in psoriatic skin, were signicantly downregulated in FAE responders after 
12 weeks (Supplementary Table 4). Several molecules of the epidermal dierentiation 
complex were signicantly downregulated after 12 weeks in responders to FAE treat-
ment including late cornied envelope 3D , involucrin and several members of the small 
proline-rich (SPRR) family. The expression of iNOS and IL-20 was signicantly reduced 
after 12 weeks of FAE treatment (Supplementary Table 4).
The list of dierentially expressed genes was analyzed by IPA. In responders, the IL-
17A pathway was most signicantly aected, with a downregulated expression of the 
chemokines CCL20, CXCL1 and CXCL6, the antimicrobial peptides β-defensin 2 (DEFB4), 
psoriasin (S100A7), calgranulin-A (S100A8) and calgranulin-B (S100A9) and the cytokines 
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IL-8 and IL-17A (Table 2). When validating these ndings with qRT-PCR, we conrmed a 
signicant decrease in the expression of these genes after 12 weeks of FAE treatment 
(Supplementary Figure 2). STAT3 expression was signicantly (-2.3-fold, P<10-12) down-
regulated in biopsies of lesional psoriatic skin of responders after 12 weeks of FAE treat-
ment (Supplementary Table 4). To verify that STAT3 protein was also downregulated, 
immunouorescent staining of phospho-STAT3 on these skin biopsies was performed. 
This showed a clear reduction at week 12 in responders, which is indicative of repression 
of the Th17 pathway (Figure 1).
Furthermore, a downregulation of the expression of the pro inammatory cytokines IL-
1β, IL-22, IL-36α (IL-1F6) and IL-36γ (IL-1F9) and an upregulation of the anti-inammatory 
IL-37 (IL-1F7) was associated with successful FAE treatment (Supplementary Table 4).
Table 1. Complete list of dierentially expressed genes in FAE treated patients (responders and non-re-
sponders) week 0 versus week 12.
Gene name Description Fold change P-value
DCD dermcidin 7.52 2.97 x 10-4
SCGB2A2 secretoglobin, family 2A, member 2 6.23 1.39 x 10-3
SCGB1D2 secretoglobin, family 1D, member 2 4.06 7.43 x 10-4
PIP prolactin-induced protein 3.80 3.35 x 10-2
KRT19 keratin 19 3.15 2.05 x 10-5
CA6 carbonic anhydrase VI 2.78 4.73 x 10-6
THRSP thyroid hormone responsive 2.70 4.33 x 10-2
ATP6V0A4 ATPase, H+ transporting, lysosomal V0 subunit a4 2.50 9.27 x 10-10
LGR5 leucine-rich repeat containing G protein-coupled 
receptor 5
2.399 1.12 x 10-2
CLDN10 claudin 10 2.342 7.94 x 10-3
DNER delta/notch-like EGF repeat containing 2.33 5.46 x 10-3
NQO1 NAD(P)H dehydrogenase, quinone 1 2.24 <10-12
PPARGC1A peroxisome proliferator-activated receptor gamma 2.16 2.60 x 10-7
RHPN2 rhophilin, Rho GTPase binding protein 2 2.12 1.96 x 10-4
KRT7 keratin 7 2.08 5.79 x 10-4
BTC betacellulin 2.04 3.84 x 10-5
SLC12A2 solute carrier family 12, member2 2.03 3.04 x 10-5
S100A9 S100 calcium binding protein A9 -2.07 1.37 x 10-3
HTR3A 5-hydroxytryptamine (serotonin) receptor 3A, 
ionotropic
-2.14 4.94 x 10-9
DSC2 desmocollin 2 -2.23 4.70 x 10-7
LCN2 lipocalin 2 -2.41 3.91 x 10-2
PTX3 pentraxin 3, long -2.48 1.55 x 10-4
MMP1 matrix metallopeptidase 1 -2.59 4.24 x 10-9
S100A7A S100 calcium binding protein A7A (psoriasin) -4.44 6.78 x 10-6
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Dierentially expressed genes in non-responders to FAE
In the non-responding patients, a dierential expression of 35 genes was found: 2 of 
these were downregulated and 33 were upregulated. IPA showed activation of the 
glutathione signaling pathway (microsomal glutathione S-transferase 1 (MGST), gluta-
Canonical pathways FAE 
responders P-value Upregulated Downregulated
Role of IL-17A in psoriasis 8.98 × 10-11 CCL20, CXCL1, CXCL6, DEFB4A/
DEFB4B, IL8, IL17A, S100A8, S100A9
Role of cytokines in mediating 
communication between cells
3.78 × 10-7 IL37 IL8, IL20, IL24, IL12B, IL17A, IL1A, 
IL1B, IL1RN, IL36A, IL36G, IL36RN
Atherosclerosis signaling 1.75 × 10-6 IL37, PLA2R1 ALOX12B, ALOX15B, IL8, IL1A, IL1B, 
IL1RN, IL36A, IL36G, IL36RN, MMP1, 
PLA2G3, PLA2G2A, PLA2G4D, 
S100A8, SERPINA1
Dendritic cell maturation 1.13 × 10-4 IL37, LEPR, PIK3C2G, 
PLCB4
CCR7, FCGR1A, FCGR1B, FCGR3B, 
IL12B, IL1A, IL1B, IL1RN, IL36A, 
IL36G, IL36RN, LTBR, STAT1
LXR/RXR activation 1.4 × 10-4 IL37 ARG2, CCL7, IL1A, IL1B, IL1RN, IL36A, 
IL36G, IL36RN, LDLR, NOS2, S100A8, 
SAA1, SERPINA1
IL-10 signaling 2.16 × 10-4 IL37 ARG2, IL1A, IL1B, IL1RN, IL36A, 
IL36G, IL36RN, IL4R, STAT3
p38 MAPK signaling 2.74 × 10-4 EEF2K, HSPB3, IL37 IL1A, IL1B, IL1RN, IL36A, IL36G, 
IL36RN, PLA2G3, PLA2G2A, 
PLA2G4D, STAT1
Eicosanoid signaling 3.36 × 10-4 AKR1C3, PLA2R1 ALOX12B, ALOX15B, FPR2, LTB4R, 
PLA2G3, PLA2G2A, PLA2G4D
Communication between 
innate and adaptive immune 
cells
3.49 × 10-4 IL37 CCR7, IL8, IL12B, IL1A, IL1B, IL1RN, 
IL36A, IL36G, IL36RN
LPS/IL-1 mediated inhibition of 
RXR function
8.08 × 10-4 ABCC3, ALDH3A2, 
ALDH6A1, GSTM3, 
HS3ST6, IL37, SULT1E1, 
UST
ALAS1, ALDH1A3, HMGCS1, 
HS3ST3A1, IL1A, IL1B, IL1RN, IL36A, 
IL36G, IL36RN
Canonical pathways FAE non-
responders
P-value Upregulated Downregulated
Glutathione redox reactions 7.92 × 10-4 GPX2, MGST1
Putrescine biosynthesis III 5.63 × 10-3 ODC1
Nrf2-mediated oxidative stress 
response
1.29 × 10-2 GPX2, MGST1, NQO1
Superoxide radicals 
degradation
1.68 × 10-2 NQO1
Xenobiotic metabolism 
signaling
7.92 × 10-4 MGST1, NQO1, 
PPARGC1A
Table 2. Pathways aected by FAE in responders (top 10) and non-responders (all) following 12 weeks of 
FAE treatment.
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thione peroxidase 2 (GPX2), the Nrf2 pathway (MGST1, NQO1 and GPX2), superoxide 
radicals degeneration (NQO1) and that of xenobiotic mechanism signaling (MGST1, 
NQO1, peroxisome proliferator-activated receptor (PPARGC1A). These pathways were 
enriched in non-responders, but also in responding patients (Table 2).
Comparison of gene expression pro les between FAE and etanercept
The di erentially expressed genes in the skin of FAE responders before and after treat-
ment were compared with the di erentially expressed genes before and after successful 
treatment with etanercept (10). When using the same cuto  values (>2-fold change, 
P<0.05), we found 112 upregulated and 208 downregulated genes (Figure 2a). We 
compared the change in gene expression of psoriasis related molecules during FAE and 
etanercept treatment and found an overlap of 122 signi cantly downregulated genes 
and of 35 signi cantly upregulated genes. Overlapping downregulated genes included 
CCL20, CXCL1, DEFB4 and several S100 family genes (Figure 2a). All overlapping genes 
are known markers of the psoriatic transcriptome (21-23) and are likely important for 
lesion improvement as they were downregulated during successful FAE as well as etan-
ercept treatment.
Several molecules and pathways that were di erentially expressed in FAE treated 
patients did not alter during etanercept treatment. FAE downregulated 170 genes and 
upregulated 131 genes that were not di erentialy a ected by etanercept treatment 
(Table 4). FAE speci c pathways included the Nrf2, superoxide radicals degradation, 
eicosanoid signaling and IL-17 signaling in  broblast pathways (Figure 2). NQO1 is 
part of the Nrf2 pathway (24). The aryl hydrocarbon receptor (AHR) can regulate the 
Nrf2 pathway and AHR knockdown in keratinocytes partly inhibits NQO1 induction by 
coal tar (25). During FAE treatment the AHR was not di erentially expressed, however 
Fig. 1. Reduction of phospho-STAT3 protein in the psoriatic epidermis during FAE treatment indica-
tive of inhibition of the Th17 pathway. Immuno uorescent staining in lesional psoriatic skin of a repre-
sentative responder patient to FAE treatment week 0 and at week 12. Phospho-STAT3 in green. Nuclei were 
stained with DAPI. Scale bar: 10 μm.
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the AHR signaling pathway was dierentially expressed in FAE responders, but not in 
etanercept responders.
Transcription factors
The dierential expression of transcription factors due to FAE treatment was compared 
with etanercept treatment. In etanercept responders 5 transcription factors were dier-
entially expressed, whereas in the FAE responders 9 transcription factors were dieren-
tially expressed (Table 3). FAE treatment specically reduced the transcription regulator 
NFκBIZ (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, 
zeta) and PTTG1 (pituitary tumor transforming gene 1) in lesional psoriatic skin (Table 
Etanercept 86 170 FAE
Number of genes downregulated 
following 12 weeks of treatment
Number of genes upregulated 
following 12 weeks of treatment
(a)
Top 5
SERPINB4, 
DEFB4A/DEFB4B, TCN1, 
S100A12, KRT16 
(b) Complete list FAE specific canonical pathways 
following 12 weeks of treatment
Role of IL-17A in arthritis
Top 5
IL37, ADH1B, 
LEPR, KRT15, 
CHP2
122 Etanercept 77 131 FAE35
Top 5
S100A7A, MMP1, PTX3, 
IL20, SOST
Top 5
AKR1B10, ZC3H12A, 
IFI6, TWF1, HERC6
Top 5
BTC, AADAC, 
NQ01, FLG, 
CYP4F3
Top 5
ADIP0Q, SORBS1, 
FABP4, SCGB1D2, 
PIP
p<0.0001
p<0.05
Eicosanoid signalling
LPS/IL-1 mediated inhibition of RXR
Tryptophan degradation 
IL-17A signalling in fibroblasts
Differential regulation of cytokine production,
in macrophages and T helper cells by IL-17
Aryl hydrocarbon receptor signalling
Hepatic cholestasis
Salvage pathways of pyrimidine deoxyribonucleotides
Citrulline-nitric oxide cycle
Phospholipases
Superoxide radicals degradation
Role of JAK1 and JAK3 in cytokine signalling
MSP-RON signalling
MIF-mediated glucocorticoid regulation
T helper cell differentiation
Heparan sulfate biosynthesis
Airway pathology in chronic obstructive pulmonary disease
IL-9 signalling
Retinol biosynthesis
Hematopoiesis from pluripotent stem cells
Fig. 2. Overlap in gene expression proles of responders to treatment with FAE or etanercept. Com-
parison of gene expression proles in psoriatic skin of patients achieving >75% improvement in PASI score 
following 12 weeks of treatment with either oral FAE or etanercept. (a) Venn-diagram comparing the over-
lap in genes signicantly (>2-fold change and p<0.05) downregulated or upregulated following 12 weeks 
of treatment. (b) Complete list of canonical pathways aected by FAE in responders following 12 weeks of 
treatment.
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3). In addition, FAE specically upregulated the transcription factors NR3C1 (Nuclear 
Receptor Subfamily 3, Group C, Member 1/ glucocorticoid receptor) and GATA3, which is 
an important regulator in T cell dierentiation (26). These transcription factors were not 
dierentially expressed during etanercept treatment.
DISCUSSION
This study assessed the mode of action of FAE by analyzing its eects on the gene 
expression prole in lesional psoriatic skin before and after 12 weeks of FAE treatment. 
We compared our ndings of FAE treatment with a previously published study that 
investigated gene expression during etanercept treatment (10). The comparison shows 
that FAE and etanercept have a considerable overlap in the aected pathways leading 
to psoriasis improvement, including the IL-17 pathway. Responders to FAE treatment 
showed a dierential expression after 12 weeks of many antimicrobial peptide genes. 
Antimicrobial peptides are signicantly upregulated in psoriatic skin representing a 
disturbance in innate immunity, an important aspect of the pathogenesis of the disease 
(27). Human β-defensin 2 even serves as a psoriasis disease severity biomarker (28). The 
dierential expression during successful FAE treatment is similar to the molecular eects 
of other systemic treatments for psoriasis and may represent a ngerprint of a successful 
psoriasis treatment response.
In vitro, dimethylfumarate (DMF) and its primary metabolite monomethylfumarate 
(MMF) induce the expression of the Nrf2/NQO1 pathway in endothelial cells (29). The 
Nrf2 pathway can be regulated by FAE in neurons and neuroprotective eects of fuma-
rates are dependant on Nrf2-mediated anti-oxidative pathways (24). An FAE-formulation 
containing dimethylfumarate (BG-12, Biogen Idec) was recently approved by the FDA 
Table 3. Dierentially expressed transcription factors in etanercept and FAE treated patients.
FAE Etanercept
Upstream 
regulator Fold change P-value
Upstream 
regulator Fold change P-value
NFKBIZ -2.96 2.96 × 10-3 EHF -5.33 5.30 × 10-3
EHF -2.53 1.39 × 10-2 STAT1 -3.11 8.00 × 10-7
STAT3 -2.28 4.72 × 10-4 TP63 -2.49 2.86 × 10-11
PTTG1 -2.22 4.58 × 10-2 STAT3 -2.18 1.22 × 10-7
ELF3 -2.06 1.01 × 10-3 ZEB1 2.03 1.05 × 10-3
STAT1 -2.00 3.50 × 10-6      
NR3C1 2.12 4.62 × 10-2      
GATA3 2.12 4.58 × 10-2      
ZEB1 2.30 4.58 × 10-2      
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for the treatment of multiple sclerosis (30, 31). The nervous system and neuronal factors 
promote inammation in psoriasis lesions, which are characterized by a high density 
of nerves and an increased expression of neurotrophins (32). The Nrf2 pathway has an 
important antioxidative function and is involved in epidermal barrier function (33). Our 
results show that in FAE treated responding as well as non-responding patients the Nrf2 
pathway is activated and the expression of its major eector molecule NQO1 is induced. 
The aryl hydrocarbon receptor (AHR) can regulate the Nrf2 pathway and AHR knock-
down in keratinocytes partly inhibits the induction of NQO1 by coal tar (25). However, 
during FAE treatment the AHR was not dierentially expressed, therefore additional 
mechanisms might play a role in FAE induced activation of the Nrf2 pathway. The Nrf2 
pathway was dierentially expressed in FAE responders as well as non-responders, but 
not in etanercept treated patients, which suggests an FAE specic eect.
In addition, the glutathione pathway was only activated in FAE treated patients and 
not in the etanercept group. This was evidenced by an upregulation of several gluta-
thione transferases and depletion enzymes in responding as well as in non-responding 
Table 4. FAE-specic induced downregulated (a) and upregulated (b) molecules (top 20), not regulated by 
etanercept therapy in responders at 12 weeks of treatment.
(a)
Gene name Description Fold change Adjusted p-value
S100A7A S100 calcium binding protein A7A -47.656 < 10-12
MMP1 matrix metallopeptidase 1 -10.493 < 10-12
PTX3 pentraxin 3, long -5.56 1.93 × 10-6
IL20 interleukin 20 -5.481 < 10-12
SOST sclerostin -4.78 2.04 × 10-4
LRG1 leucine-rich alpha-2-glycoprotein 1 -4.748 6.60 × 10-11
GJB2 gap junction protein, beta 2, 26kDa -4.608 6.60 × 10-11
TNIP3 TNFAIP3 interacting protein 3 -4.578 3.53 × 10-10
SPRR3 small proline-rich protein 3 -4.558 3.19 × 10-7
FPR1 formyl peptide receptor 1 -4.541 < 10-12
XDH xanthine dehydrogenase -4.246 2.71 × 10-9
HAS3 hyaluronan synthase 3 -3.845 < 10-12
IL36A interleukin 36, alpha -3.601 2.87 × 10-4
C15orf48 chromosome 15 open reading frame 48 -3.525 8.64 × 10-9
ACTA1 actin, alpha 1, skeletal muscle -3.483 3.61 × 10-3
IL17A interleukin 17A -3.379 1.06 × 10-5
LCE3D late cornied envelope 3D -3.333 1.41 × 10-2
SLPI secretory leukocyte peptidase inhibitor -3.175 < 10-12
TDO2 tryptophan 2,3-dioxygenase -3.084 1.40 × 10-5
CDH26 cadherin 26 -3.067 4.99 × 10-9
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patients including glutathione peroxidase 2 (GPX2), microsomal glutathione S-transfer-
ase 1 (MGST1) and glutathione S-transferase mu 3 (GSTM3). The activation suggests a 
specic eect of FAE, however it is not critical for substantial psoriasis plaque clearance. 
Therefore, FAE dependant glutathione depletion might not be required for improve-
ment of clinical disease. In vitro, dimethylfumarate has been shown to interfere with the 
glutathione pathway in human monocytes and T cells as well as in mouse dendritic cells 
(34, 35). Dimethylfumarate binds to glutathione and the consequent functional deple-
tion of intracellular glutathione leads to the induction of heme oxygenase-1 (HO-1) (35). 
HO-1 induction leads to an inactivation of STAT1 which prevents IL-12p35 transcription. 
Transcription of IL-23p19 is also impaired due to binding of a part of HO-1 to the IL-
23p19 promoter (34). In previous in vitro studies, HO-1 was identied as a key molecule 
induced by FAE. However, a study that determined glutathione S-transferases (GSTs) 
genotyping and phenotyping found no dierences in allelic variants and enzymatic 
activity of GSTT1 and responder status to FAE treatment (36).
FAE have shown in vitro eects on T cells (37) and helper (Th) cell dierentiation (38, 
39). GATA3 is an important transcription factor and regulator in T cell development and 
regulation by GATA3 leads to Th2 cell dierentiation (26), in addition GATA3 is involved 
(b)
Gene name Description Fold change Adjusted p-value
BTC betacellulin 4.705 9.24× 10-8
AADAC arylacetamide deacetylase 4.154 2.95× 10-4
NQO1 NAD(P)H dehydrogenase, quinone 1 3.995 < 10-12
FLG laggrin 3.765 8.98× 10-4
CYP4F3 cytochrome P450, family 4, subfamily F3 3.588 < 10-12
LOR loricrin 3.557 3.94× 10-3
SLC1A6 solute carrier family 1, member 6 3.552 7.97× 10-9
AKR1C1/C2 aldo-keto reductase family 1, member C2 3.551 < 10-12
SPINK7 serine peptidase inhibitor, Kazal type 7 3.151 3.37× 10-2
SGCG sarcoglycan, gamma 3.03 2.16× 10-10
CLDN11 claudin 11 3.008 5.29× 10-8
CYP39A1 cytochrome P450, family 39, subfamily A1 2.979 < 10-12
SOSTDC1 sclerostin domain containing 1 2.957 2.90× 10-9
ANGPTL1 angiopoietin-like 1 2.95 4.80× 10-4
SCEL sciellin 2.836 < 10-12
SCARA5 scavenger receptor class A, member 5 2.834 5.60× 10-8
GSTM3 glutathione S-transferase mu 3 2.832 < 10-12
IL17D interleukin 17D 2.781 6.03× 10-12
DCT dopachrome tautomerase 2.7 3.01× 10-11
ELMOD1 ELMO/CED-12 domain containing 1 2.685 4.59× 10-5
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in normal epidermal development (15). GATA3 was signicantly upregulated only in the 
FAE treated responders, but not in the etanercept treated responders. This suggests that 
Th2 cell development/skewing is an important target of FAE, which is also illustrated by 
the known induction of IgE by FAE. In addition, NR3C1 was signicantly upregulated. 
This glucocorticoid receptor is important for normal cutaneous development and in ke-
ratinocyte specic glucocorticoid receptor knockout mice the epidermis shows altered 
levels of many innate immunity genes including S100A8 (calgranulin-A) and S100A9 
(calgranulin-B) (40). The FAE specic upregulation represents a shift from an abnormal 
to normal phenotype of the epidermis in responders to FAE treatment. The transcrip-
tion factor PTTG1 is involved in keratinocyte proliferation and dierentiation and is 
overexpressed in psoriatic skin. Overexpression of PTTG1 results in an overproduction 
of TNF-α (41). FAE specically reduced the expression of PTTG1 that was not reduced in 
etanercept treated patients.
The NFκBIZ (IκBζ) gene encodes the transcription factor IκBζ, which is required for 
Th17 development in mice. NFκBIZ decient mice are not able to produce Th17 cells 
(42, 43). The observed downregulation of IκBζ expression in our human psoriatic skin 
samples likely is important in the inhibition of the Th17 pathway, although this should 
be conrmed in further experiments. Interestingly, this transcription factor was not dif-
ferentially expressed in etanercept treated patients, but only in FAE treatment respond-
ers.
In conclusion, FAE specic induced pathways in the skin include activation of the 
Nrf2 and glutathione pathways. Response-to-treatment related FAE specic molecules 
are the transcription factors PTTG1 and NR3C1, respectively important in keratinocyte 
regulation and normal cutaneous development, and GATA3 and NFκBIZ, respectively 
important in Th2 and Th17 cell development.
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Supplementary Table 1: Dosage schedule of fumaric acid ester treatment.
Week Fumarates 105 mg tablets/day Fumarates 215 mg tablets/day
1 1 -
2 2 -
3 3 -
4 - 1
5 - 2
6 - 3
7 - 4
8 - 5
9-12 - 6
Fumarates 105 mg (Pharmacy ‘de Magistrale Bereider’, Oud-Beijerland, the Netherlands) contains 30 mg 
dimethylfumarate and 75 mg calcium-monoethylfumarate per enteric-coated tablet. Fumarates 215 mg 
contains 120 mg dimethylfumarate and 95 mg calcium-monoethylfumarate per enteric-coated tablet.
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Supplementary Table 4: Top 20 of genes signicantly downregulated in responders following 12 weeks 
of treatment with FAE.
Gene name Description Fold change Adjusted 
P-value
SERPINB4 serpin peptidase inhibitor -70.51 5.44 × 10-10
DEFB4A/DEFB4B defensin, beta -55.43 < 10-12
S100A7A S100 calcium binding protein (psoriasin) -47.66 < 10-12
TCN1 transcobalamin I (vit B12 binding protein) -35.59 < 10-12
S100A12 S100 calcium binding protein -25.51 6.03 × 10-12
KRT16 keratin 16 -20.06 < 10-12
PI3 peptidase inhibitor, skin derived -19.17 6.03 × 10-12
IL8 interleukin 8 (CXCL8) -17.02 6.03 × 10-12
KRT17 keratin 17 -15.71 < 10-12
SPRR2C small proline-rich protein -15.33 5.91 × 10-9
IL19 interleukin 19 -14.81 1.14 × 10-10
LCN2 lipocalin 2 -14.06 < 10-12
KLK6 kallikrein-related peptidase -11.90 6.03 × 10-12
KRT6A keratin 6A -11.26 < 10-12
KRT6B keratin 6B -10.99 < 10-12
MMP1 matrix metallopeptidase -10.49 < 10-12
LTF lactotransferrin  -9.93 7.62 x 10-9
RHCG R h family C glycoprotein  -9.67 < 10-12
CXCL1 chemokine (C-X-C- motif ) ligand 1  -8.87 < 10-12
ATP12A ATPase, H+/K+ transporting nongastric alpha 
polypeptide
 -8.61 2.12 × 10-8
Supplementary Fig. 1. Clinical response during FAE treatment. (a) Change in median PASI in the total 
group of patients (n=50) during FAE treatment. Bars represent median and interquartile range. Wilcoxon 
Signed Rank Test *P<0.05. (b) PASI reduction in the selected responders (n=4) and non-responders (n=5) 
after 12 weeks. Bars represent median and interquartile range. Mann-Whitney U test *P<0.05.
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Supplementary Fig. 2. Selected molecules for con rmation by qRT-PCR in responding patients after 
12 weeks of FAE treatment. The mRNA expression was measured by quantitative RT-PCR in biopsies from 
psoriatic lesions at baseline and after 12 weeks of FAE treatment in the responders (n=6-15). The Y-axis 
shows expression relative to that of the housekeeping gene ABL1. Wilcoxon Signed Rank Test, *P<0.05, 
error bars indicate the SEM.
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ABSTRACT
Background
Ustekinumab is a fully human anti-p40 mAb which neutralizes IL-12 and IL-23, thereby 
interfering with Th1/Th17 pathways and keratinocyte activation, and is highly eective 
in psoriasis. During ustekinumab treatment, some of our patients noticed reduced 
Koebnerisation of non-involved skin and less new plaque formation. Objectives were 
to determine whether ustekinumab improves psoriasis-related gene expression and 
tape-strip responses in non-involved skin.
Methods
Before and 4 weeks after ustekinumab treatment, non-involved skin was tape-stripped. 
After 5 h, biopsies were taken from untouched and tape-stripped skin. The mRNA 
expression of psoriasis-related markers such as NGF, GATA3 and IL-22RA1, and several 
antimicrobial peptides (AMP) was quantied. Leucocyte counts and a broad range of 
inammatory serum proteins were analysed to get insight into the systemic alterations.
Results
Four weeks following a single ustekinumab injection, NGF showed a signicant 
decrease, whereas GATA3 and IL-22RA1 expression increased, indicative of reduced 
responsiveness to epidermal triggering. This was accompanied by an increase of the 
inammation-related serum proteins GPNMB, MST1 and TRADD. The baseline and the 
tape-strip-induced expression of the AMP DEFB4 (hBD-2), S100A7 and LL-37 remained 
unaltered. Clinically, after 4 weeks, 8 out of 11 patients showed a 50% PASI improvement, 
which was accompanied by a signicant reduction in serum hBD-2 levels. No changes 
were noted in total leucocytes, CRP, and sedimentation rate.
Conclusions
These ndings indicate that ustekinumab reduces psoriasis-related gene expression in 
non-involved psoriatic skin, making it more resistant to exogenous triggering, without 
disturbing its antimicrobial response. In parallel, ustekinumab modulates important 
circulating inammation-related proteins.
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INTRODUCTION
Psoriasis is an inammatory skin disease induced by an aberrant interaction between 
the immune system and the skin, in which the IL-23/Th17 axis is critical (1). Ustekinumab 
is a human monoclonal Ab against the shared p40 subunit of IL-12 and IL-23 (2). In clini-
cal trials, ustekinumab achieved PASI-75 (75% reduction in Psoriasis Area and Severity 
Index) in 60% of patients with moderate to severe psoriasis after 8 weeks of therapy 
(3, 4). Some patients showed a prolonged PASI-75 response following three injections 
of ustekinumab (3, 4). In some of our patients, this prolonged eect was accompanied 
by the prevention of new plaque formation and less Koebnerization after skin trauma 
(Supplemental Table 1). The mechanisms underlying this prolonged clinical response to 
ustekinumab remain unclear. Until now, research has focused on involved skin and on a 
limited set of systemic inammatory markers.
Previous studies showed that after 12 weeks of treatment, ustekinumab induced 
minimal alterations in the percentage of CLA+ T cells in plaques with no signicant 
alterations in the percentage of CD45RA+, CD45RO+, CD25+, HLA-DR+, and CXCR3+ 
cells (5). Serum levels of IL-8, IL-10, TNF-α, sICAM-1, and CCL27 remained unchanged 
during clinically eective ustekinumab treatment (6). In vitro, ustekinumab eectively 
neutralized IL-12 and IL-23 produced by activated human PBMC, resulting in decreased 
expression of skin homing and activation markers, and IL-12- and IL-23-induced cytokine 
secretion (5, 7). The latter is critical in the epidermal response to cutaneous triggering 
by tape-stripping and induction of antimicrobial peptides (AMP) (7, 8). AMP can trig-
ger chemotaxis, angiogenesis, and keratinocyte proliferation, which are all important 
features in the pathogenesis of psoriasis. Among the AMP, especially β-defensin-2 
(hBD-2) is overexpressed in psoriatic plaques relative to atopic dermatitis and healthy 
skin (9, 10). The importance of hBD-2 in psoriasis is underscored by the increase in 
DEFB4, the gene coding for hBD-2, genomic copy number in patients with psoriasis (11). 
Systemic hBD-2 levels show a positive correlation with disease activity as assessed by 
the PASI score (12). Strongly increased levels were also found in the urine of psoriasis 
patients whereas hBD-2 could not be detected in urine of healthy controls. Interestingly, 
rheumatoid arthritis patients showed hBD-2 serum levels similar to control individuals. 
These ndings suggest that increased systemic hBD-2 levels are almost entirely derived 
from psoriatic plaques (12). Ustekinumab signicantly reduced psoriasis-related gene 
expression in plaques, including hBD-2 and S100A7, down to levels of non-involved skin, 
but not to the levels of healthy skin (13). The production of AMP is highly dependent 
on IL-22 (8). Eects of IL-22 are mediated via the IL-22 receptor, which is composed of 
two subunits IL-22RA1 and IL-10R2, and subsequently via STAT3, a psoriasis-associated 
marker relevant for epidermal hyperplasia (14).
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The prolonged clinical response, together with our observations of prevention of new 
plaque formation and a reduced Koebner response during ustekinumab treatment, led 
us to hypothesize that ustekinumab does not only act on the ongoing pathogenic pro-
cesses in inamed skin, but also has protective inhibitory eects in non-involved skin. 
Non-involved skin has an intermediate gene expression prole that lies in between pso-
riatic and normal skin, and is also called ‘pre-psoriatic’ skin (15). Little is known about the 
eects of biologics in non-involved skin in general and specically about ustekinumab.
Tape-stripping is considered a cutaneous trigger mimicking the Koebner response 
and the initiation of psoriasis, because it rapidly induces several psoriasis-related his-
tological alterations and molecular markers such as hBD-2 and S100A7 (16), and nerve 
growth factor (NGF) (17). The transcription factor GATA3 is classically involved in Th2 
dierentiation, but GATA3 is also crucial in epidermal dierentiation, epidermal barrier 
formation and in the formation of lamellar bodies which store several antimicrobial 
peptides such as LL-37 and hBD-2 (18, 19). GATA3 is essential for formation of a normal 
healthy epidermal architecture and proper functioning of the epidermal lipid barrier-
innate immune axis (20). Furthermore, β-defensins and S100A proteins are upregulated 
in the skin of epidermis-specic GATA3 knock-out mice (20). We recently showed that 
epidermal GATA3 is downregulated in psoriatic plaques, during wound healing, and in 
non-involved psoriatic skin 5 h after tape-stripping (21).
We hypothesized that by blocking IL-12/IL-23, ustekinumab would reduce the ‘pre-
psoriatic’ expression levels of psoriasis-related genes in non-involved skin to levels com-
parable with healthy skin. Hence, the aim of our study was to assess whether successful 
ustekinumab treatment inhibited the expression of psoriasis-related markers and AMP 
in non-involved skin and their response to tape-stripping, thereby preventing new 
plaque formation. In addition, we analysed the inammatory changes in serum induced 
by ustekinumab using a broad cytokine-array, and measured hBD-2 levels as a marker of 
psoriasis disease activity.
MATERIALS AND METHODS
Patients and ustekinumab treatment
Eleven patients (5 male, 6 female), age range 29-71 years, all from native European/
Dutch origin and a PASI score > 10, were enrolled after informed consent. All patients 
(Table 1) did not receive systemic therapy or UVB treatment for at least three months or 
topical treatment for at least three weeks prior to the start of the study. At start and 4 
weeks after rst injection, the clinical severity was assessed using the PASI score. Patients 
received a subcutaneous injection of 45 mg ustekinumab (Stelara™, Janssen, Belgium) 
at start. The study was approved by the medical ethical committee of the Erasmus MC 
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(ethical review board registration number 234.237/2003/210) and conducted accord-
ing to the Declaration of Helsinki principles. Following this study, the included patients 
continued with ustekinumab treatment according to national guidelines.
Tape-stripping
Tape-stripping of non-involved psoriatic skin is a model for studying epidermal events 
in the initiation of psoriasis (16, 17). At baseline and 4 weeks following injection of 
ustekinumab, an area of non-involved skin (3x2 cm) was tape-stripped consisting of 
repeated (40 times) application of sellotape and removal of stratum corneum until the 
skin got a shiny appearance (22). Tape-stripping was standardized for time of the day (all 
before noon) and anatomical body site (medial side of the knee) and at least 3 cm away 
from a psoriatic plaque. During the subsequent 6 months, the tape-stripped areas were 
assessed monthly by clinical scoring (Koebner positive or negative).
Biopsies and RNA extraction
Before initiation of treatment and 4 weeks following rst injection of ustekinumab, 5mm 
biopsies were taken from tape-stripped and adjacent non-involved skin, 5 h after tape-
stripping, using local anaesthesia. The biopsies were divided into one part for immuno-
histochemistry and another for quantitative mRNA analysis. Epidermis was separated 
from the dermis after incubation in 1 mg/ml protease X (Sigma Aldrich, Zwijndrecht, the 
Netherlands) for 90 min at 37 °C. Total RNA was isolated from the epidermis, using Gen-
Elute Mammalian Total RNA Miniprep kit (Sigma Aldrich). RNA purity and integrity was 
veried by scanning with an Agilent 2100 Bioanalyzer using the RNA 6000 NanoLabChip.
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
RNA was transcribed into cDNA, and RT-PCR was conducted as previously described (21-
23). The sequences of the used primers and probes of selected markers were all based 
on the Exiqon probe library system (Exiqon, Vedbaek, Denmark) and are listed in Table 1. 
In order to investigate the short term eects of ustekinumab on the epidermal response 
to tape-stripping, we measured the expression of the psoriasis-related markers: GATA3, 
IL-22 receptor alpha 1 (IL-22RA1), NGF, DEFB4 (hBD-2), S100A7, LL-37, and STAT3. Abel-
son murine leukemia viral oncogene homolog (ABL1) was used as a reference gene in 
all qPCR experiments. Expression of this gene remained stable during treatment with 
ustekinumab.
Immunouorescence
For immunouorescent staining, cryosections were xed for 10 min in 4% paraformal-
dehyde in PBS. Monoclonal Ab anti-GATA3 (1:100; Santa Cruz Biotechnology, Santa 
Cruz, CA) was used as primary antibody. TxR-conjugated antibodies (1:100, Abcam, 
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Cambridge, MA) were used to detect the primary antibody. Fluorescent images were 
taken with an Axio Imager uorescence microscope (Carl Zeiss Mircoimaging GmbH, 
Jena, Germany).
Serum sampling
Blood samples were taken at baseline and 4 weeks following single injection of 
ustekinumab. Samples were centrifuged, and serum was collected and frozen at -80 ºC 
until analysis. As global markers of systemic inammation, we investigated erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), and leucocyte counts (monocytes, 
immature granulocytes, neutrophils, eosinophils and lymphocytes).
Serum proinammatory cytokinearray analysis
Simultaneous detection of 507 unique growth factors, cytokines, and receptors was per-
formed using glass slide-based microarrays (RayBiotech, Inc., Norcross, GA) coated with 
capture antibodies, according to the manufacturer’s instructions. Briey, serum samples, 
taken at start and 4 weeks following injection of ustekinumab from 4 randomly chosen 
patients with a PASI reduction greater than 50% at week 4, were independently dialyzed 
and biotinylated. The biotinylated serum samples were added to 4 individual protein 
array slides. After incubation with Cy3-labelled streptavidin, the arrays were scanned 
using a laser confocal scanner (Tecan Benelux; Mechelen, Belgium). Internal controls 
were included as a control of performance. Total signal strength for specic proteins was 
based on the average of a triplicate. Since this protein array does not allow for the quan-
tication of proteins by comparison with a standard curve, data were normalized using 
the internal control as indicated by the manufacturer, and were log2 transformed. This 
strategy provided a relative estimate of marker abundance in the sample. Because the 
protein array detects only relative expression levels and not absolute values, there is no 
Table 1. Primer sequences
HUGO
gene name
Synonym Forward primer 5’-3’ Reverse primer 5’-3’
ABL1 Abelson murine leukemia
viral oncogene homolog 1
t g g a g a t a a c a c t c t a a g c a t a a c t a 
a a g g t 
g a t g t a g t t g c t t g g g a c c c a 
CAMP LL-37, cathelicidin t c g g a t g c t a a c c t c t a c c g g t c t g g g t c c c c a t c c a t 
DEFB4 hBD-2 t c a g c c a t g a g g g t c t t g t a g g a t c g c c t a t a c c a c c a a a 
GATA3 GATA-binding factor 3 g c t t c g g a t g c a a g t c c a g c c c c a c a g t t c a c a c a c t 
IL22RA1 IL-22 receptor, alpha 1 c a c c t c c c a a c t c c c t g a c g t g c t c c t g g a t g a a g c 
NGF nerve growth factor t c c g g a c c c a a t a a c a g t t t g g a c a t t a c g c t a t g c a c c t c 
S100A7 psoriasin c t g c t g a c g a t g a t g a a g g a c g a g g t a a t t t g t g c c c t t t 
STAT3 signal transducer and activator
of transcription 3
t g a t g c a g t t t g g a a a t a a t g g c a t g t c a a a g g t g a g g g a c t c 
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dened lower detection limit. However, to increase the specicity, we have removed all 
data values smaller and equal to the noise level (based on the negative control values). 
Next we only kept measurements that had values above the negative control for each 
timepoint and for all 4 samples, and this resulted in data remaining for 240 proteins. 
We have normalized the dataset for each sample protein array to its mean to allow for 
better comparison between samples. Proteins were selected that showed dierential 
expression across all 4 donors, based on 2-sided paired t-test.
Bioinformatics analysis
Out of the total of 507 proteins, 490 proteins were recognized by Ingenuity Pathway 
Analysis (IPA, Ingenuity Systems) and therefore suitable for further bioinformatics analy-
sis. The dierentially expressed proteins in serum at 4 weeks after ustekinumab injection 
were subjected to IPA to detect interactions with psoriasis related proteins.
ELISA
Serum samples of 0 and 4 weeks of patients (n=11) were analyzed for hBD-2 concentra-
tion using ELISA. Anity-puried chicken anti-hBD-2 was used to coat 96-well microtiter 
plates. After blocking with 1% (v/v) BSA, samples were diluted to t the calibration 
curve-range (33-500 pg/ml), followed by goat anti-hBD-2 (Abcam) as a detection an-
tibody, and amplication using the ABC kit (Vector Laboratories, Inc., Burlingame, CA). 
All steps were followed by appropriate rinsing in phosphate-buered saline with 0.05% 
(v/v) Tween-20. The serum hBD-2 concentrations were read from a calibration curve of 
recombinant hBD-2 (Pepro Tech, Inc., Rocky Hill, NJ), with a detection limit of 0.03 ng/ml.
Statistics
Experimental data were tested for statistical signicance at P<0.05 using a Student’s 
paired t-test (one-tailed) with GraphPad Prism v5.04 (GraphPad Software, Inc., La Jolla, 
CA). P-values are designated as P<0.05 (*) and P<0.01 (**).
RESULTS
Clinical ecacy of ustekinumab treatment
The clinical ecacy of ustekinumab was apparent from the PASI score at week 4. The 
mean PASI reduction in all patients was 55% (range 0-75%). Overall 8 out of 11 patients 
achieved a greater than 50% reduction in their PASI score (PASI>50) at week 4, a level 
of improvement qualifying them as responders. Three patients (numbers 4, 9, and 10) 
showed high initial PASI (Table 2) and all three did not reach a PASI-50 reduction at week 
4 (Fig. 1).
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Table 2. Demographics, disease characteristics, and medical history of patients
No Age PASI
Start
Koebner Psoriasis type Weight (kg) Previous treatments
wk 0 wk 4
1 ♀ 50 11 neg neg Plaque 70 NB-UVB, MTX, fumaric acid, 
etanercept
2 ♂ 47 17 neg neg Plaque 90 NB-UVB, MTX, fumaric acid, 
etanercept
3 ♀ 31 15 neg neg Plaque/Guttate 56 NB-UVB, MTX, fumaric acid
4 ♂ 62 25 neg neg Plaque; large BSA 90 NB-UVB, PUVA, MTX, fumaric acid, 
etanercept, iniximab
5 ♀ 71 11 neg neg Plaque 80 NB-UVB, MTX, fumaric acid
6 ♀ 38 12 neg neg Plaque 90 NB-UVB, MTX, cyclosporin
7 ♀ 67 15 neg neg Plaque 100 NB-UVB, PUVA, fumaric acid, 
etanercept,
8 ♀ 38 10 neg neg Plaque 70 MTX, fumaric acid, etanercept
9 ♂ 48 25 pos pos Plaque; large BSA >100 NB-UVB, MTX, fumaric acid, 
efalizumab, iniximab
10 ♂ 58 25 pos pos Plaque; large BSA 80 MTX, fumaric acid, etanercept, 
iniximab
11 ♂ 29 13 neg neg Plaque 90 NB-UVB, MTX, fumaric acid
NB-UVB: narrow band UVB; MTX: methotrexate; PUVA: psoralen + UVA
Fig 1. PASI response to ustekinumab treatment
Clinical response to ustekinumab treatment. Eight out of eleven patients achieved at least PASI-50 and 
PASI-75 at respectively week 4 and week 16 (collectively displayed as lower line with full circles). Three 
patients (4, 9, 10) did not reach 50% improvement at week 4 and therefore received a double dose (90 mg) 
of ustekinumab. These patients had higher initial PASI scores (note interrupted y-axis) and their mean PASI 
improvement at week 16 was 57%. The x-axis represents time in weeks, the y-axis mean PASI-score +/- SEM.
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Response of psoriasis related markers to tape-stripping of non-involved skin
The mRNA expression in tape-stripped non-involved skin was measured 5 h following 
tape-stripping (TS) and compared with the baseline expression in non-involved skin 
(PN). Before treatment, tape-stripping signi cantly suppressed the expression of GATA3 
and IL-22RA1, whereas NGF and STAT3 expression increased (respectively P-values of 
0.02, 0.01, 0.02 and 0.04). All three AMP (DEFB4, S100A7 and LL-37), showed an upward 
trend following tape-stripping, but this did not reach statistical signi cance (Fig. 2).
E ects of ustekinumab on psoriasis-related markers in non-involved skin
The epidermal mRNA expression of psoriasis-related epidermal markers was  rst mea-
sured in non-involved unmanipulated skin, before and 4 weeks after  rst injection of 
ustekinumab. In responders (n=8), the expression of epidermal GATA3 and IL-22RA1 
mRNA showed a signi cant increase (P=0.01 and 0.03 respectively) compared to pre-
treatment baseline levels. We observed no changes in the expression of NGF, DEFB4, 
LL-37, S100A7 and STAT3 (Fig. 3a). GATA3 protein expression was also detected in situ, 
in the same biopsies. Before ustekinumab treatment GATA3 was expressed only in the 
basal layer of non-involved skin (Fig. 4a). Four weeks after injection of ustekinumab, 
GATA3 expression increased in intensity and was now present in multiple epidermal cell 
layers, extending up to the granular layer (Fig. 4b).
E ects of ustekinumab on the epidermal response to skin triggering by tape-
stripping
Four weeks after injection of ustekinumab, tape-stripped skin showed a signi cant 
upregulation of both GATA3 and IL-22RA1 mRNA compared to tape-stripped skin before 
treatment (P=0.01). An opposite e ect was observed with the induction of NGF by tape-
stripping, which was signi cantly inhibited following ustekinumab injection (P=0.01). 
Fig 2. Response of psoriasis related markers in non-involved skin to tape-stripping
The x-axis represents non-involved psoriatic skin (PN) and tape-stripped skin (TS), before treatment. Each 
data point in non-involved skin is linked to the corresponding data point in tape-stripped skin per indi-
vidual patient. Selected donors comprise only patients showing >50% PASI improvement to ustekinumab 
treatment (n=8). The y-axis represents the gene expression of selected epidermal psoriasis-markers GATA3, 
IL-22RA1, NGF, DEFB4, S100A7, LL-37 and STAT3, relative to ABL (*P<0.05, **P<0.01, by paired t-test).
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Fig 4. Early response to ustekinumab is paralleled by increased GATA3 expression in non-involved 
skin.
(a) Before treatment, immuno uorescence staining of non-involved skin showed modest GATA3 protein 
expression in the suprabasal layers of the epidermis. After 4 weeks of ustekinumab treatment, a stronger 
GATA3 protein expression was seen in the basal and the suprabasal epidermal layers (b). Images of repre-
sentative responder to ustekinumab treatment, and displayed at a magni cation of 100x, with scale bar 
representing 50 μm.
Fig 3. Ustekinumab targets non-involved: increased GATA3 and IL-22RA1, reduced NGF, whereas 
DEFB4, LL-37 and S100A7 remain unaltered in response to tape-stripping
Epidermal mRNA levels of GATA3, IL-22RA1, NGF, DEFB4, S100A7, LL-37 and STAT3 in non-involved psoriatic 
skin (a) and tape-stripped skin (b), before (week 0) and 4 weeks following injection with 45 mg ustekinum-
ab. The x-axis represents time in weeks and the y-axis represents the gene expression of selected epidermal 
markers relative to ABL. Note the interruption of the y-axis with DEFB4, S100A7 and LL-37. Each data point 
represents an individual patient before and after therapy with >50% PASI improvement (n=max 8, *P<0.05, 
**P<0.01, by paired t-test).
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In contrast, ustekinumab did not clearly aect the tape-strip-induced expression of the 
AMP DEFB4, S100A7, LL-37, and of STAT3 (Fig. 3b).
The Koebner response to tape-stripping of non-involved skin
All patients that were considered responders to ustekinumab (n=8), based on a PASI >50 
improvement at week 4, did not develop a Koebner response upon rst tape-stripping, 
as assessed by visual scoring. Patients 9 and 10 showed positive Koebner responses to 
tape-stripping (Table 2).
Ustekinumab does not aect general serum inammatory markers and 
leucocyte counts
At start, and 4 weeks following rst ustekinumab injection, blood samples from patients 
were evaluated for the eects of ustekinumab on the general serum inammatory marker 
ESR, and leucocyte counts. These were in all patients within normal ranges. No signi-
cant alterations were observed in ESR or in the leucocyte counts during ustekinumab 
treatment (data not shown).
Ustekinumab treatment aects several inammation-related serum proteins.
We have identied 3 proteins that show a signicant upregulation by ustekinumab 
treatment (Table 3): transmembrane glycoprotein NMB (GPNMB; also denoted as os-
teoactivin), macrophage stimulating 1 (MST1; also known as macrophage stimulating 
protein (MSP), and tumour necrosis factor receptor type 1-associated DEATH domain 
(TRADD).  Using IPA, a set of 9 molecules (amongst them IL12B) was identied that 
are known to have direct interactions with 2 or 3 of the 3 identied protein. From this 
analysis it is clear that all 3 molecules are heavily involved in the control of IL12B. To 
control for bias in our analysis we checked several random sets of 3 molecules out of the 
total set of 490 unique proteins on the chip and with these random sets of 3 we did not 
nd any shared interacting molecules, instead only unique interactors for each of the 3 
randomly chosen molecules were identied. In addition, while 2 out of the 3 identied 
proteins have a direct interaction with IL12B (66%), when we look at all 490 proteins, 
only 59 show a direct interaction with IL12B (12%) (Table 3). We believe this approach 
shows a clear enrichment for IL12B related signaling that is specic for the top 3 proteins 
identied from the protein array experiments.
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Successful ustekinumab treatment of psoriasis is associated with 
downregulation of serum hBD-2
The release of hBD-2 in serum by psoriatic plaques is thought to be driven by Th1/
Th17 stimulation. Serum hBD-2 signicantly decreased (P=0.0171) in responders to 
ustekinumab (Fig. 5), whereas three non-responding patients did not show a signicant 
change in hBD-2 (data not shown).
Table 3. Bioinformatics prediction of interacting molecules with GPNMB, MST1 and TRADD
Interactors for
GPNMB/MST1/TRADD
# interact with 
GPNMB/MST1/TRADD
% interact with 
GPNMB/MST1/TRADD
# interact with 
all 490
% interact with 
all 490
CASP8 2 66.7 65 13.3
ERK 2 66.7 106 21.7
FAS 2 66.7 51 10.4
IKBKB 2 66.7 20 4.1
IL6 3 100.0 171 35.0
IL12B 2 66.7 59 12.1
NFKBIA 2 66.7 71 14.5
STAT1 2 66.7 88 18.0
TNF 2 66.7 175 35.8
Fig 5. Serum hBD-2 levels correlate with ustekinumab-induced clinical improvement
hBD-2 serum protein levels in responders to ustekinumab treatment, before (week 0) and 4 weeks follow-
ing 45 mg ustekinumab. The x-axis represents time in weeks, the y-axis hBD-2 in ng/ml. Results displayed as 
oating boxes +/- SEM. Results were statistically analysed by paired t-test (* P<0.05).
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DISCUSSION
This study demonstrates that clinically eective ustekinumab treatment improves 
psoriasis-related gene expression in non-involved psoriatic skin without disturbing its 
antimicrobial response. Ustekinumab increased the expression of GPNMB, MST1 and 
TRADD, all known controllers of IL-12B. This improvement of systemic inammation may 
contribute to the observed ndings in non-involved skin. Our nding that successful 
ustekinumab treatment does not inuence AMP responses to cutaneous triggering, 
suggests a stable AMP function in innate skin immune defence during ustekinumab.
Our results show that ustekinumab enhances the epidermal expression of GATA3 
and IL-22RA1 in non-involved skin. We recently introduced epidermal GATA3 expres-
sion as a marker that is inversely correlated with psoriatic disease activity (21, 24). The 
observed increase in GATA3 expression in both non-involved and tape-stripped skin by 
ustekinumab therapy may reect a reduction of the pre-psoriatic state (15).
IL-22R signaling is important in regulating the expression of inammatory molecules 
and AMP in epithelia, especially in psoriasis (25). Previous studies in psoriasis did not 
demonstrate any eect of drugs such as cyclosporin or calcipotriol on IL-22R mRNA 
expression in vivo (26). Our nding that IL-22RA1 is decreased in untreated and non-
involved psoriatic skin within 5 h following tape-stripping, adds to the understanding of 
IL-22 responses, especially following wounding and in psoriasis. The suppressive eects 
of ustekinumab on the induction of epidermal IL-22RA1 mRNA by tape-stripping in 
combination with lowered IL-22 serum levels could represent a compensatory feedback 
mechanism in the skin (27).
Keratinocyte cultures from non-involved psoriatic skin show ten-fold more NGF 
production compared to keratinocytes from healthy individuals. The role of NGF in the 
pathogenesis of psoriasis is further substantiated by the observation that K252a, an NGF 
receptor antagonist, improved psoriasis (28). A similar improvement was achieved by 
directly inhibiting NGF with a neutralizing antibody (28). The reduced upregulation of 
NGF mRNA following tape-stripping may reect further stabilization of non-involved 
skin during ustekinumab treatment.
Tape-stripping enhances epidermal AMP expression, irrespective of the genetic 
background of the skin disease, such as psoriasis and atopic dermatitis (16). The expres-
sion levels of epidermal DEFB4, S100A7, LL-37 and STAT3 remained unaltered, both in 
unmanipulated non-involved skin and in triggered non-involved skin, indicating that 
after a dose of 45 mg ustekinumab, the epidermal antimicrobial response remains intact 
during ustekinumab-induced clearance of psoriasis.
Previous reports on the treatment of psoriasis showed only limited systemic eects of 
ustekinumab. However, these studies were limited in the total number of serum proteins 
studied. The combined use of bioinformatics analysis and a large-scale screening of 
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serum protein changes after a single ustekinumab injection generated a novel set of 
proteins which respond to successful treatment. GPNMB has been characterized as a 
negative regulator of T cell activation and its upregulation mediates the tyrosine kinase 
inhibitor-mediated inhibition of DC function (29) MST1 functions together with RAPL, 
which is a protein that binds the small GTPase Rap1, and is required for the adhesion of 
lymphocytes (30). TRADD protein functions as an adaptor in the tumour necrosis fac-
tor receptor (TNFR)1 signaling complex, regulating both apoptosis and in ammatory 
signals (31).
Taken together, the e ect of ustekinumab is twofold (Fig. 6):  rst by neutralizing IL-12 
and IL-23, the Th1/Th17 in ammatory cascade is interrupted in psoriasis plaques, lead-
ing to a PASI decline, a drop in circulating (probably plaque-derived) in ammatory 
hBD-2, and an increase in IL-12B related proteins. Second, ustekinumab induces a shift 
in non-involved skin gene expression towards patterns of healthy skin, thereby raising 
the threshold for skin triggering and new plaque formation.
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Fig 6. Model for the mode of action of ustekinumab in the clearance and prevention of psoriasis
We propose that ustekinumab has a twofold mode of action:  rst by neutralizing IL-12 and IL-23 in lesional 
psoriatic skin, the Th1/Th17 in ammatory cascade is interrupted, leading to clinical improvement, assessed 
by PASI decline and a change in circulating IL-12B-related proteins, including GPNMB, MST1, TRADD, and 
hBD-2. Second, ustekinumab induces a shift in non-involved skin gene expression towards healthy skin, 
thereby raising the threshold for skin triggering and new plaque formation.
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Supplemental table 1. Patients reporting the prevention of new psoriatic plaques and Koebneriza-
tion during ustekinumab treatment.
PASI
Start
PASI-75 at 
wk 12
ustekinumab
Patient- 
reported 
prevention of 
new plaques
Previously 
Koebner 
positive
Prevention of Koebner after 
accidental provocation during 
ustekinumab.
♀ 11 Yes Yes Unaware Unaware
♀ 15 Yes Yes Yes Yes
♀ 11 Yes Yes Unaware Yes
♀ 15 Yes Yes Yes Yes
♂ 18 Yes Yes Yes Yes

CHAPTER 6
Potential serum biomarkers of treatment 
response to ustekinumab in patients with 
psoriasis: a pilot study
A.J. Onderdijk
A.S. IJpma
S.P. Menting
E.M. Baerveldt*
E.P. Prens*
*these authors share last authorship
Br J Dermatol 2015 Jul 2. doi: 10.1111/bjd.13997
114 CHAPTER 6
ABSTRACT
Background
Biologic blockade of the IL-12/23 p40 subunit by ustekinumab represents a treatment 
option for psoriasis. However, it is an expensive drug and about 30% of patients does not 
reach a PASI-75 improvement within 12 weeks. It would be cost-ecient and time-saving 
if the response to treatment could be predicted before the start of therapy. This pilot 
study sought to compare serum cytokine proles in samples taken before ustekinumab 
treatment, in patients with psoriasis who responded and who did not respond to treat-
ment, in order to identify biomarkers associated with clinical response.
Methods
Cytokines were measured in serum samples taken from patients before start of 
ustekinumab treatment using a broad 507-cytokine array. Patients were divided in 
responders and non-responders on basis of their PASI scores at week 12 (PASI>75% 
improvement: responder, PASI< 50% improvement: non-responder). Results were statis-
tically analyzed using Partek; interpretation analysis was done using Ingenuity Pathway 
Analysis.
Results
Responders to ustekinumab (n=4) displayed an activated type I and type II interferon 
signature and an upregulation of cytokines including IL-12p40, IFNB1, IFNAR2, IL-1B, 
IL-20, VEGF, IL17RB and IL-36B compared to non-responders (n=4) at baseline.
Conclusions
An activated interferon type I/II signature and an upregulation of cytokines including 
IL-12p40, IFNB1, IFNAR2, IL-1B, IL-20, VEGF, IL17RB and IL-36B in serum of patients with 
psoriasis at start of ustekinumab treatment is associated with a successful treatment 
response. A combination of these molecules could propose an interesting predictive 
biomarker set for treatment response. Larger studies are warranted to conrm these 
ndings.
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INTRODUCTION
Psoriasis is a chronic inammatory skin disease of which the precise pathogenesis is still 
unknown. The current view is that in genetically predisposed individuals, the epidermal 
cells are triggered by diverse environmental factors such as mechanical trauma or cer-
tain drugs. This results in the production of a large amount of antimicrobial peptides 
that form complexes with self DNA or RNA (1, 2). Plasmacytoid and dermal dendritic 
cells are activated by these complexes and start to produce IFN-α, IL-1, IL-12 and IL-
23. These cytokines lead to the activation of innate lymphoid cells and γδ T cells and 
induce the dierentiation of Th1 and Th17 cells and LL-37 specic T cells that migrate 
to the skin. In the skin these T cells and the subsequent production of additional pro-
inammatory mediators eventually lead to a vicious cycle of inammation and the clini-
cal red scaly plaques in psoriasis patients (1-4). Research has led to the development of 
drugs targeting specic cytokines and cells of the immune system that are important in 
psoriasis. Biologics are drugs consisting of animal or human protein and are produced 
with recombinant DNA and in vitro cell culture techniques. Currently available biolog-
ics for psoriasis target the function of TNF-α, IL-17A or IL-12/23 and include etanercept 
(anti-TNF receptor fusion protein), adalimumab and iniximab (anti-TNF-α antibodies), 
anti-IL-17(receptor) molecules and ustekinumab. Ustekinumab is a fully human immu-
noglobulin monoclonal antibody targeting the p40 subunit shared by IL-12 and IL-23. 
This prevents binding to the IL-12Rβ1 receptor unit on immune cells and subsequent 
signaling. The evaluation of the ecacy of therapies in psoriasis is based on Psoriasis 
Area and Severity Index (PASI) scoring. Ustekinumab is ecacious, reaching >75% PASI 
improvement in 66% of patients after 12 weeks of therapy (5). However, it is an expensive 
treatment with monthly costs of 1.200 euros per patient in the Netherlands (information 
provided by the producer). Considering the costs of ustekinumab treatment it would be 
very expedient to predict the chance of successful treatment before the start of therapy. 
For the purpose of this study treatment success is dened as a >PASI 75% improvement 
(6). Studies have focused on analyzing immunological eects of treatments in an attempt 
to get more insight into the pathogenesis of psoriasis. In several studies alterations in se-
rum proteins during treatment were analyzed and correlated with the clinical response 
to systemic treatment including methotrexate and ustekinumab (7-11). However only 
a limited number of cytokines were studied and no predictors of therapeutic response 
were found. By using a broad serum cytokine array we sought to nd markers that could 
predict the response to treatment and would identify responders and non-responders 
before the start of treatment. This would prevent the unnecessary treatment of patients 
that will never respond to ustekinumab, the primary non-responders. We therefore ret-
rospectively investigated serum cytokine levels before the start of treatment in a small 
group of responders as well as non-responders to ustekinumab.
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MATERIALS AND METHODS
Patients and samples
Serum samples were obtained before the start of treatment with ustekinumab (subcu-
taneous injections at weeks 0, 4, and 16) (Table 1). Responders to ustekinumab were 
dened as having >75% PASI improvement at week 12. Non-responders were dened by 
failure to reach PASI 50 at week 12. Serum samples from 4 responders, 4 non-responders 
and 4 healthy controls were obtained. Patient characteristics are shown in Table 1. 
Patients did not receive any systemic antipsoriatic therapy in the 2 months preceding 
venipuncture. All patients provided informed consent. The study was approved by the 
local medical ethical committee (registration number 104.050/SPO/1990/30 – MEC 
99.785 version 19 April 2011) and conducted according to the Declaration of Helsinki 
principles.
Cytokine array
In order to assess the pre-treatment serum cytokine prole, broad semi-quantitative 
protein expression proling was done using a glass slide-based microarray (Ray biotech, 
Inc., Norcross, GA, USA). These microarrays are composed of capture antibodies specic 
for 507 cytokine proteins. The assay was performed according to the instructions of the 
manufacturer. Briey, serum samples were dialyzed and biotinylated and then added 
to individual protein array slides. The serum samples from responders, non-responders 
and healthy controls were independently analyzed. After incubation with Cy3-labelled 
streptavidin, the uorescence signal was detected using a laser confocal scanner (Tecan 
Benelux; Mechelen, Belgium). Internal controls were included as a control of perfor-
mance. Total signal strength for specic proteins was based on the average of a triplicate. 
As this protein array does not allow for quantication of proteins by comparison with 
a standard curve, data were normalized using the internal control as indicated by the 
manufacturer. As a measure for background level correction we used the values of the 
negative control of the individual samples as the background level and all expression 
levels lower to this value were set to the value of the negative control.
Bioinformatical analysis
Data were uploaded in Partek 6.6 (Partek Incorporated, St. Louis, Missouri, USA), quan-
tile normalized and log2 transformed and analyzed by ANOVA test (responders versus 
non-responders). All non-responders appeared to be men and all the responders were 
women. This led to the exclusion of one gender specic protein named 6Kine. Proteins 
dierentially expressed (P<0.05; >1.8 fold change) were subjected to Ingenuity Pathway 
Analysis (Qiagen, Redwood City, CA, USA). For the enrichment analysis (and calculation 
of the canonical pathways) 1.8 fold change was taken as a cut o. Canonical pathways 
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are based on literature and represent biological functions of molecule sets. Upstream 
regulators were analyzed by selection on the basis of z-score (>2 or >-2). For the hier-
archical clustering and data representation in Table 4, the quantile normalized values 
of each probe were used to calculate the relative values of each sample compared to 
the average of all samples for each probe. These relative ratio values were modied to a 
relative fold change scale. For graphical display purposes the maxima of the data range 
were set from -3 to +3. Hierarchical clustering was performed both for the rows and the 
columns. The complete linkage clustering method was used for both rows and columns 
and Euclidean clustering was used to determine both row and column dissimilarity.
RESULTS
Responders versus non-responders
Dierentially expressed molecules in responders versus non-responders at baseline
In ustekinumab responders, 27 molecules were upregulated and 27 molecules were 
downregulated at baseline compared with non-responders (Table 2). Upregulated mol-
ecules included several chemokines such as chemokine ligand 11 (CCL11), chemokine 
receptor 5 (CXCR5), and chemokine ligand 1(CX3CL1), cytokines such as IL-1beta (IL-1B), 
IL-17 receptor B (IL-17RB), IL-12B (IL-12p40), IL-36beta (IL-36B), IL-20, IL-17 receptor A 
(IL-17RA) and IL-1 receptor-like 1 (IL-1R1). Several growth factors were upregulated in re-
sponders including teratocarcinoma-derived growth factor 1 (TDGF1), growth hormone 
receptor (GHR), broblast growth factor 20 (FGF20), vascular endothelial growth factor 
(VEGF), insulin-like growth factor receptor 1 (IGF1R) and growth hormone 1 (GH1). Down-
regulated molecules in responders included frizzled family receptor 6 and 7 (FZD6/7), 
IL-27 (IL27), Toll-like receptor 2 (TLR 2), IL-17 receptor D (IL-17RD), intercellular adhesion 
molecule 5 (ICAM5), transforming growth factor beta 1 (TGFB1) and chemokine recep-
tor 9 (CCR9). Interestingly several IFN signaling genes were upregulated in responders 
including interferon receptor 1 and 2 (IFNAR1, IFNAR2) and interferon-beta 1 (IFNB1), 
with a 5-fold average upregulation compared to non-responders. Mostly molecules of 
the Th1/Th17 and IFN signaling pathways were upregulated in responders versus non-
responders.
Dierentially expressed canonical pathways in responders versus non-responders at baseline
Responders to ustekinumab dierentially expressed the canonical pathways: ‘the role of 
Wnt signaling’, the role of JAK1, JAK2 and TYK2 in interferon signaling’ and the ‘interferon 
signaling’ pathway, compared to non-responders (Table 3). Interestingly in most of the 
dierentially expressed pathways, IFNB1 (interferon beta), IFNAR1 (interferon receptor 1), 
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Table 2 Heatmap cytokines upregulated (red) and downregulated (green) in responders versus non-re-
sponders before the start of ustekinumab treatment.
Symbol Gene name Responders Non-responders
Th1/Th17 pathway
IL17RA interleukin 17 receptor A
IL17RB interleukin 17 receptor B
IL12B interleukin 12B (IL-12p40)
IL1B interleukin 1 beta
IL36B interleukin 36 beta
IL1RL1 interleukin 1 receptor-like 1
IFN signalling
IFNAR2 interferon (alpha beta and omega) receptor 2
IFNB1 interferon beta 1
IFNAR1 interferon (alpha beta and omega) receptor 1
Cytokine/chemokine activity
CCL11 chemokine (C-C motif ) ligand 11
CXCR5 chemokine (C-X-C motif ) receptor 5
IL20 interleukin 20
CX3CL1 chemokine (C-X3-C motif ) ligand 1
Wnt signalling
DKK4 dickkopf WNT signaling pathway inhibitor 4
DKK3 dickkopf WNT signaling pathway inhibitor 3
T cell regulation/proliferation
CD80 CD80 molecule
TNFRSF21 tumor necrosis factor receptor superfamily
Granulocyte/macrophage
CSF2RA colony stimulating factor 2 receptor alpha
Growth factors/others
GHR growth hormone receptor
FGF20 broblast growth factor 20
VEGFA vascular endothelial growth factor A
GDNF glial cell derived neurotrophic factor
IGF1R insulin-like growth factor 1 receptor
GH1 growth hormone 1
ICAM3 intercellular adhesion molecule 3
TDGF1 teratocarcinoma-derived growth factor 1
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Table 2 Heatmap cytokines upregulated (red) and downregulated (green) in responders versus non-re-
sponders before the start of ustekinumab treatment (continued).
Symbol Gene name Responders Non-responders
Th1/Th17 pathway
IL17RD Interleukin 17 receptor D
IL27 interleukin 27
Cytokine/chemokine activity
CCL3 chemokine (C-C motif ) ligand 3
CCR9 chemokine (C-C motif ) receptor 9
Wnt signalling
FZD6 frizzled family receptor 6
FZD7 frizzled family receptor 7
Growth factors
TGFA transforming growth factor. alpha
ACVR2A activin A receptor. type IIA
ESM1 endothelial cell-specic molecule 1
TGFB1 transforming growth factor beta 1
TGFBR1 transforming growth factor beta receptor 1
BMPR1B bone morphogenetic protein receptor type IB
Others
SPARC secreted protein acidic cysteine-rich 
(osteonectin)
EDAR ectodysplasin A receptor
SLC2A5 solute carrier family 2, member 5
GPC5 glypican 5
SIGLEC9 sialic acid binding Ig-like lectin 9
HCRT hypocretin (orexin) neuropeptide precursor
ICAM5 intercellular adhesion molecule 5 
telencephalin
GPNMB glycoprotein (transmembrane) nmb
LBP lipopolysaccharide binding protein
CXCR1 chemokine (C-X-C motif ) receptor 1
CXCR2 chemokine (C-X-C motif ) receptor 2
CSF1R colony stimulating factor 1 receptor
FZD5 frizzled class receptor 5
IL17F interleukin 17F
TNFRSF6B tumor necrosis factor receptor superfamily, 
member 6b, decoy
VCAM1 vascular cell adhesion molecule 1
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IFNAR2 (interferon receptor 2) and TGFBR1 (transforming growth factor beta receptor 1) 
molecules play an important role. In addition, the canonical pathway ‘role of cytokines 
in mediating communication between immune cells’ was dierentially expressed in 
responders, containing several key cytokines in psoriasis pathogenesis including IL-1β, 
IL-20, IL-12B, IL-27, IL-17F and IL-36B (Table 3).
Upstream regulators in responders versus non-responders at baseline
Ingenuity Pathway Analysis predicted and activated state (z-score>2) of key genes 
and/or molecules of a signaling pathway based on the downstream targets (including 
several chemokines, growth factors and cytokines). NKFB1 (nuclear factor of kappa 
light polypeptide gene enhancer in B-cells 1), IFNG (IFN-γ), IL-3 and RAF1 (Raf-1 proto-
oncogene) were predicted to be activated as upstream regulators with an activation 
z-score of respectively 2.8, 2.4, 2.3, and 2.2 in responders versus non-responders (Table 
4). IPA predicted an inhibited activation state of RBPJ (involved in Notch signaling) and 
IL-27RA (z-score respectively 2.2, and 2.0) (Table 4).
Table 3 Canonical pathways dierentially expressed in responders versus non-responders before the start 
of ustekinumab treatment.
Canonical pathway  P-value Molecules
Role of Wnt/GSK-3β signaling in the pathogenesis of 
inuenza
1.28 E-03 IFNB1,FZD6,FZD5,IFNAR1,FZD7
Role of JAK1, JAK2 and TYK2 in interferon signaling 1.11 E-02 IFNB1,IFNAR2,IFNAR1
Interferon signaling 1.11 E-02 IFNB1,IFNAR2,IFNAR1
Wnt/β-catenin signaling 1.17 E-02 TGFBR1,DKK3,TGFB1,FZD6,DKK4,FZD
5,ACVR2A,FZD7
Growth Hormone signaling 2.05 E-02 GHR,IGF1R,GH1
PPARα/RXRα activation 2.16 E-02 GHR,TGFBR1,TGFB1,IL1RL1,IL1B,GH
1,ACVR2A
Renal cell carcinoma signaling 3.31 E-02 VEGFA,TGFB1,TGFA
Inhibition of angiogenesis by TSP1 3.31 E-02 VEGFA,TGFBR1,TGFB1
Role of lipids/lipid rafts in the pathogenesis of 
inuenza
3.40 E-02 IFNB1,IFNAR1
Role of cytokines in mediating communication 
between immune cells
3.52 E-02 IL20,IL12B,TGFB1,IFNB1,IL27,IL1B,IL
17F,IL36B
Factors promoting cardiogenesis in vertebrates 3.52 E-02 TGFBR1,TGFB1,TDGF1,FZD6,FZD5,B
MPR1B,ACVR2A,FZD7
Regulation of IL-2 expression in activated and anergic 
T lymphocytes
4.88 E-02 TGFBR1,CD80,TGFB1
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Hierarchical clustering
The dierentially expressed molecules between responders and non-responders were 
analyzed by hierarchical clustering. This clearly shows the serum cytokine prole dier-
ences between responders and non-responders (Figure 1). Healthy controls showed a 
diverse pattern in gene expression (data not shown).
DISCUSSION
The results of this pilot study imply that psoriasis patients responding to ustekinumab 
treatment express an activated IFN type I/II signature and have a dierent cytokine pro-
le in their serum at baseline compared to non-responders. This cytokine prole could 
be helpful in distinguishing between patients that will respond to ustekinumab therapy 
and patients that are not likely to respond.
Treatment with ustekinumab costs 1.200 euros per patient per month in the Neth-
erlands (information provided by the producer) and in general, treatment response is 
evaluated after 3 months of treatment. Currently an array set for the analysis of one 
serum sample costs about 100 euros for the measurement of 40 cytokines (information 
provided by manufacturer RayBiotech). When larger sample sets are used these costs 
will decrease, in addition the costs of cytokine arrays in general are declining. Predicting 
treatment response could prevent the unnecessary treatment of 30% of ustekinumab 
treated patients and therefore be cost-saving.
Recent studies showed more favorable responses to ustekinumab treatment in pso-
riasis patients with a positive HLA-Cw6 (12, 13). Two studies failed to identify predictive 
factors for treatment response in the serum of patients. These studies only investigated 
Table 4 Upstream regulators responders versus non-responders before the start of ustekinumab treatment.
Upstream 
regulator
Fold change Predicted Activation
z-score
Target molecules in dataset
RBPJ Inhibited -2.24 GDNF,IL17RA,IL1B,TDGF1,VEGFA
IL27RA -3.55 Inhibited -2.00 CD80,IL12B,IL1B,IL27
IL3 -1.37 Activated  2.28 CCL11,CD80,CSF1R,IL12B,IL17RB,IL1B,IL1RL1,VCAM
1,VEGFA
RAF1 Activated  2.20 CXCR5,IGF1R,IL12B,IL1B,VEGFA
NFKB1 Activated  2.77 CCL11,CD80,CSF2RA,CX3CL1,CXCR5,IFNB1,IL12B,IL1B
,IL20,VCAM1,VEGFA
IFNG  3.01 Activated  2.37 CCL11,CCL3,CD80,CSF1R,CX3CL1,ESM1,GDNF,IFNB1,
IGF1R,IL12B,
IL17RA,IL17RB,IL1B,IL1RL1,IL27,TGFB1,TGFBR1,VCA
M1,VEGFA
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a few molecules including TNF-α, CCL27, IL-22 and VEGF (11, 14). In our study these 
molecules were also not predictive for treatment response, except for VEGF. In our 
study 507 serum cytokines were analyzed before the start of psoriasis treatment with 
ustekinumab in order to identify responders and non-responders on basis of a cytokine 
prole and not just one molecule. Our most important ndings are that responders are 
Fig 1. Hierarchical clustering of non-responders (left) and responders (right).
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characterized by an activated IFN I/II signature and a combination of a set upregulated 
proinammatory cytokines including IL12B (IL-12p40), IFNB (IFN-β), IFNAR2, IL1B (IL-1β), 
IL17RB (IL-17 receptor B) IL-20, VEGF and IL36B (IL1F8).
Type I IFNs (IFN-α and IFN-β) and type II IFNs (IFN-γ) are activated in psoriatic plaques 
and are important in the initiation of psoriasis via IFN-α production (15, 16). IFNAR1 
is a receptor for IFN-α and IFN-β. Binding of these cytokines to the receptor leads to 
phosphorylation of JAKs, TYK and STAT. Interestingly, because our responders displayed 
a strong type I IFN signature type I as well as type II; a successful treatment response by 
ustekinumab likely relies on the inhibition of this IFN-signature including IFN-γ, because 
IL-12 is necessary for Th1 induced IFN-γ production. By blocking the interaction of IL-12 
and T cells, IFN-γ production is inhibited, thereby also inhibiting its eects on dermal 
macrophages and (plasmacytoid) dendritic cells and the subsequent inammatory 
changes in the skin. In patients who do not have a strong IFN signature likely other 
proinammatory pathways are important for the development of psoriasis and in these 
patients ustekinumab apparently is not ecacious. In our responders next to molecules 
of type I and type II IFN pathways also many molecules involved in Th1/Th17 signaling 
were upregulated.
Wnt genes play a role in tissue homeostasis and the expression of Wnt is increased 
in lesional psoriatic skin (17). It has been shown that IFN-γ stimulation induces Wnt 
mRNA in cultured keratinocytes. In responders versus non-responders the Wnt signaling 
pathway was induced, which may indicate a more inammatory state in responders, 
likely caused by the more prominent interferon signature in responders compared to 
non-responders.
The activated upstream regulators NFKB1, IL-3 and RAF1 were upregulated in respond-
ers versus non-responders. NFκB is a key transcriptional regulator involved in many 
inammatory disorders including psoriasis. IL-3 is involved in the production, dieren-
tiation of granulocytes, dendritic cells and macrophages. RAF1 regulates MAP, Erk and 
NFκB pathways which also participate in psoriasis inammation. Taken together these 
molecules are illustrative for a more active inammatory state in responders compared 
to non-responders.
IL-27 serum levels are increased in patients with psoriasis and correlate with disease 
severity (18) and IL-27 activates Th1 mediated responses in imiquimod-induced psoria-
sis (19). In addition there is a signicant correlation between IFN-γ and IL-27 levels. IL-27 
alone induces Th1-cell-attracting chemokines, however in the presence of TNF-a, IL-27 
exerts a suppressive function in keratinocytes (18, 20). In our study the upstream regula-
tor IL-27 receptor was inhibited and also the IL-27 cytokine was reduced in responders 
compared to non-responders. This could indicate that in psoriasis the presence of IL-27 
might make patients more resistant to ustekinumab therapy.
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In conclusion, this study has identied a set of serum markers that is associated with a 
positive treatment response to ustekinumab. Before the start of therapy, responders to 
ustekinumab display an activated type and type II IFN signature in their serum together 
with an upregulation of IL-12p40, IFN-β, IFNAR2, IL-1β, IL-20, IL-17RB, VEGF and IL36B. 
However, conrmation of our results in a larger cohort is warranted.
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ABSTRACT
Background
Clinical improvement of psoriasis induced by IL-4 treatment has been ascribed to 
changes in dermal inammatory cells, such as activation of Th2 cells and tolerization of 
dendritic cells by suppressing IL-23 production. The pathologic epidermal alterations in 
psoriatic lesional skin include increased epidermal expression of IL-1β, IL-6, S100A7 and 
hBD-2 and a downregulated expression of the epidermal transcription factor GATA3. 
Eects of IL-4 on the epidermal compartment of psoriasis lesions were not previously 
investigated. Therefore, we investigated whether IL-4 directly aects above mentioned 
psoriatic markers in the epidermal compartment.
Methods
We cultured freshly isolated psoriatic epidermal cells, whole psoriatic and healthy skin 
biopsies, human keratinocytes and Langerhans cells with IL-4.
Results
The secretion of IL-1β and IL-6 by psoriatic epidermal cells was inhibited by IL-4 via 
transcriptional and post-transcriptional mechanisms, respectively. In normal skin, IL-4 
inhibited IL-1β- and IL-17A-induced hBD-2 expression in vitro. In addition, IL-4 reduced 
the protein expression of hBD-2 in psoriatic skin biopsies and induced phospho-STAT6 
protein. Epidermal GATA3 mRNA and protein were signicantly upregulated by IL-4 in 
epidermal cells and keratinocytes.
Conclusions
Our data argue that IL-4 improves psoriasis not only via modication/induction of Th2 
cells and type II dendritic cells, but also via direct inhibition of inammatory cytokines 
in resident IL-4 receptor-expressing epidermal cells and thereby alters the psoriatic skin 
phenotype towards a healthy skin phenotype.
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INTRODUCTION
Psoriasis is a chronic inammatory skin disease characterized by red and scaly skin 
lesions. Although many aspects of the immunopathogenesis of psoriasis have been 
claried, the exact sequence of pathogenic events remains unclear. The current concept 
is that psoriatic plaques (PP) arise as the result of interplay between inammatory cells 
and genetically predisposed keratinocytes (KC) (1-4). Expression levels of antimicrobial 
peptides are highly upregulated in (non)lesional psoriatic skin, and they are considered 
to play a role in the induction of psoriasis via immune-modulation such as recruitment of 
leucocytes (5, 6). The activated epidermis is characterized by a high keratin 17 (K17) and 
a low GATA3 expression, high levels of antimicrobial peptides such as psoriasin (S100A7) 
and β-defensin-2 (hBD-2), growth factors including nerve growth factor (NGF), and the 
proinammatory cytokines IL-1β and IL-6 (2, 7-9). These molecules activate IL-23 produc-
ing dendritic cells (DC), resulting in the induction of skin T cells that produce cytokines 
such as TNF-α, IFN-γ, IL-17 and IL-22. This interplay is of key importance in inducing the 
regenerative epidermal hyperproliferative phenotype in psoriatic skin (6, 10).
Psoriasis is seen as the opposite of atopic dermatitis, because of the contrasting im-
mune cell subsets involved. In psoriasis Th1/Th17 cells are the major players, and in early 
atopic dermatitis lesions Th2 cells and their cytokines are important (11). Psoriatic lesions 
are characterized by a relative absence of Th2 cells, and a strong Th1/Th17 signature (12, 
13). The prototypic Th2 cytokine IL-4 is primarily regarded as a master switch essential 
for Th2 dierentiation (14). IL-4 also has anti-inammatory properties by downregulat-
ing IL-1, TNF-a, IL-6, IL-8, IL-12 and IL-17 production in many dierent cell types such as 
monocytes, DC and macrophages (15-17). In addition, IL-4 can inhibit the production of 
antimicrobial peptides in KC (18). In psoriatic epidermal cells, the expression of the IL-4 
receptor is increased (19). Fumarate treatment induces IL-4-producing Th2 cells in vivo 
and generates type II dendritic cells (DCs) that produce IL-10 instead of IL-12 and IL-23 
(20). Clinical improvement of psoriasis is accompanied by activation of IL-4 signaling 
pathways including upregulated expression of GATA3 (21). GATA3 is crucial in epidermal 
development, and its expression is strongly downregulated in active PP, whereas adding 
IL-4 to ex vivo healthy skin explants signicantly enhances epidermal GATA3 expres-
sion (2). We hypothesize that IL-4 induces a shift away from Th1/Th17 inammation, by 
which the altered balance of proinammatorycytokines and growth factors in PP may 
be reversed, and levels of epidermal GATA3 may be normalized.
Studies in murine psoriasiform models have indeed demonstrated that transdermal 
IL-4 gene therapy partially prevents the ‘psoriasis-like’ phenotype (22) and these models 
conrmed the role of IL-4 in Th2 dierentiation (14, 22, 23). Psoriasis patients treated with 
recombinant human IL-4 also showed impressive clinical improvement, up to 68% PASI 
reduction in 6 weeks (24), which equals clinical improvement seen with anti-IL-12/23p40 
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therapy (ustekinumab) (25). This IL-4 induced improvement was initially attributed to 
its eects on the Th1/Th2 balance in the dermal inltrate (24). Later it was shown that 
IL-4 treatment reduces the cutaneous expression of IL-23p19 and IL-17, and reduces the 
expression of IL-1β, IL-6 and IL-23 in dermal DC (26).
Despite the importance of the epidermal compartment in the pathogenesis of psoria-
sis, previous studies focused merely on the eect of IL-4 on the dermal inltrate. So far, 
the direct eects of IL-4 on human KC and especially freshly isolated psoriatic epidermal 
cells (EC) are largely unknown.
We investigated whether IL-4 could inhibit epidermal inammatory repsonses analo-
gous to its dermal or systemic anti-inammatory eects. The aim of this study was to 
further explore the function of IL-4 in epidermal inammation and especially on the 
expression of typical psoriasis markers such as IL-1β, IL-6, IL-23p19, S100A7, hBD-2, NGF, 
K17 and GATA3, using (1) PP biopsies and healthy skin explants, (2) freshly isolated EC 
from PP, (3) cultured HaCaT cells and normal human keratinocytes, (4) Langerhans cells, 
and (5) activated PBMC as a representative of the dermal inltrate.
MATERIALS AND METHODS
Patients and controls
All patients were included following informed consent. Skin shaves or biopsies (depend-
ing on the experiment) were taken from plaques of 25 patients with moderate to severe 
psoriasis. Patients did not receive any local therapy in the 2 weeks preceding biopsy, nor 
systemic therapy in the previous 2 months before biopsy. Healthy control skin specimens 
were obtained from 15 healthy patients undergoing plastic breast or abdominal surgery 
at the Erasmus MC, or Sint Franciscus Hospital Rotterdam. The study was approved by 
the local medical ethical committee (registration number 104.050/SPO/1990/30 – MEC 
99.785 version 19 April 2011) and conducted according to the Declaration of Helsinki 
principles.
Epidermal cell suspensions and PBMC
Skin shaves were obtained using a Davies Gold Series dermatome (Stopler Medical, 
Utrecht, the Netherlands). Briey, split skin dermatome specimens were left oating in 
a solution of 0.25% trypsin and 0.1% EDTA in PBS for 1 h to separate the epidermis from 
the dermis, followed by preparation of single epidermal cell suspensions as previously 
described (27). Previous immunostainings have shown that epidermal cell suspensions 
contain mainly keratinocytes (95%), 3-4% melanocytes and the remaining 1 to 2% 
consists of HLA-DR+ LC. Epidermal cells were incubated for 1-24 h at 37°C and 5% CO2, 
at 1x106 viable cells/ml in RPMI-1640 medium with 25mM HEPES, 2mM glutamax-l, 100 
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U/ml penicillin, 100 ug/ml streptomycin and 0.1% human serum. PBMC were cultured 
at 5x106 in RPMI-1640 with HEPES, glutamax-l, 0.5% PenStrep and 2% human serum. 
Epidermal cells and PBMC were stimulated with IL-1β (100 U/ml, Glaxo, Geneva, Switzer-
land) in the presence or absence of IL-4 (100 ng/ml, Peprotech, Rocky Hill, New Jersey) or 
10-7 M dexamethasone (Sigma Aldrich St. Louis, MO, USA) for 4 h. In addition, PBMC were 
cultured with LPS (Escherichia coli 026:B6; Difco Laboratories, Detroit, MI) for 16 h in the 
presence or absence of IL-4 and 10-7 M dexamethasone.
Keratinocytes
Primary human keratinocytes were obtained from skin from healthy donors and were 
kindly provided by Dr. A. Ghalbzouri, University Leiden and Dr. H. Niehues and Prof. Dr. 
J. Schalkwijk, Radboud UMC, Nijmegen. Cells were cultured until they reached 75% con-
uence and plated in 12-well plates with Dermalife medium (LifeLine Cell Technology, 
Walkersville, MD). Cells were then placed in IMDM containing 0.5% AB serum, 100 U/ml 
penicillin, 100 ug/ml streptomycin, 2mM glutamax-1, 25mM HEPES and stimulated with 
IL-1β (100 U/ml, Glaxo, Geneva, Switzerland), TNF-α (5 ng/ml) and IL-17A (100 ng/ml, 
R&D systems, Europe) in the presence or absence of IL-4 (100 ng/ml, Peprotech, Rocky 
Hill, New Jersey).
Langerhans cells
Langerhans cells were isolated from excised skin of healthy persons undergoing plastic 
surgery. Single cell suspensions were prepared using standard methods (28). Briey, 
Langerhans cells were isolated using paramagnetic bead selection according to the 
protocol from the manufacturer (Invitrogen, Life Technologies). The epidermal cells 
were labeled with the sodium-azide free moAb HLA-DR (Dako) and CD207 (Langerin) 
(Beckman Coulter) and incubated with Dynabeads (goat anti-mouse IgG) and isolated 
by magnet separation (Stem Cell Technologies). After this cells were collected in a 96 
well plate at a 100.000 cell per well and stimulated with IL-1β (100 U/ml, Glaxo, Geneva, 
Switzerland), TNF-α (1 ng/ml) in the presence or absence of IL-4 (100 ng/ml, Peprotech, 
Rocky Hill, New Jersey).
Quantitative PCR analysis
Total mRNA was extracted using the GeneElute Mammalian Total RNA kit (Sigma-
Aldrich). cDNA was made using 1 μg of total RNA template, with SuperScript II reverse 
transcriptase (Invitrogen) and oligo(dT). PCR was performed using the ABI PRISM 7900 
sequence-detection system (Applied Biosystems). ABL1 was chosen as a reference 
housekeeping gene (29).The PCR primer sequences and probe numbers are specied 
in Table I.
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ELISA
IL-1β (full length and processed) and IL-6 were measured with commercially available 
ELISAs (Invitrogen) using the protocols provided by the manufacturer. The cut-os of 
the ELISA system were dened as negative control + 3 SD.
Ex-vivo short-term skin culture in the transwell system
Whole skin biopsy explants were cultured as previously described (30). Briey, four-
millimeter punch biopsies were placed in punched-out holes in a transwell membrane 
placed in a 12-well plate. Biopsies were cultured in medium with or without IL-4 (100 
ng/ml, Peprotech, Rocky Hill, New Jersey) and IL-1β (10 ng/ml, R&D systems, Europe) or 
IL-17A (100 ng/ml, R&D systems, Europe). Medium consisted of IMDM supplemented 
with 0.5% PenStrep, HEPES glutamine and 0.5% human AB serum. The well-plates were 
placed at 5% CO2, 37C° for 24 h. After culture, one quarter was placed in thermolysin for 
1 h to separate the dermis from the epidermis for independent analysis of epidermal 
and dermal mRNA. Other whole explants were placed in lysisbuer containing 2.5% 
β-mecaptho-ethanol for whole biopsy mRNA analysis.
hBD-2 staining
Sections on glass slides were dipped in xylene and incubated in ethanol and then 
washed in dH2O. The slide were put in Tris-EDTA buer pH 9.0 at 96°C for 30 minutes, and 
transferred into a blocking solution (PBS-0.5% tween, 2% BSA, 1% NMS) for 30 minutes. 
The primary antibody (goat-anti-human anti-hBD-2 1:250, Abcam, Cambridge, UK) was 
added in PBS-0.5% tween, 1% BSA, and incubated for 60 minutes at room temperature. 
The slides were rinsed and the secondary biotinylated rabbit-anti-goat antibody (1:400) 
was added followed by streptavidin poly-horseradish peroxidase (1:500) and incubated 
for 45 minutes. Staining was visualized using 3-AEC as the substrate. Sections where 
counterstained with haematoxylin.
Immunouorescence
HaCaT were cultured on Teon coated diagnostic slides (De Beer Medicals, the Nether-
lands) at a density of approximately 1x104 cells per well in RPMI-1640, 5% FCS, without 
HEPES and antibiotics. After 24 h of adaptation, the culture medium was aspirated and 
replaced by medium with or without cytokines. For immunouorescent stainings, cryo-
sections from PP skin biopsies and slides with cultured HaCaT KC were xed for 10 min 
in 4% paraformaldehyde in PBS. A mouse monoclonal anti-GATA3 antibody (1:100 clone 
HG3-31; Santa Cruz Biotechnology, Santa Cruz, CA) was used as the primary antibody. 
Donkey anti-mouse DyLight594 antibody (1:800, Jackson Immunoresearch, West Grove, 
PA, USA) was used as secondary antibody.
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For the phospho-STAT6 staining, cryosections were simultaneously xed and permeabi-
lized with ice-cold methanol for 20 minutes, blocked with 1% BSA in PBS, and incubated 
at 4 °C overnight with phospho-STAT6 rabbit-anti-human antibody (1:100, R&D systems). 
DyLight-488 conjugated donkey-anti-rabbit antibody (1:800; Jackson ImmunoResearch 
Inc., West Grove, PA, USA) was used to detect the primary antibody. Nuclei were stained 
with DAPI (4’,6-diamidino-2-phenylindole; Thermo Fisher Scientic Inc, USA). Pictures 
were taken with an Axio Imager uorescence microscope (Carl Zeiss Mircoimaging 
GmbH, Jena, Germany).
Statistical analysis
Wilcoxon signed rank test and one way ANOVA with Bonferroni’s post-test were used for 
statistical analysis using GraphPad Prism v5.04 (GraphPad Software, Inc., La Jolla, CA). 
Results are described as medians and P-values are designated as P<0.05 (*), P<0.01 (**) 
and P<0.001 (***).
RESULTS
IL-4 inhibits the mRNA expression of IL-1β and the secretion of IL-6 by psoriatic 
epidermal cells
IL-4 is known as a negative regulator of proinammatory gene expression and is ca-
pable of downregulating cytokine production in many dierent cell types (16, 17). IL-1β 
is produced by monocytes, macrophages and NK cells and IL-6 is produced by T cells, 
broblast and macrophages. To investigate whether proinammatory cytokine produc-
tion is inhibited by IL-4, we cultured activated PBMC in the presence of IL-4 and analysed 
the mRNA expression (Fig 1A). Because the baseline expression and release of IL-1β and 
IL-6 is normally low in PBMC, we induced a proinammatory situation and show that 
in proinammatory conditions (triggered by LPS) IL-4 inhibits the induced expression 
of IL-1β and IL-6. IL-4 appears to be a potent inhibitor of IL-1β, to a degree comparable 
with dexamethasone (Fig 1A). By using epidermal cell suspensions we tried to come 
close to the eect of IL-4 in vivo, by studying this ex vivo. In freshly isolated PP EC, IL-4 
inhibited IL-1β mRNA expression, but not IL-6 mRNA (Fig 1B). To check whether these 
ndings would also result in a reduced protein secretion, we cultured PBMC for 16 h 
and PP EC for 4 and 24 h, with or without IL-4 and measured the cytokine release with 
ELISA. As measured by ELISA, PBMC incubated with LPS for 16 h showed a signicant 
reduction in IL-1β and IL-6 secretion in the presence of IL-4 but not after treatment with 
dexamethasone (Fig 2A). In PP EC, IL-4 reduced the protein secretion of IL-6 after 24 h, 
but not of IL-1β (Fig 2B).
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IL-4 downregulates gene expression of IL-1β, but not IL-6 in the epidermis and 
whole psoriatic skin
We investigated whether IL-4 could reverse the aberrant psoriatic epidermis into the 
phenotype of healthy epidermis using a transwell culture system. The IL-1β mRNA ex-
pression was signi cantly reduced in the psoriatic epidermis and in whole PP biopsies 
when cultured for 24 h in presence of IL-4 (Fig 3A and 3B). The IL-6 mRNA expression 
was not altered by the presence of IL-4. The signi cant mRNA reduction of IL-1β was 
also observed in whole PP biopsies (Fig 3B) and whole NN biopsies (data not shown). 
IL-4 stimulation did not a ect IL-6 mRNA expression in whole biopsies from PP (Fig 3B).
Figure 1. IL-4 reduces LPS-induced IL-1β and IL-6 mRNA expression in human PBMC and inhibits 
mRNA expression of IL-1β in psoriatic epidermal cells. PBMC from healthy controls (n=7) cultured for 16 
h, in the presence or absence of IL-4 (100 ng/ml) or 10-7 M dexamethasone for 4 h (A). E ects of IL-4 on IL-1β 
and IL-6 mRNA expression in psoriatic epidermal cells (PP EC) (n=7) cultured with or without IL-4 (100 ng/
ml) for 4 h (B). Dots connected by a line represent cells from the same individual in di erent conditions. One 
way ANOVA with Bonferroni’s post-test and Wilcoxon signed rank test, results are displayed with median, 
P<0.05 (*), P<0.01 (**) and P<0.001 (***).
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IL-4 inhibits IL-1β mRNA expression induced by proin ammatory cytokines in 
cultured keratinocytes
To con rm our results we stimulated normal human keratinocytes with various proin-
 ammatory conditions. At the mRNA level IL-4 signi cantly reduced the IL-1β expression 
that was induced by a proin ammatory cytokine cocktail consisting of IL-1β+TNF-α 
orIL-17A (Supplemental Fig 1A). The mRNA expression of IL-6 was not inhibited, but 
from the literature and our previous experiments it is known that IL-6 is regulated at 
the post-transcriptional level (31). At the protein level IL-4 did not signi cantly reduce 
Figure 2. IL-4 inhibits the release of LPS-induced IL-1β and IL-6 by PBMC and the release of IL-6 in 
psoriatic epidermal cells. ELISA using supernatants of the same stimulated PBMC (with 2 additional sam-
ples) incubated with LPS for 16 h with or without IL-4 or 10-7 M dexamethasone for 4 h n=9 (PBMC) (A). 
Psoriatic epidermal cells (PP EC) without or with IL-4 (100 ng/ml), supernatants were harvested at 4 and 24 
h and tested by ELISA (n=5) (B). Dots connected by a line represent cells from the same individual under 
di erent conditions. One way ANOVA with Bonferroni’s post-test and Wilcoxon signed rank test. Results are 
displayed with median, P<0.05 (*), P<0.01 (**) and P<0.001 (***).
138 CHAPTER 7
the release of IL-1β induced by the proin ammatory cytokines, but IL-4 did reduce in all 
cases the release of IL-6 induced by the proin ammatory cytokines; however without 
reaching statistical signi cance (Supplemental Fig 1B).
Figure 3. IL-4 downregulates the expression of IL-1β mRNA in psoriatic epidermis and psoriatic bi-
opsies. RT-PCR using mRNA from psoriatic epidermal sheets (PP epidermis) (A) and whole biopsies from 
psoriatic skin (PP whole skin) (B), stimulated with or without IL-4 in a skin explant culture system for 24 h. 
Psoriatic biopsies (PP) without or with IL-4 (100 ng/ml), supernatants were harvested at 24 h and tested by 
ELISA (n=5). IL-6 was diluted 1:100 (C). Wilcoxon signed rank test, results are displayed with median, P<0.05 
(*) and P<0.01 (**).
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IL-4 reduces the expression of IL-1β induced by proinammatory cytokines in 
Langerhans cells
Because the inhibitory eect of IL-4 on proinammatory cytokine production in epider-
mal cell suspensions was stronger than in single keratinocytes, we wondered whether 
epidermal Langerhans cells were involved in the observed results in the epidermal cell 
suspensions. We therefore puried Langerhans cells from healthy skin using paramag-
netic beads up to a purity of 99% and stimulated them in culture. Also in Langerhans 
cells IL-4 signicantly reduced the expression of IL-1β, induced by proinammatory 
cytokines, but IL-6 mRNA was not (Supplemental Fig 2). The cytokine release of IL-1β 
and IL-6 was not signicantly reduced by IL-4 (data not shown). Our results are largely 
in agreement with ndings of Matsue et al. who showed that LC are the major source of 
IL-1β mRNA in mouse skin (32).
IL-4 inhibits IL-1β and IL-17 induced hBD-2 expression and IL-1β induced 
S100A7 expression
The expression of the antimicrobial peptides S100A7 and hBD-2 is increased in PP, which 
reects the altered state of epidermal activation and barrier function in psoriasis. The 
baseline expression of hBD-2 and S100A7 in normal skin is low (33). However in culture, 
with increasing time of culture, NN skin begins to show a more inammatory prole with 
increased mRNA levels of hBD-2, S100A7 and reduced levels of GATA3 which represents 
a wound heling eect (data not shown). We checked whether IL-4 could reduce the ex-
pression levels of these antimicrobial peptides in psoriatic epidermis. Quantitative PCR 
using mRNA derived from PP epidermis and whole PP skin, revealed no signicant dier-
ences in S100A7 and hBD-2 expression after culturing for 24 h with IL-4 (Supplemental 
Fig 3A). However a signicant decrease in both markers was detected after 24 h in whole 
NN biopsies (Supplemental Fig 3). In addition, IL-4 signicantly inhibited IL-1β and IL-17 
induced hBD-2 expression (Fig 4A) and IL-1β induced S100A7 expression (Supplemental 
Fig 3C). We performed immunohistochemical staining for hBD-2 in psoriatic skin bi-
opsies and this shows a clear reduction in hBD-2-staining by IL-4 (Figure 4B). Note the 
absence of staining in the dermis, as it is known that hBD-2 in serum is originated from 
the epidermis and migrates through the dermis into the blood ow (34).
IL-4 downregulates gene expression of NGF, but not IL-23p19 and upregulates 
STAT6 expression in psoriatic skin
K17 is not expressed in healthy skin, but is expressed in hyperproliferative skin conditions 
such as psoriasis. Stimulation of biopsies with IL-4 did not result in a signicant change 
in K17 expression in epidermal psoriatic as well as in whole PP skin (Supplemental Fig 4).
IL-4 stimulation did not aect IL-23p19 mRNA expression in epidermal nor whole 
PP skin. Lesional epidermal NGF mRNA expression was not signicantly reduced after 
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culturing for 24 h in presence of IL-4, but NGF mRNA was signi cantly reduced in both 
whole PP and NN cultured biopsies (Supplemental Fig 4). IL-4 exerts its function via 
the signal transducer STAT6 (35). To see whether e ects of IL-4 stimulation on PP also 
involved this pathway, we measured STAT6 mRNA levels. In the presence of IL-4, STAT6 
mRNA expression was signi cantly upregulated in PP epidermis and whole PP biopsies 
Figure 4. IL-4 inhibits IL-1β and IL-17A induced hBD-2 expression in normal skin. RT-PCR using mRNA 
from normal skin (NN) stimulated with or without IL-4 (100 ng/ml), IL-1β (10 ng/ml) or IL-17A (100 ng/ml) for 
24 h (A). Dots connected by a line represent cells from the same individual under di erent conditions. The 
hBD-2 mRNA expression/ABL is shown. One way ANOVA with Bonferroni’s post-test, results are displayed 
with median, P<0.05 (*), P<0.01 (**) and P<0.001 (***). Immunohistochemical staining of hBD-2 in PP biop-
sies cultured with 100 ng/ml IL-4 for 24 h or without (control). Note the absence of epidermis derived hBD-2 
staining (red) in the dermis when cultured with IL-4 (B).
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(Supplemental Fig 4). Immunouorescence staining conrms that IL-4 stimulation of 
psoriatic biopsies leads to an increase in the expression of phospho-STAT6 (Fig 5).
IL-4 upregulates expression of GATA3 in psoriatic skin and human skin KC
Epidermal GATA3 expression is downregulated under regenerative, inammatory and 
hyperproliferative skin conditions and is highly expressed in normal steady state condi-
tions. Stimulation of PP with IL-4 strongly upregulated GATA3 mRNA expression in the 
epidermis and in whole biopsies from PP (Fig 6A). As shown previously (2), IL-4 also 
enhanced epidermal GATA3 mRNA expression in cultured healthy skin (Supplemental 
Fig 4). Immunouorescent staining of cryosections from PP biopsies cultured with 
IL-4 led to a bright and upregulated red GATA3 signal in the majority of the cells in the 
epidermis; whereas minimal GATA3 staining was visible in biopsies cultured in medium 
alone (Fig 6B). However, the psoriatic epidermis is composed of dierent cell types, 
including lymphocytes and Langerhans cells, which could respond to IL-4 and modify 
GATA3 expression in KC via paracrine signaling. To specically assess the response of KC 
Figure 5. IL-4 stimulation leads to an increase in the protein expression of phospho-STAT6 in psori-
atic skin biopsies. Immunouorescence staining of phospho-STAT6 in PP biopsies stimulated with 100 ng/
ml IL-4 for 24 h and without (control). Phospho-STAT6 was stained in green and nuclei are stained in blue 
with DAPI. The scale bar represents 100 μm.
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and to exclude the contribution of other resident epidermal or dermal cells, the e ect 
of IL-4 on HaCaT cells was investigated using in situ immuno uorescent staining. After 
24 h of stimulation, IL-4 induced a strong upregulation of GATA3 expression and GATA3 
was also expressed in the nucleus, whereas minimal staining of GATA3 was observed in 
HaCaT cultured in medium alone (Fig 6B).
DISCUSSION
This study shows that IL-4 has a strong anti-in ammatory e ect on the psoriatic epi-
dermis ex vivo. Hence, the therapeutic e ects of IL-4 in the treatment of psoriasis may 
Figure 6. IL-4 upregulates GATA3 mRNA expression in psoriatic epidermal sheets and whole psoriatic 
skin and upregulates the protein expression in cultured psoriatic epidermis and in cultured human 
skin keratinocytes. RT-PCR using mRNA from epidermal sheets (PP epidermis) and whole biopsies from 
psoriatic skin (PP whole skin) stimulated with or without IL-4 for 24 h (A). Wilcoxon signed rank test, results 
are displayed with median, P<0.05 (*). Biopsies from PP skin and HaCaT were cultured for 24 h without IL-4 
and with IL-4 and analyzed by immuno uorescent microscopy (results were repeatable). Note the main 
induction of GATA3 in the epidermis (red  uorescent staining) by IL-4 and the preferential nuclear localiza-
tion in HaCaT. The bar represents 100μm for PP biopsies and 20μm for HaCaT (B).
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not be solely explained by its eects on the dermal inltrate, but also by eects on the 
epidermal compartment. By the inhibition of IL-1β and IL-6 in psoriatic epidermal cells, 
IL-4 acts early in the immunological cascade in psoriasis. In addition, IL-4 inhibits IL-1β 
and IL-17A-induced antimicrobial peptide expression in normal skin and hBD-2 protein 
in psoriatic skin ex vivo, a hallmark of psoriatic lesional epidermal skin. Psoriatic EC 
produce increased levels of several members of the IL-1 family of cytokines including IL-
1β (36), which is capable of inducing the regenerative epidermal phenotype in normal 
human skin (9, 37-39), and upregulates IL-6, IL-8, TNF-a and hBD-2 expression (36, 37). 
More importantly, IL-1β together with IL-23 is crucial in inducing Th17 and Th22 dieren-
tiation and IL-17 and IL-22 production (6, 40). Our results indicate that IL-4 is a powerful 
inhibitor of IL-1β mRNA expression and protein secretion, and via that pathway, IL-4 
may be able to reverse the psoriatic phenotype towards a healthy skin phenotype at the 
beginning of the inammatory cascade. IL-23-mediated psoriatic epidermal hyperplasia 
is dependent on IL-6, which is also known to hamper regulatory T cell function in PP skin 
(41, 42). Hence we expected IL-4 to inhibit IL-6 mRNA expression in PP skin. We did not 
observe an eect on IL-6 mRNA expression in our experiments, however in psoriatic EC 
the secretion of IL-6 protein was inhibited by IL-4. Thus the expression of IL-1β and IL-6 is 
reduced in psoriatic EC, but likely via dierent mechanisms; IL-1β possibly via inhibition 
of gene transcription and IL-6 via inhibition of translation or secretion. These dierences 
are likely explained by the conclusion that IL-6 is regulated in epidermal skin cells at the 
post-transcriptional level via enhancing the stability of IL-6 mRNA. Indeed it has been 
previously shown that IL-6 mRNA levels do not correspond to IL-6 protein levels (31, 43).
In the activated PBMC, representing the dermal inltrate, we see an inhibition of LPS-
induced IL-1β as well as IL-6 cytokine release by IL-4. In addition stimulation of cultured 
keratinocytes and puried LC was done to specify the dierent cell types involved. IL-4 
reduced IL-1β mRNA expression in keratinocytes and puried Langerhans cells, and 
IL-6 protein in all keratinocyte cell lines. In vitro the eects of IL-4 were more subtle 
than observed in the psoriatic ECS. This can be explained by 1) synergistic interactions 
between KC and LC in contiguous intact skin ex vivo compared to a single cell in vitro 
environment, 2) the proinammatory environment in psoriatic EC diers from our arti-
cial in vitro proinammatory cytokine environment, 3) time of culture, 4) the genetically 
predisposed psoriatic EC respond dierently to IL-4 than the healthy skin KC and LC used 
in our experiments, 5) the upregulation of the IL-4 receptor on psoriatic epidermal cells 
may lead to a larger eect of IL-4 in psoriatic EC, 6) we cannot rule out that melanocytes 
and sporadic Merkel cells are also a target for IL-4 (44).
 The observed upregulation of phospho-STAT6 indicates that the anti-inammatory 
eects of IL-4 are mediated via a pathway involving at least STAT6.
HBD-2 and S100A7 are typical markers of alterations in epidermal activation and skin 
barrier function in psoriasis and in atopic dermatitis. In fact, serum hBD-2 has been pro-
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posed as a biomarker of psoriatic disease activity (34). Because IL-1β stimulation leads 
to upregulated expression of hBD-2, and IL-1β secretion can be inhibited by IL-4, we 
expected IL-4 to reduce hBD-2 expression in psoriatic skin. We conrmed that hBD-2 
protein was reduced in psoriatic skin after exposure to IL-4. Addition of IL-4 to a Th1 
cytokine cocktail, led to inhibition of hBD-2 in keratinocytes (33). This is in line with our 
ndings and that of other investigators using IL-4 in KC (47, 48).
Other markers of the regenerative psoriatic phenotype include NGF, IL-23p19, K17 
and GATA3. NGF plays a role in the pathogenesis of psoriasis and can modulate inam-
mation by regulating neuropeptides, angiogenesis, cell tracking molecules and T cell 
activation (49). NGF is not only produced by nerves, but also by several immune cells, 
endothelial cells, broblasts and KC. In psoriasis patients, NGF expression is increased 
in both lesional and non-lesional KC (50). NGF is strongly induced by IL-1, and its im-
portance is demonstrated by the fact that NGF is a strong inducer of TNF-α (49-51). In 
our experiments we observed a trend towards reduction of the epidermal NGF expres-
sion. However, IL-4 signicantly reduced NGF in whole PP biopsies ex vivo, probably via 
inhibiton of IL-1β. This suggests additional inhibition by IL-4 of NGF producing dermal 
cells including DC, macrophages and broblasts (52).
IL-23p19 is increased in PP and can be produced by KC, but DC are the main source 
(40, 53, 54). Reports showed that IL-23 production by DC is inhibited by IL-4 and that 
downmodulation of DC and IL-23p19 is an early eect during psoriasis treatment (20, 
26). We did not observe a reduction in IL-23p19 mRNA expression in epidermal and 
whole PP skin after IL-4 stimulation. However, this corresponds with a previous study 
stating that psoriatic KC lack intrinsic aberrant expression of IL-23 and therefore IL-23 
may not be further reduced by IL-4 in culture conditions (54). In addition, IL-1 β and IL-6 
are necessary for Th17 induction by DC (6, 10). Because of the early inhibition of IL-1β 
and IL-6 by IL-4, likely DC are not activated and new IL-12 and IL-23 production and the 
consequent Th17 dierentiation are inhibited.
GATA3 is a crucial transcription factor in KC homeostasis (55), activation and prolifera-
tion (56), and epidermal GATA3 is downregulated in PP and during wound healing (2). 
We show that the expression of GATA3 is strongly upregulated by IL-4 in KC and also in 
psoriatic epidermis. The prominent increased protein expression of GATA3 in nuclei of 
the KC indicates nuclear translocation and an activated state. GATA3 mRNA and protein 
in psoriatic skin were signicantly upregulated by IL-4, comparable to its expression in 
healthy skin. Our results are in line with previous reports which collectively underscore 
the importance of KC in the pathogenesis of psoriasis (57). This is further illustrated by 
the observation that during etanercept (anti-TNF-α) treatment of psoriasis, epidermal 
improvement precedes dermal improvement (58). The eects of IL-4 on the epidermis 
are likely mediated through the upregulated IL-4R on psoriatic KC (19). This IL-4R up-
regulation could be the result of a negative feedback loop in an attempt to restore the 
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epidermis from its inammatory state. The relative low levels of IL-4 in psoriatic skin can 
be replenished by the addition of exogenous IL-4, hence driving the cytokine balance 
in inamed psoriatic skin away from the TH1/Th17-dominated pathologic state via the 
upregulated IL-4 receptor.
In conclusion, our results indicate that IL-4 not only improves psoriasis via modication 
of dermal Th2 cells and induction of type II DC function, but also has anti-inammatory 
and anti-regenerative eects on the psoriatic epidermal compartment and is thereby 
able to shift a psoriatic skin phenotype towards a healthy skin phenotype.
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Supplemental Fig 1. IL-4 signi cantly reduces IL-1β mRNA expression induced by IL-1β+TNF-α or 
IL-17A in normal human keratinocytes. RT-PCR using mRNA from normal human keratinocytes (KC) cul-
tured for 2 h with IL-1β (100 U/ml) + TNF-α (5 ng/ml) or IL-17A (100 ng/ml), with or without IL-4 (100 ng/ml) 
(A). The Y axis shows the mRNA expression of IL-1β and IL-6 relative to the expression of the housekeeping 
gene ABL. Supernatants of keratinocytes were collected after 16 h and tested by ELISA (B). Dots connected 
by a line represent cells from the same individual in di erent conditions. Results are displayed with median, 
paired t-test, P<0.05 (*) and P<0.01 (**).
152 CHAPTER 7
Supplemental Fig 2. IL-4 signi cantly downregulates IL-1β mRNA expression in Langerhans cells. 
RT-PCR using mRNA from Langerhans cells (LC) cultured for 16 h with IL-1β (100 U/ml) + TNF-α (1 ng/ml) or 
IL-17A (100 ng/ml), with or without IL-4 (100 ng/ml). The Y axis shows the mRNA expression of IL-1β and IL-6 
relative to the expression of the housekeeping gene ABL (A). Supernatants of Langerhans cells were col-
lected after 16 h and tested by ELISA (B). Dots connected by a line represent cells from the same individual 
in di  erent conditions. Wilcoxon signed rank test, results are displayed with median, P<0.05 (*).
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Supplemental Fig 3. IL-4 inhibits S100A7 and hBD-2 mRNA expression and IL-1β induced S100A7 
expression in normal skin. RT-PCR using mRNA from psoriatic epidermal sheets (PP epidermis), normal 
skin (NN) and whole psoriatic skin (PP) stimulated with or without IL-4 (100 ng/ml). There was a consider-
able inter-donor variation in the mRNA expression levels, to illustrate the e ect in the individual patients 
more clearly we used a ratio (control was set as ‘1’). The Y axis shows the mRNA expression relative to the 
expression of ABL (A, B). RT-PCR using mRNA from NN stimulated and with or without IL-4 (100 ng/ml) and 
IL-1β (10 ng/ml) or IL-17A (100 ng/ml) for 24 h. Dots connected by a line represent cells from the same indi-
vidual in di erent conditions (C). Wilcoxon signed rank test and one way ANOVA with Bonferroni’s post-test, 
results are displayed with median, P<0.05 (*) and P<0.01 (**).
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Supplemental Fig 4. IL-4 downregulates NGF expression in normal skin and psoriatic skin, upregu-
lates STAT6 gene expression in psoriatic epidermal sheets as well as in whole psoriatic skin, and up-
regulates GATA3 expression in whole normal skin and whole psoriatic skin. RT-PCR using mRNA from 
epidermal sheets (left column) and whole biopsies from psoriatic skin (PP) and whole biopsies from normal 
skin (NN) (right column) stimulated with or without IL-4 in a skin explant culture system for 24 h. There was 
a considerable inter-donor variation in the mRNA expression levels, to illustrate the e ect in the individual 
patients more clearly we used a ratio (control was set as ‘1’). The Y axis shows the mRNA expression rela-
tive to the expression of ABL. Wilcoxon signed rank test, results are displayed with median, P<0.05 (*) and 
P<0.01 (**).
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CHAPTER 8
General discussion
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IMPLICATIONS AND SUGGESTIONS FOR FUTURE RESEARCH
Psoriasis and comorbidities
Psoriasis is a chronic skin disease that aects approximately 320.000 people in the Neth-
erlands. The disease reaches further than the skin and has been associated with comor-
bidities including non-alcoholic fatty liver disease (1), diabetes (2) and cardiovascular 
disease (3). A possible mechanism for the association between cardiovascular disease 
and psoriasis is systemic inammation. However, the relationship between psoriasis 
and cardiovascular comorbidities is still under discussion. In a retrospective analysis 
of patients with moderate to severe psoriasis the 10-year risk of developing coronary 
heart disease or stroke was increased 28% compared with the general population (4). 
This association is found in many studies, but may be caused by the lack of adjustment 
in the analysis for confounding factors including body mass index, cholesterol, blood 
pressure and diabetes. When correcting for these factors no increased risk for cardio-
vascular disease was found in a population based study, conducted in a limited number 
of patients (5). In addition, in a large recent cohort study neither psoriasis nor severe 
psoriasis were associated with the risk of major cardiovascular disease after adjusting for 
known cardiovascular disease risk factors (6). Dierences in outcome between studies 
are likely to be explained by study design.
Research in the rheumatoid arthritis eld shows that adequate treatment prevents fu-
ture complications and comorbidities (7). In a prospective study Ahleho et al. showed 
evidence for an improvement in myocardial dysfunction in patients with severe psoriasis 
treated with biologics (8). In addition, Wu et al. found a reduced risk for myocardial in-
farction in psoriasis patients treated with anti-TNF-α therapy compared to patients with 
only topical treatment (9). In contrast, Abuabara et al. found no reduced risk for myo-
cardial infarction in psoriasis patients treated with systemic therapies (methotrexate, 
cyclosporin, alefacept, efalizumab, adalimumab, etancercept and iniximab) compared 
to UVB phototherapy (10).
At the molecular level, the systemic inammation seen in atherosclerotic plaque 
formation resembles the inammation seen in psoriasis. A meta-analysis derived tran-
scriptome, consisting of 1.000 genes that were found to be dierentially expressed be-
tween lesional and non-lesional psoriatic skin from ve individual transcriptomes, was 
analyzed with Ingenuity Pathway Analysis (IPA) (11). By this analysis, genes that co-occur 
in other disease pathways could be detected. The most important pathways as detected 
by IPA were atherosclerosis signaling, fatty acid metabolism, cardiovascular disease and 
cardiac hyperplasia (11). Interestingly, techniques including uorodeoxyglucose (FDG) 
PET/CT-scans, an established measure for cardiovascular disease, allow in vivo measure-
ment of inammation by visualizing metabolic uptake of FDG by macrophages and 
other inammatory cells. In a pilot study FDG PET/CT in psoriasis patients with moderate 
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to severe psoriasis versus controls showed an increased metabolic uptake of FDG in the 
joints and an increased uptake in the aorta, also after correction for cardiovascular risk 
factors (12). In a recent study FDG PET/CT also showed that mild psoriasis is associated 
with arterial inammation (13). In conclusion, experimental evidence suggests that pso-
riasis is not only an inammatory skin disease, but that inammation is also present in 
other organs. Likely in a few years serum biomarkers as a measure for systemic (vascular) 
inammation will become available. Whether this inammation leads to an increased 
risk for cardiovascular disease remains to be established. The inuence of treatment on 
the risk for cardiovascular disease has to be studied more in depth. If such an eect 
could be demonstrated, it is commonly assumed that it will have a major impact on 
future treatment.
Systemic treatment of psoriasis
Fumaric acid esters (FAE) are used in the treatment for psoriasis, but they are used less 
than expected considering their clinical ecacy, side eect prole and costs (dimethyl/
ethylhydrogenfumarate costs about 150 euros per month). FAE are considered a safe 
and eective treatment option for psoriasis (14, 15). However side eects have been de-
scribed including common side eects as ushing and gastro-intestinal complaints and 
less frequent side eects including kidney and liver function disturbances, leucocytope-
nia and lymphocytopenia. Several case reports described the occurrence of reversible 
proteinuria (16) and acute kidney failure or Fanconi syndrome (17). In addition recently 
progressive multifocal leukoencephalopathy (PML) has been described in several case 
reports (18, 19). However, in these case reports patients had severe lymphopenia for a 
long period of time and standard lab controls and measures as advised were not met 
(cessation of therapy in case of severe lymphocytopenia). Frequent serum creatinine, 
lymphocyte counts and urine testing for proteinuria are proposed. In the Netherlands 
three unlicensed FAE-formulations are available: a formulation with dimethylfumarate 
(DMF) and monoethylfumarate (MEF), a formulation with solely DMF, and a formula-
tion with solely DMF in slow-release form (Psorinovo). In the body dimethylfumarate 
is rapidly degraded into monomethyl fumarate. In a randomized controlled trial a 
dimethylfumarate-formulation was compared with a formulation consisting of dimeth-
ylfumarate and monoethylfumarate and no statistically signicant dierences in ecacy 
were found (20). In current guidelines it is advised to consider fumaric acid esters as rst 
choice systemic monotherapy (Psoriasis guideline of the Dutch Society of Dermatology 
and Venereology). One of the reasons that fumaric acid esters are not used by every 
dermatologist could be the lack of knowledge concerning the underlying mechanisms. 
In our study we show that fumaric acid esters act on the glutathione system and Nrf2 
pathway and that specically in responder patients the transcription factors PTTG1, 
NR3C1, GATA3 and NFκBIZ are regulated. More knowledge on the mechanistic proper-
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ties of this compound will likely increase its use in psoriasis treatment. Currently trials 
are ongoing that compare dierent forms of fumaric acid esters (clinicaltrials.gov). 
Unfortunately only brand name drugs are studied at the moment and not the basic 
combination of compounds that are prepared by the pharmacist, so that the costs will 
increase when these become registered for the treatment of psoriasis. Future research 
should focus on the mechanistic targets of the anti-inammatory eect of fumaric acid 
esters in psoriasis in vitro and in vivo (imiquimod-induced psoriasiform inammation 
model). This will increase our knowledge on the pathogenesis of psoriasis and could 
identify future targets for treatment.
Recombinant IL-4 has been used in trial setting in the past as a therapy for psoriasis 
(21). Currently, IL-4 is no longer used because of the availability of other biologics that 
interfere more specically in the immunopathogenesis of psoriasis. Despite this, we 
showed that the eects of IL-4 on skin and skin cells can teach us more about the patho-
genesis of psoriasis and that this knowledge can reveal new and other molecular targets 
for psoriasis treatment. IL-4 not only aects immune cells in the dermal compartment 
such as T cells and dendritic cells (DC) (21), but also acts on the epidermal compart-
ment and increases GATA3 expression and reduces the release of IL-1β, a cytokine that 
acts early in the ‘psoriasis cascade’, by epidermal cells (this thesis). Our study shows an 
additional role for the eects on keratinocytes, that are underappreciated as immune 
cells, and Langerhans cells (LC). Future research could investigate topical options for 
IL-4 treatment. Despite the relatively large size of the molecule (18 kDa), currently avail-
able options for transdermal drug delivery could overcome this diculty (22). By using 
a T cell driven 3D skin inammation model that has many characteristics of epidermal 
psoriasiform skin inammation this could be explored further in vitro (23). In addition, 
in the transwell model this could be used to study this ex vivo (24).
Biologics have extended the therapeutic arsenal signicantly and side eects seem to 
be mild and reversible, but long term side eects are unknown because of the relatively 
short follow up until now. Side eects in patients do not seem to be biologic specic, but 
are rather a consequence of the general immunosuppressive eect. In general, biologics 
have a therapeutic success rate between 70-90% (PASI improvement of >75%). Biologics 
are the last treatment option for moderate to severe psoriasis, partly because of the high 
costs. Treatment with biologics is expensive, but not adequately treating psoriasis also 
leads to high economic cost because of sick leave and unemployment. Biologic treat-
ment decreases work limitations and improves work productivity and reduces work days 
missed in patients (25). The precise costs and benets are very dicult to evaluate, but 
this issue is extremely relevant, especially due to the current public health care debate 
and the predicted increase in health care costs in the near future.
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Identifying responders and non-responders to treatment
We aimed to identify responders and non-responders to ustekinumab therapy by 
analyzing 507 cytokines in serum samples taken from patients before the start of treat-
ment. We show that patients responding to ustekinumab treatment have a strong IFN 
type I/II signature in their peripheral blood (serum) compared to non-responders. A 
limitation of our study is the small number of patients studied, but as a pilot study is 
scientically valid (26). Nevertheless, our results have to be veried in a larger cohort. 
When this study is extended with more patients, it might be possible to predict in the 
near future whether patients will respond to therapy or not on the basis of their cy-
tokine prole and previously calculated cut-o values. This mathematical model could 
then predict the likelihood of treatment response based on cytokine prole. Not only 
serum cytokine values are to be included in this model, but also patient characteristics 
including smoking behavior and body weight that were shown to aect the clinical 
response to ustekinumab and other biologics. Patients who smoke are more likely to be 
non-responders (27, 28). Molecular studies that identify psoriasis subsets and nd mo-
lecular predictors of treatment response will reduce the burden of psoriasis for patients, 
because it is frustrating to use a therapy for months without a signicant improvement 
of the skin lesions. Establishing the right therapy rapidly, increases patient satisfaction. 
In addition, this individualized treatment approach (29) will eventually decrease health 
care costs, which is interesting due to the current public health discussion. Characteriza-
tion of the proteome, metabolome and microbiome of a patient is now possible. In the 
future this individual data will likely become important in clinical decision making and 
individualized treatment (29). To make this possible, investments in these projects are 
required. It will be possible in the near future, by drawing a blood sample to predict for 
this individual patient on the basis of a set biomarkers the likelihood of a signicant 
response to an individual treatment. Clinicians can use this information to discuss treat-
ment options with their patients.
Biologics have extended the therapeutic arsenal, although many questions are cur-
rently unanswered with regard to biologic treatment. Some outstanding questions are: 
when can treatment be nished with biologics? How big is the chance for the develop-
ment of neutralizing antibodies when restarting treatment? Is it possible to extend the 
time between injections without losing clinical ecacy? Does adding methotrexate lead 
to a higher eectivity and less formation of neutralizing antibodies? How can we predict 
whether a patient will respond to treatment or not? In order to optimize and individual-
ize psoriasis therapy these questions have to be studied, because the answers and the 
identication of psoriasis subtypes will lead to a more individualized treatment.
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Biosimilars
In the near future the active substance of several biologics will come o-patent (adali-
mumab and etanercept). This means that other pharmaceutical companies can produce 
and bring a similar compound or drug on the market, these are called biosimilars. 
Because the pharmaceutical compound of the original biologic has already extensively 
been tested, regulations for bringing these biosimilars on the market are less strict. 
Likely, this will lead to a reduction in research and production costs for the companies 
and therefore the prices of these drugs will be lower than that of the original compound. 
That these drugs are similar does not mean that they are equal. A small dierence in the 
production process can lead to dierences in clinical and immunological eects and also 
in side eects. Because these drugs are not as extensively tested as the original drugs, 
this can be a concern. On the other hand because they are designed and produced using 
more sophisticated analytical tools, some companies even speak of a biobetter product 
than the originator. A producer may for example slightly modify known immunogenic 
sites of a current biologic, making it less immunogenic, while keeping all other originator 
properties. Also the anity of the molecule or its biologic properties such as antibody 
dependent cytotoxicity may be enhanced by minimal modications of the molecule. So 
biosimilars may represent a useful extension of the current therapeutic arsenal in the 
treatment of psoriasis.
Quality of life and patient-reported outcome measures
Psoriasis has a large impact on the quality of life of patients and the prevalence of 
depression is increased compared to the general population (30, 31). Despite our cur-
rent knowledge about the pathogenesis of the disease and many available therapeutic 
options, psoriasis is still a major health issue. Not every therapy works for every patient 
and depending on the type of treatment >30% of patients are non-responders (32-34). 
Establishing the right treatment for a psoriasis patient can take months to years and 
when an optimal therapy is found, ecacy is not always long lasting. A questionnaire in 
2.070 Dutch psoriasis patients pointed out that only 54% is satised with their current 
treatment regime (35). Patients on topical treatment are less satised than patients on 
systemic treatment, despite potential side eects on dierent internal organs, general 
immunosuppression and an increased risk for skin cancer (35). The improvement in skin 
disease by drugs can be easily monitored by applying the PASI score. In studies clinical 
ecacy is usually dened as a PASI improvement of >75%. But what is the exact deni-
tion of successful treatment? Clinical ecacy is not only represented by the PASI score, 
because clinical success of a treatment depends on more factors than clearing of the skin 
disease (36). In addition, patients who have a lower quality of life respond less to psoria-
sis treatment (37). Interestingly, in clinical practice it becomes clear that the denition of 
clinical success diers considerably between patients. Some patients are satised with 
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a small reduction of their plaques and a reduction in itch, while others are only satised 
when their whole body is cleared of psoriasis. In addition, the improvement in PASI score 
does not always parallel the improvement in quality of life. For the dermatologist it is 
therefore essential to establish the exact needs and questions of a patient and together 
make a treatment plan for the individual patient. Therefore, besides measuring the PASI 
score, it is also important to measure quality of life and satisfaction with the current 
treatment (depending on eectivity, safety, use of the drug and contact with the doctor). 
This will become increasingly important in general clinical practice (38). These are called 
patient-reported outcome measures (PROM) (39). Treating the skin is only part of the 
work that has to be done. In the next years likely there will be more attention directed 
to this eld of research. Ideally a dened and validated set of questions on quality of life 
that can be asked during a consultation allows to quickly assess whether a patient needs 
more attention for this. Much can be improved in the currently used PROM as to date 
no PROM assesses the full impact of psoriasis in a validated and sensitive manner (39).
The placebo and nocebo eects
The placebo eect can be dened as the therapeutic change on placebo, while the 
nocebo eect can be dened as an ill eect during placebo. Placebos are important 
controls in clinical research to separate the specic drug eect from other eects. Neu-
rotransmitter pathways are thought to mediate placebo eects. Interestingly, genomics 
can eect response to placebo, likely via genetic variations in these neurotransmitter 
pathways, making a subset of patients more prone to placebo response (40).
The nocebo eect has been studied in neurological clinical practice, urological clinical 
practice, in itch and other clinical conditions (41-44). Usually the most common and 
most severe side eects (1-10% change to take place) of a drug are mentioned to pa-
tients. Mentioning these side eects increases the change for these side eects to take 
place (42, 43). It could be argued that only severe side eects have to be mentioned, so 
the chance for increasing the risk of innocent side eects is not unnecessarily increased. 
To our knowledge the nocebo eects on side eects due to systemic treatment in pso-
riasis treatment have never been investigated. One can imagine that this also holds true 
for the eect of treatment and possible side eects in psoriasis patients. It would be 
interesting to evaluate the nocebo eect in psoriatic clinical practice, for example in the 
treatment with FAE on ushing and gastro-intestinal side eects. An explanation for the 
nocebo eect can perhaps be derived from the concept of the skin-brain axis. There are 
three mechanisms activated in the body when a person encounters psychosocial stress, 
including 1) activation of the hypothalamic-pituitary-adrenal (HPA) axis, 2) activation of 
the sympathetic nervous system and 3) the release of neuropeptides from peripheral 
nerve endings, providing evidence for a skin-brain axis. Illustrative for this is the tempo-
ral relationship between psychosocial stress and the exacerbation of psoriasis (45, 46). 
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In psoriasis patients experiencing an eect of stress on their clinical disease, alterations 
in the HPA axis have been shown compared to patients that do not experience eects 
of stress on their disease and healthy controls (47). In addition, skin homing CLA+ T 
cells are increased in patients with psoriasis when compared to healthy controls as the 
result of stress (48). This could be an explanation for the exacerbation of the disease 
after a stressful event in psoriasis patients. The skin-brain axis connects psychological, 
immunogenic and neurogenic factors that all play a role in psoriasis.
Neurogenic inammation
The inuence of neuroimmunological factors in the pathogenesis of psoriasis is highly 
underappreciated. Nerves and neuropeptides play an important role in the induction 
and maintenance of human and imiquimod-induced psoriasis (this thesis). We described 
a patient with resolution of his psoriasis after iatrogenic denervation. In addition the 
induction of psoriasis by imiquimod is reduced in denervated skin. Denervation leads 
to a change in immunologic processes and the immunologic function of the skin (this 
thesis). Possibly this leads to a diminished inux of inammatory cells and a subsequent 
reduced induction of psoriasis in the imiquimod mouse model. A possible explanation 
for this could be the reduced blood ow after denervation. However, additional research 
on the vasculature in the back skin did not show dierences between denervated 
murine skin and control skin (data not shown). Denervation leads to a change in skin 
temperature regulation (48). Measuring temperature is not reliable for denervation be-
cause inammation due to the surgical denervation will likely increase skin temperature 
on the short term. Whether the nerves and neuropeptides play a direct causal role or 
via the subsequent events after denervation needs to be further elucidated. Nerves 
and antigen-presenting cells like LC and DC lie in close proximity. An explanation for 
the inhibition of imiquimod-induced inammation could be that denervation leads to 
a dysfunction of the DC or their mobility (49). A subset of sensory neurons expressing 
TRPV1 and Nav1.8 is essential to drive the inammatory response in imiquimod-induced 
psoriasiform skin inammation and dermal DC are in contact with these nociceptors. Se-
lective or genetic ablation of these nociceptors prevents IL-23 production from dermal 
DC and subsequent recruitment of inammatory cells (49). Interestingly our gene array 
analysis of denervated murine skin also identied an inhibition of leucocyte recruitment 
during imiquimod treatment. Calcitonin gene-related peptide (CGRP) has a chemotactic 
eect (50). The decrease in CGRP production after denervation might be responsible for 
the inhibition of leucocyte recruitment as in our mouse model CGRP was consistently 
low in the denervated skin. CGRP and its receptors could be potential therapeutic targets 
for psoriasis therapy. CGRP has many functions including vasodilation and chemotaxis. 
In the KC-Tie2 mouse model the skin possesses clinical and immunological features of 
psoriasis by ectopic expression of the angiopoietin receptor Tie2. Ward et al. showed 
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that re-injection with CGRP in denervated skin induces the KC-Tie2 skin phenotype that 
resembles psoriasis (51).
Imiquimod is a TLR7 agonist in mice that signals via the receptor on macrophages, 
DC and plasmacytoid DC via MyD-88 dependant signaling pathways and via this route 
activates the transcription factor NF-κB. In humans, imiquimod used for indications 
including genital warts, actinic keratosis and supercial basal cell carcinoma, can in-
duce and exacerbate psoriasis. On the basis of these ndings the imiquimod-induced 
psoriasiform mouse model was developed (52). This imiquimod-induced psoriasiform 
skin inammation is dependent on the IL-17/IL-23 axis and is considered a model that 
largely resembles human psoriasis (53, 54). This mouse model was developed by our 
group and used by many other study groups to investigate the induced psoriasiform 
skin inammation (55-57) and these studies revealed many new insights. The main 
route of imiquimod-induced inammation is via the MyD-88 pathway, because MyD-88 
decient mice show a much milder disease phenotype (58).
In conclusion, the imiquimod-induced psoriasiform mouse model is a functional 
model considering the resemblance of the IL-17/IL-23 axis with human psoriasis. In light 
of our results for CGRP in this model, it would be interesting to deplete CGRP in vivo in 
psoriatic plaques or to block the CGRP receptor to investigate whether this also improves 
human psoriasis. Capsaicin is an agonist for the TRPV1 receptor and depletes substance 
P and CGRP (59). Capsaicin improves pruritis and clinical PASI score in psoriasis patients 
(60), which could be due to the depletion of CGRP by capsaicin (59).
Treg cells are decreased in psoriatic lesions and these cells have less suppressive 
capacities compared with Treg from healthy controls. Interestingly, in the denervated 
mice, FOXP3 counts were signicantly higher compared to controls. For future research 
it would be worthwhile to investigate whether neuropeptides decrease the numbers 
and function of Treg. Ten days after denervation nerves regenerate into the murine back 
skin (61). It would be of interest whether after re-growth of the nerves, application of im-
iquimod induces psoriasiform skin inammation in denervated mice skin and whether 
this is accompanied by a decrease in FOXP3+ cells and an increase of CGRP.
In the KC-Tie2 mouse model the skin possesses clinical and immunological features 
of psoriasis by ectopic expression of the angiopoietin receptor Tie2. Botox (botulinum 
toxin A) decreases psoriasiform skin inammation and acanthosis in these mice and 
this is accompanied by a decrease of inltrating CD4+ and CD11c+ DC (62). Botox 
inhibits the secretion of the neuropeptides SP and CGRP by nerves and this could be 
an explanation for the reduced psoriasiform skin inammation. Treatment with Botox 
was studied in inverse psoriasis and improved subjective patient symptomatology but 
also objectively reduced erythema and maceration in the treated areas (63). In addition 
a case report showed clinical improvement after o-label injection of Botox in plaque 
psoriasis (64). Currently, Phase I trials are being carried out that investigate the use of 
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Botox injections in the treatment of human psoriasis. This might be a good treatment 
option for recalcitrant plaques on a limited number of locations. For psoriasis that covers 
the whole body other treatment options are more feasible.
We studied the role of the vasoactive intestinal peptide (VIP) in the pathogenesis of 
psoriasis and showed that the expression of the VPAC1 receptor is increased in lesional 
skin and decreases during plaque clearance by fumaric acid esters. Interestingly the 
cytokine IL-17A induces the expression of this receptor in healthy skin. It is known that 
the eect of VIP signaling via VPAC1 on T cells mediates Th17 inammation. VPAC1 could 
therefore be a therapeutic target in psoriasis treatment, but more research is needed to 
study whether blocking this receptor on psoriatic T cells indeed decreases IL-23 induced 
Th17 inammation. There is a great need to unravel the pathogenesis of psoriasis in 
more detail and thereby expand (neurogenic) therapeutic targets for future treatment. 
In future experiments it would be very interesting to investigate the dierent cell types 
in psoriasis that respond to VIP signaling and to study the receptor balance of VPAC1 
and 2 in these cell types. In addition it would be of interest to investigate whether 
blockade of the VPAC1 receptor results in decreased psoriasiform skin inammation. The 
rst step would be to investigate this in vitro/ex vivo in T cells, the most likely cell type 
involved. After conrmation of the reduction in proinammatory cytokine production 
by blockade of the VPAC1 receptor an in vivo study could be performed for example in 
the imiquimod-induced psoriasiform skin model.
Research identied a possible role for LL-37 specic T cells in the pathogenesis of 
psoriasis (65). In addition, a role for peptidoglycan was suggested (66). These studies 
unravel new possible therapeutic targets in the treatment of psoriasis. Psoriasiform 
skin inammation arises from a combined action of multiple players that disturb the 
homeostasis in the skin. The balance can be reset temporarily by therapeutic interven-
tions. Despite these interventions, exacerbations not only occur after cessation of treat-
ment, but also during treatment. The combined action of genes, innate and adaptive 
immunity, neurogenic immunology and psycho-immunology (skin-brain-axis) leads to 
psoriasiform skin inammation. Therapies can target most of these factors and future 
research should cover all of these objectives.
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Figure 1. Overview of psoriasis in ammation and targets of fumaric acid esters (FAE), ustekinumab 
(anti-p40) and IL-4.
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Table 1. Outstanding questions and possible therapeutic targets
Clinical research
Does treating psoriasis lower the risk for future (cardiovascular) complications?
How can we better dene treatment success and individualize psoriasis therapy?
How can we predict treatment success? 
Does psychotherapy improve treatment outcome?
Are biosimilars as safe and eective as innovator biologics?
Does blocking CGRP improve psoriasis? 
Does blocking the VPAC1 receptor improves psoriasis?
Is neuropeptide blockage with topical therapy feasible? 
Immunopathogenesis/translational research
Do neuropeptides aect T reg function?
Can responders to ustekinumab be identied by analyzing the IFN I/II activation in serum?
Can responders to other biologics be predicted by cytokine prole?
Can psoriasis patient subsets be identied based on clinical and immunological features?
Do immunologically dierent psoriasis subsets have a dierent risk for cardiovascular complications?
Are LL-37 and or peptidoglycan specic T cells required for the induction of psoriasis?
Possible therapeutic targets 
CGRP (depletion) 
VPAC1 receptor (blockade) 
IL-4 (stimulation) 
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SUMMARY AND MAIN FINDINGS
In Chapter 1 an introduction to the subjects described in this thesis is given. Psoriasis 
is a common chronic inammatory skin disease with a prevalence of 2 to 3% in the 
Western population. Approximately 20 to 25% of patients with psoriasis develop a 
psoriatic plaque after skin injury (for example after extensive scratching, surgery, tattoo 
placement or needle piercing), which is called the Koebner phenomenon. The Koebner 
phenomenon can also be triggered by tape-stripping of the skin, invoked by applying 
and removing adhesive tape to and from the skin 20 to 40 times in rapid succession. 
Mechanical trauma is one the diverse environmental factors, including infections and 
certain drugs (antimalarials, lithium, β-adrenergic antagonists, systemic corticosteroids, 
indomethacin) that may trigger genetically predisposed epidermal cells. This results in 
the production of antimicrobial peptides (AMP) that form complexes with self DNA or 
RNA. These complexes activate plasmacytoid dendritic cells (DC) to produce type I IFN-α, 
Table 1. Main ndings of this thesis.
What was already known?
Nerves and neuropeptides
Circumstantial evidence suggests that neurogenic inammation plays a role in the pathogenesis of psoriasis
Denervation due to trauma or surgery locally clears psoriasis
Neuropeptides and nerve density are increased in lesional psoriatic skin
Treatment
Clinically eective FAE inhibit dendritic cell maturation and keratinocyte proliferation in vitro
Ustekinumab downregulates psoriasis-related gene expression in lesional skin
IL-4 improves psoriasis in patients (phase II trial)
 
What does this thesis add?
Nerves and neuropeptides
Iatrogenic nerve damage in psoriasis patients ameliorates skin inammation via IFN type I signaling pathways
Denervation prevents skin inammation in the imiquimod-induced psoriasiform mouse model and this is 
accompanied by an inhibition of CGRP, a suppressed number of CD11c+ and CD4+ cells and an increase in 
FOXP3+ cells 
The expression of VPAC1 is increased in psoriatic skin and decreases during FAE treatment
VPAC1 expression is induced by IL-17A in normal skin 
Drugs
FAE treatment selectively induces glutathione and Nrf2 pathway genes in psoriatic skin
The transcription factors PTTG1, NR3C1, GATA3 and NFκBIZ are specically regulated in FAE responders
Ustekinumab improves psoriasis-related gene expression also in non-involved psoriatic skin without inhibition 
of the antimicrobial response
An IFN type I/II signature in serum may predict successful treatment response to ustekinumab
IL-4 down-regulates IL-1β and IL-6 and induces GATA3 in psoriatic epidermal cells
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IL-12 and IL-23. In addition, the numbers of innate lymphoid cells (ILC) that produce IL-
22, a key driver of epidermal thickening, and IL-17A-producing γδ T cells are increased in 
lesional psoriatic skin and are likely to play a role in the initiation of psoriasis. IFN-α, IL-12 
and IL-23 activate the dierentiation of skin-homing CLA+ Th1/Th17 cells in the lymph 
nodes. In the skin, IL-22 and IL-17A and probably other cytokines produced by ILC, γδ 
T cells, Th1, Th17 and likely the LL-37 specic T cells cause activation and proliferation 
of the keratinocytes. This results in the production of more proinammatory mediators 
and more AMP that are not only produced by T cells, but also by macrophages, neutro-
phils and broblasts. Eventually, this causes a vicious cycle of inammation that leads 
to thickening and scaling of the inamed skin. This view however does not include the 
role of neurogenic inammation in psoriasis. Our interest in the role of nerves and neu-
ropeptides in the pathogenesis of psoriasis was aroused by a patient referred to us by 
dermatologist Dr. J. Boer of the Deventer Hospital. This patient had unilateral clearance 
of his psoriasis after peripheral nerve damage caused by repeated surgery because of a 
complicated fracture of his left underarm.
Neurogenic inammation
Involvement of neuroimmunological factors in the pathogenesis of psoriasis is sup-
ported by the following observations: 1) clearance of psoriatic lesions after inadvertent 
denervation 2) the symmetrical distribution of psoriasis lesions on the body 3) the role 
of stress in psoriasis exacerbations, and 4) the increase in nerve density and neuropep-
tides in lesional skin. In this thesis we show clinical as well as experimental data that 
illuminate molecular pathways as well as neuromolecular pathways that play a role in 
the pathogenesis of psoriasis. In Chapter 2 we describe a patient with local unilateral 
resolution of psoriasis due to iatrogenic denervation following multiple orthopedic sur-
gical procedures because of a bone fracture of his left arm. By analysing the associated 
molecular changes by gene expression proling in aected skin in comparison with 
the contralateral skin that was not denervated, we found repressed genes that are 
associated with barrier function and suppression of genes involved in interferon (IFN) 
signaling such as interferon alpha-inducible protein 27 (IFI27) and interferon regulatory 
factor 9 (IRF9). Clinically the Koebner reaction could not be induced in the denervated 
skin of this patient. We asked whether not only the maintenance of psoriasis depends 
on an intact peripheral nervous system, but if also the initiation of psoriasis could be 
prevented by denervation. Because our results were limited to one patient we aimed to 
analyse underlying molecular mechanisms of denervation in the imiquimod-induced 
psoriasiform mouse model. In this model we assessed that denervation inhibited the 
induction of imiquimod-induced psoriasiform inammation. This clinical reduction was 
accompanied by an inhibited expression of calcitonin gene-related peptide (CGRP) a 
suppressed number of CD11c+ and CD4+ cells and an increase in FOXP3+ cell numbers 
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in denervated skin. In addition, by microarray analysis we found alterations in genes 
involved in leucocyte recruitment. Denervated skin showed a strong suppression at 
the level of individual immune cells, including activation, responses, quantity, and 
chemotaxis and these patterns were mostly linked by Ingenuity Pathway Analysis (IPA) 
to antigen presenting cells and granulocytes. Based on these results we conclude that 
peripheral nerves are important regulators in the induction as well as the maintenance 
of psoriasis by regulating skin barrier function, type I IFN signaling and leucocyte re-
cruitment. Several neuropeptides have been implicated in the pathogenesis of psoriasis 
including CGRP, substance P (SP) and vasoactive intestinal peptide (VIP). In vitro studies 
have shown that the immunologic outcome of VIP depends on the ratio between its 
receptors VPAC1 and VPAC2 on the responder T cells, and that VPAC1 is important for VIP 
mediated Th17 dierentiation. In psoriasis there is a chronic Th17 mediated inamma-
tion in the skin. In chapter 3 we therefore investigated whether these receptors have an 
altered expression pattern in psoriatic skin compared to normal skin, because this would 
suggest a role in the pathogenesis of psoriasis. By analysing the expression of its recep-
tors in lesional, non-lesional and normal skin at baseline as well as during therapy we 
found that the expression of VPAC1 is increased in psoriatic lesional skin and decreases 
during plaque clearance by fumaric acid esters (FAE). In addition we hypothesized 
that this aberrant expression could be caused by the altered cytokine environment in 
psoriatic lesional skin compared to normal skin. Stimulation of normal skin with IL-17A 
induced the expression of VPAC1 and stimulation with IL-4 induced VPAC2 expression. 
In vitro, IL-4 reduced the VPAC1 receptor expression in PBMC. Because the eect of VIP 
signaling is dependent on the receptor balance and VPAC1 signaling mediates Th17 
activation, the prominent VPAC1 expression and increased levels of VIP in psoriatic skin 
might contribute to the vicious cycle of inammation in psoriatic skin. Likely the in-
creased VPAC1 expression cannot be counter regulated, because the relatively low levels 
of IL-4 in psoriatic skin. These results suggest that this receptor might be an interesting 
therapeutic target in the treatment of psoriasis.
Treatment studies
Fumaric acid esters (FAE) are used in Europe for the treatment of psoriasis. However, 
they are less used than expected on basis of their clinical ecacy and favorable safety 
prole. This could be due to the partly unknown mechanisms of action by which FAE 
improve psoriasis. In chapter 4 we therefore made a comparison of regulated genes 
and pathways in psoriatic skin during FAE and anti-TNF-α treatment with etanercept to 
identify FAE specic pathways. FAE treatment specically induced glutathione and Nrf2 
pathway genes in psoriatic lesional skin. In responders, FAE specically regulated the 
transcription factors PTTG1, NR3C1, GATA3 and NFκBIZ, which are important in normal 
cutaneous development, and Th2 and Th17 pathways, respectively.
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Ustekinumab is a highly eective biologic that is used in the treatment of psoriasis. 
Ustekinumab neutralizes IL-12 and IL-23 by targeting the shared p40 subunit, thereby in-
terfering with the Th1/Th17 pathways and keratinocyte activation. Some of our patients 
reported reduced Koebnerization of non-involved skin and less new plaque formation 
during ustekinumab treatment. We therefore investigated whether these clinical obser-
vations could be explained by improved psoriasis-related gene expression and tape-
strip responses in non-involved skin during ustekinumab treatment. We analysed skin 
biopsies of non-lesional and tape-stripped skin of patients before and during treatment. 
After 4 weeks, 8 out of 11 patients showed a clinical 50% PASI improvement, which was 
accompanied by a signicant reduction in serum hBD-2 levels. After 4 weeks following a 
single ustekinumab injection, nerve growth factor (NGF) showed a signicant decrease, 
whereas GATA3 and IL-22RA1 expression increased, indicative of reduced responsive-
ness to epidermal triggering. The baseline and tape-strip-induced expression of the 
AMP hBD-2, S100A7 and LL-37 remained unaltered during treatment. These ndings 
indicate that ustekinumab reduces psoriasis-related gene expression in non-involved 
psoriatic skin, making it more resistant to exogenous triggering, but without disturbing 
its antimicrobial response.
Ustekinumab is an eective, but expensive therapy with monthly costs of 1.200 euros 
per patient in the Netherlands. Despite its high ecacy, about 30% of patients treated 
with ustekinumab do not reach a PASI-75 improvement within 12 weeks. If the response 
to treatment could be predicted before the start of ustekinumab this would be cost-
ecient and time-saving. In the study described in Chapter 6 we therefore sought to 
identify markers and cytokine proles for treatment response to ustekinumab. Serum 
samples taken before ustekinumab treatment in patients with psoriasis who responded 
and who did not respond to treatment were analyzed by cytokine array and IPA, in order 
to identify biomarkers associated with clinical response. An activated IFN type I/II signa-
ture in the serum of patients with psoriasis at the start of ustekinumab treatment was 
associated with a successful treatment response. Before the start of therapy, respond-
ers to ustekinumab display an activated type and type II IFN signature in their serum 
together with an upregulation of IL-12p40, IFN-β, IFNAR2, IL-1β, IL-20, VEGF and IL36B. 
This could be a predictive biomarker set for a positive response to treatment. Identifying 
non-responders before the start of therapy by serum analysis would be cost saving. A 
limitation of this study is that only a small group of patients was tested. Nevertheless, 
this pilot study provides an interesting setup for future experiments in a larger cohort.
Psoriasis patients treated with recombinant human IL-4 showed impressive clinical 
improvement in a clinical trial setting, with up to 68% PASI reduction in 6 weeks, which 
equals clinical improvement seen with ustekinumab. Currently, IL-4 is not used in the 
treatment for psoriasis because of the availability of other biologics that interfere more 
specically in the pathogenesis of psoriasis. The importance of IL-4 in psoriasis is illustrated 
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by the following set of observations: 1) clinical improvement of psoriasis is accompanied 
by activation of IL-4 signaling pathways, 2) the IL4/IL-13 gene is an identied psoriasis 
risk variant, 3) the expression of the IL-4 receptor is increased in psoriatic epidermal cells, 
and 4) FAE treatment induces IL-4-producing Th2 cells in vivo. The IL-4 induced clinical 
improvement was initially attributed to its eects on the Th1/Th2 balance in the dermal 
inltrate. Later it was shown that IL-4 treatment reduces the cutaneous expression of 
IL-23p19 and IL-17 and that IL-4 reduces expression of IL-1β, IL-6 and IL-23 in dermal DC. 
Eects of IL-4 on the epidermal compartment of psoriasis lesions were not previously 
investigated. In Chapter 7 we hypothesized that IL-4 induces a shift away from Th1/
Th17 inammation, by which the altered balance of proinammatory cytokines and 
growth factors in psoriatic skin is reversed in the epidermal compartment. In addition, 
IL-4 inhibited IL-1β and IL-17A-induced AMP expression ex vivo, a hallmark of psoriatic 
lesional epidermal skin. Our study shows that IL-4 has a strong anti-inammatory eect 
on the psoriatic epidermis ex vivo. Hence, the therapeutic eects of IL-4 in the treatment 
of psoriasis may not be solely explained by its eects on the dermal inltrate, but also 
by eects on the epidermal compartment, in particular anti-inammatory eects on 
keratinocytes and Langerhans cells. By the inhibition of IL-1β and IL-6, IL-4 acts early in 
the immunological cascade in psoriasis.
Current view on psoriasis pathogenesis
Despite extensive research, the pathogenesis of psoriasis is not completely solved. This 
is presumably because there is not just one cause for the disease and because there 
is heterogeneity in psoriasis clinical subtypes. Psoriasis is caused by a multifactorial 
interaction of immunogenic events that together lead to chronic inammation in the 
skin and eventually the formation of the clinical visible red indurated scaly skin lesions. 
The pathogenesis involves diverse genetic, neuroimmunogenic and immunological as-
pects. Moreover, the burden of the disease reaches further than the skin and includes a 
decreased quality of life and an increased risk for comorbidities including cardiovascular 
disease. Our current view also embraces the role of neurogenic factors in the pathogen-
esis of psoriasis.
In summary, in psoriasis, genetically predisposed epidermal cells are triggered by 
diverse environmental factors such as mechanical trauma or certain drugs. This trigger-
ing leads to the release of neuropeptides such as NGF by epidermal cells and peripheral 
nerve endings, which cause vasodilation and chemotaxis of diverse immune cell types. 
In addition, this leads to a marked release of AMP that form complexes with self DNA 
or RNA. These complexes activate plasmacytoid DC, to produce IFN-α, IL-12 and IL-23. 
Other initiators in the inammatory cascade are ILC that can produce IL-22, which is 
known to be a key driver of epidermal thickening and is increased in psoriatic lesional 
skin. In addition IL-17A-producing γδ T cell numbers are increased in lesional psoriatic 
skin. The cytokines IFN-α, IL-12 and IL-23 activate the dierentiation of CLA+ Th1/Th17 
cells in the lymph nodes that migrate to the skin. In the skin these ILC, γδ T cells, Th1, 
Th17, neuropeptides and likely the LL-37 specic T cells and their cytokines cause acti-
vation and proliferation of the keratinocytes. The increased levels of VIP and signaling 
via the upregulated VPAC1 receptor in the epidermis and possibly on T cells results in 
a sustained Th17 directed inammatory prole. The interplay between these cells and 
the proinammatory environment results in the production of more proinammatory 
mediators and more AMP and neuropeptides that are not only produced by T cells, but 
also by macrophages, mast cells, neutrophils and broblasts. Eventually, this causes a 
vicious cycle of inammation that cannot be dampened by the regulatory system and 
this leads to the clinical visible thickening and scaling of the skin.
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In hoofdstuk 1 worden de onderwerpen in dit proefschrift ingeleid. Psoriasis is een 
chronische huidziekte met een prevalentie van 2 tot 3% in de Westerse populatie. Bij 
ongeveer 20 tot 25% van de psoriasis patiënten treed het Koebner fenomeen op. Hierbij 
ontstaat een psoriasis plaque na beschadiging van de huid door bijvoorbeeld overmatig 
krabben, een operatie of het zetten van tatoeages of piercings. Dit zogenaamde Koebner 
fenomeen kan ook uitgelokt worden door het tape-strippen van de huid, waarbij plak-
band 20 tot 40 keer kort achter elkaar wordt aangebracht en daarna abrupt verwijderd 
van de huid. Mechanische beschadiging van de huid is een van de omgevingsfactoren, 
naast infecties en bepaalde medicijnen (antimalaria tabletten, lithium, β-adrenerge an-
tagonisten, systemische corticosteroïden en indomethacin), die psoriasis kan uitlokken 
bij erfelijk belaste personen. Dit resulteert in de productie van antimicrobiële peptides 
(AMP), die complexen vormen met zelf DNA of RNA. Deze complexen zorgen ervoor 
dat de plasmacytoïde dendritische cellen (DC) geactiveerd worden en type I IFN-α, 
IL-12 en IL-23 gaan produceren. Innate lymfoïde cellen (ILC), die IL-22 produceren, en 
(de nog omstreden) IL-17A-producerende γδ T cellen, zijn in grote aantallen aanwezig 
in lesionale psoriasis huid. Deze cellen spelen waarschijnlijk een belangrijke rol bij de 
initiatie van psoriasis.
IFN-α, IL-12 en IL-23 zorgen voor de dierentiatie van CLA+ Th1/Th17 cellen, die vanuit 
de lymfeklieren naar de huid migreren. In de huid zorgen IL-22, de IL-24 familie, IL-17A 
en waarschijnlijk ook andere cytokines die geproduceerd worden door ILC, γδ T cells, 
Th1, Th17 en waarschijnlijk de LL-37 specieke T cellen voor activatie en proliferatie van 
de keratinocyten. Dit resulteert in de productie van nog meer pro-inammatoire medi-
atoren en meer AMP, die niet alleen geproduceerd worden door T cellen, maar ook door 
macrofagen, neutroelen, keratinocyten en broblasten. Uiteindelijk leidt dit tot een 
vicieuze cirkel van huidontsteking die zorgt voor verdikking en schilfering van de huid.
Echter, dit scenario omvat niet de rol van het zenuwstelsel of neurogene inammatie 
bij het ontstaan van psoriasis. Onze interesse in de rol die zenuwen en neuropeptides 
spelen bij psoriasis werd gewekt door een patiënt die naar ons werd doorverwezen 
door dermatoloog dr. J. Boer van het Deventer Ziekenhuis. Bij deze patiënt verdween de 
psoriasis lokaal aan één arm, na perifere zenuwschade veroorzaakt door herhaaldelijke 
operaties in verband met een gecompliceerde botbreuk van zijn arm.
Neurogene inammatie
Betrokkenheid van neuroimmunologische factoren in de pathogenese van psoriasis 
wordt ondersteund door de volgende waarnemingen uit de dagelijkse dermatologische 
praktijk: 1) het verdwijnen van psoriasis plekken na chirurgische zenuwbeschadiging 
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(denervatie), 2) de symmetrische verdeling van psoriasis plekken over het lichaam, 3) 
de rol van psychologische stress bij de verergering van psoriasis, en 4) de toename van 
de zenuwdichtheid en neuropeptides in aangedane huid van psoriasis patiënten. In dit 
proefschrift laten we zowel klinische als experimentele data zien, die ons meer inzicht 
verschaen in de neuro-immunologische mechanismen, die een rol spelen in de patho-
genese van psoriasis. In Hoofdstuk 2 beschrijven we een patiënt bij wie de psoriasis 
plaatselijk verdween na iatrogene zenuwbeschadiging veroorzaakt door meerdere ope-
raties die werden uitgevoerd in verband met een gecompliceerde fractuur van de linker 
arm. De genexpressie in de aangedane huid werd vergeleken met de contralaterale huid, 
waarin de zenuwen niet waren aangedaan. We constateerden een verlaagde expressie 
van verschillende genen, die geassocieerd zijn met de huidbarrière en genen betrokken 
bij interferon (IFN) signalering zoals interferon alpha-inducible protein 27 (IFI27) en 
interferon regulatory factor 9 (IRF9). De inductie van het Koebner fenomeen was klinisch 
sterk verminderd in de gedenerveerde huid van deze patiënt ten opzichte van de niet-
gedenerveerde zijde. We vroegen ons af of niet alleen de instandhouding van psoriasis 
afhankelijk is van een intact perifeer zenuwstelsel, maar of ook de initiatie van psoriasis 
een intact zenuwsysteem vereist. Onze resultaten tot dusver waren echter beperkt tot 
deze ene patiënt, daarom onderzochten we deze hypothese en de onderliggende mo-
leculaire mechanismen van denervatie verder in het imiquimod-geïnduceerde psoriasis 
muismodel. In dit model stelden we vast dat denervatie de inductie van imiquimod 
geïnduceerde psoriasis sterk remt. Deze klinische remming werd vergezeld door een 
verlaagde expressie van calcitonin gene-related peptide (CGRP), een verminderd aantal 
CD11c+ en CD4+ cellen en een toename van FOXP3+ cellen in de gedenerveerde huid. 
Daarnaast vonden we door middel van microarray analyse, veranderingen in genen die 
betrokken zijn bij het aantrekken van leukocyten. Deze patronen werden door Ingenuity 
Pathway Analysis (IPA) met name gelinkt aan antigeen presenterende cellen en granu-
locyten. Op basis van deze resultaten concluderen we dat perifere zenuwen belangrijke 
regulators zijn van genen die betrokken zijn bij de barrière functie van de huid, type I IFN 
signalering en het aantrekken van leukocyten.
Verschillende neuropeptides spelen waarschijnlijk een rol in de pathogenese van 
psoriasis, waaronder CGRP, substance P (SP) en vasoactive intestinal peptide (VIP). In 
vitro studies hebben laten zien dat de immunologische uitkomst van VIP afhankelijk 
is van de ratio tussen zijn beide receptoren VPAC1 en VPAC2 op de responder T cellen, 
en dat VPAC1 belangrijk is voor VIP gemedieerde Th17 dierentiatie. Bij psoriasis is er 
een chronische Th17 gemedieerde ontsteking in de huid. In Hoofdstuk 3 onderzochten 
we daarom of deze receptoren een ander expressie patroon hebben in psoriasis huid 
vergeleken met normale gezonde huid, omdat dit een rol voor VIP in de pathogenese 
van psoriasis zou impliceren. Na analyse van de expressie van de VIP receptoren in les-
ionale, niet-lesionale en normale huid op baseline en ook tijdens therapie vonden we 
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dat VPAC1 verhoogd tot expressie komt in lesionale psoriasis huid en dat de expressie 
afneemt tijdens behandeling met fumaarzuur tabletten. We bedachten dat deze ver-
anderde expressie veroorzaakt zou kunnen zijn door een andere samenstelling van het 
cytokine milieu in psoriasis huid vergeleken met normale huid. Daarom stimuleerden 
we normale huid met IL-17A en we zagen dat dit zorgde voor verhoogde expressie 
van VPAC1. Stimulatie met IL-4 zorgde voor een inductie van VPAC2 expressie. In vitro 
reduceerde IL-4 de expressie van de VPAC1 receptor in witte bloedcellen. VIP signalering 
is afhankelijk van de receptor balans en VPAC1 signalering medieert Th17 activatie. 
De prominente VPAC1 expressie en verhoogde levels van VIP in psoriasis huid zouden 
kunnen bijdragen aan de vicieuze cirkel van inammatie in psoriasis huid. Mogelijk kan 
de verhoogde VPAC1 expressie niet worden verlaagd omdat de levels van IL-4 relatief 
laag zijn in psoriasis huid. Deze resultaten betekenen dat deze receptor een mogelijk 
interessant therapeutisch target is in de behandeling van psoriasis.
Klinisch onderzoek
Fumaraten worden gebruikt in Europa voor de behandeling van psoriasis. Ze worden 
echter minder gebruikt dan verwacht op basis van de klinische eectiviteit en het relatief 
gunstige bijwerkingenproel. Een reden hiervoor zou het deels onbekende werkingsme-
chanisme kunnen zijn. In Hoofdstuk 4 maakten we daarom een vergelijking tussen de 
gereguleerde genen en pathways in psoriasis huid tijdens behandeling met fumaraten 
en etanercept om zo fumaraat specieke signaalroutes te kunnen vinden. We maakten 
een vergelijking tussen responders en niet-responders op fumaraten. Behandeling met 
fumaraten induceerde speciek glutathione en Nrf2 pathway genen in lesionale psoria-
sis huid. In responders reguleerden fumaraten speciek de transcriptiefactoren PTTG1, 
NR3C1, GATA3 en NFκBIZ. Deze genen zijn belangrijk voor respectievelijk de normale 
ontwikkeling van de huid, Th2 en Th17 pathways.
Ustekinumab is een eectieve biologic, die wordt gebruikt in de behandeling van 
psoriasis. Ustekinumab neutraliseert IL-12 en IL-23 door binding aan de gedeelde p40 
subunit. Op deze manier interfereert ustekinumab met de Th1 en Th17 pathways en de 
activatie van keratinocyten. Sommige van onze patiënten ondervonden een verminderd 
Koebner eect van niet-lesionale psoriasis huid en merkten dat het ontstaan van nieuwe 
psoriasis huidafwijkingen verminderde tijdens de behandeling met ustekinumab. We 
onderzochten of deze klinische observaties verklaard konden worden door verbetering 
van psoriasis gerelateerde genexpressie en tapestrip reacties in niet-lesionale huid 
tijdens de behandeling met ustekinumab. We analyseerden huidbiopten van niet-
lesionale en getapestripte huid van psoriasis patiënten voor en tijdens behandeling. 
Na 4 weken lieten 8 van de 11 patiënten een PASI verbetering zien van minstens 50%, 
dit ging gepaard met een signicante reductie in serum humaan beta-defensine twee 
(hBD-2) levels. Na 4 weken liet nerve growth factor (NGF) een signicante reductie zien, 
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en waren GATA3 en IL-22RA1 genexpressie signicant toegenomen. Deze bevindingen 
zijn indicatief voor een afgenomen respons van de huid op epidermale triggering. De 
expressie van de AMP hBD-2, S100A7 en LL-37 op baseline en na tapestrip bleef gelijk 
tijdens behandeling. Deze bevindingen laten zien dat ustekinumab de psoriasis gere-
lateerde genexpressie verminderd in niet-lesionale psoriasis huid tijdens behandeling, 
waarbij de huid minder gevoelig is voor invloeden van buitenaf, echter zonder eect op 
de antimicrobiële respons.
Ustekinumab is een eectieve, maar kostbare therapie, met minimale maandelijkse 
kosten van 1200 euro per patiënt in Nederland. Ondanks de hoge eectiviteit, behaalt 
ongeveer 30% van de patiënten geen PASI-75 verbetering. Wanneer de respons op be-
handeling vooraf voorspeld kan worden, zou dit kosten en tijd sparen. In het onderzoek 
dat beschreven staat in Hoofdstuk 6 beoogden we markers te identiceren en cytokine 
proelen vast te stellen die kenmerkend zijn voor een respons op behandeling. Serum 
monsters werden afgenomen voor de start van behandeling met ustekinumab van 
patiënten met psoriasis. Patiënten die achteraf wel een goede respons op de behan-
deling hadden laten zien werden vergeleken met patiënten die geen goede respons 
op de behandeling lieten zien. Serum monsters werden onderzocht door middel van 
een cytokine array en IPA, om zo biomarkers te kunnen identiceren die geassocieerd 
zijn met klinische respons. Een geactiveerde IFN type I/II signatuur in het serum van 
patiënten aan het begin van de start met ustekinumab was geassocieerd met een suc-
cesvolle respons op behandeling. Voor de start van de behandeling is er in het serum 
van responders een geactiveerde type-I en type II IFN signatuur te zien en daarbij een 
opregulatie van IL-12p40, IFN-β, IFNAR2, IL-1β, IL-20, VEGF en IL36B. Deze set van genen 
zou een predictieve biomarker set kunnen zijn voor een positieve respons op behande-
ling. Het identiceren van niet-responders vooraf aan een behandeling door middel 
van serum analyse zou kostenbesparend kunnen werken en daarnaast veel onnodige 
behandelingstijd kunnen besparen. Een beperking van deze studie is dat er een kleine 
groep patiënten werd onderzocht. Desondanks geeft deze pilot studie een interessante 
setup voor toekomstige experimenten in een groter cohort.
In hoofdstuk 7 wordt het werkingsmechanisme van IL-4 onderzocht. Psoriasis 
patiënten die werden behandeld met recombinant humaan IL-4 lieten een duidelijke 
verbetering zien in een klinische trial, met een PASI reductie tot 68% in 6 weken. Deze 
verbetering is gelijk aan de verbetering die wordt gezien tijdens behandeling met 
ustekinumab. Momenteel wordt IL-4 niet gebruikt in de behandeling van psoriasis, 
omdat er andere eectieve biologics beschikbaar zijn, die speciek aangrijpen in de 
pathogenese van psoriasis. Het belang van IL-4 in psoriasis wordt onderstreept door de 
volgende observaties: 1) klinische verbetering van psoriasis gaat gepaard met activatie 
van IL-4 signaalroutes, 2) het IL-4/IL-13 gen is een psoriasis risico variant, 3) de expressie 
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van de IL-4 receptor is verhoogd in epidermale psoriasis cellen, en 4) behandeling met 
fumaraten induceert IL-4 producerende T cellen in vivo.
De IL-4 geïnduceerde klinische verbetering van psoriasis werd aanvankelijk gelinkt 
aan eecten op de Th1/Th2 balans in het dermale inltraat. Later werd aangetoond dat 
IL-4 behandeling the cutane expressie van IL-23p19 en IL-17 reduceert en dat IL-4 de 
expressie van IL-1β, IL-6 en IL-23 in dermale DC remt. Eecten van IL-4 op het epidermale 
compartiment van psoriasis laesies werden niet eerder onderzocht. Er werd aangetoond 
dat IL-4 zorgt voor een shift weg van Th1/Th17 inammatie, waarbij de veranderde balans 
in psoriasis huid van pro-inammatoire cytokines en groeifactoren in het epidermale 
compartiment wordt hersteld. Daarnaast remde IL-4 de IL-1β en IL-17A-geïnduceerde 
expressie van AMP ex vivo. Onze studie laat zien dat IL-4 een sterk anti-inammatoir 
eect heeft op de psoriasis epidermis ex vivo. De klinische eecten van IL-4 worden dan 
waarschijnlijk ook niet alleen verklaard door eecten van IL-4 op het dermale inltraat, 
maar ook door eecten op het epidermale compartiment, met name anti-inammatoire 
eecten op keratinocyten en Langerhans cellen. Door de inhibitie van IL-1β en IL-6, 
grijpt IL-4 vroeg aan in de immunologische cascade in psoriasis.
Huidige blik op de pathogenese van psoriasis
Ondanks uitgebreid onderzoek, is de pathogenese van psoriasis nog niet geheel opge-
helderd. Dit komt waarschijnlijk doordat er niet een oorzaak voor de ziekte is en omdat 
er veel heterogeniteit is tussen de verschillende klinische psoriasis subtypes. Psoriasis 
wordt veroorzaakt door een interactie van meerdere immunogene gebeurtenissen die 
samen leidden tot een chronische ontsteking in de huid en uiteindelijk de vorming van 
de typische scherp omschreven rode schilferende huidlaesies. De pathogenese behelst 
verschillende genetische, neuroimmunologische en immunologische aspecten. Daarbij 
reikt de ziektelast verder dan alleen de huid en worden vaak een afgenomen kwaliteit 
van leven en een verhoogd risico op verschillende comorbiditeiten genoemd, waaron-
der hart- en vaatziekten, hoewel dit nog niet helemaal opgehelderd is. Onze huidige 
hypothese belicht ook het belang van neurogene factoren in psoriasis.
Samenvattend, bij psoriasis worden genetisch gepredisponeerde epidermale cellen 
getriggerd door diverse omgevingsfactoren zoals mechanisch trauma of bepaalde 
medicijnen. Dit leidt tot de afgifte van neuropeptides zoals NGF door epidermale cellen 
en perifere zenuwuiteinden in de huid, dat vasodilatatie geeft en zorgt voor chemotaxie 
van diverse immuun celtypes. Daarnaast wordt er een veelheid aan AMP gemaakt, die 
complexen vormen met zelf-DNA of RNA. Deze complexen activeren de plasmacytoïde 
DC, die IFN-α, IL-12 en IL-23 gaan produceren. Andere initiatoren in deze inammatoire 
cascade zijn de ILC die IL-22 kunnen produceren, dat verhoogd in psoriasis huid aanwe-
zig is en een belangrijke veroorzaker van de verdikking van de huid. Daarbij zijn mogelijk 
de aantallen IL-17A producerende γδ T cellen verhoogd in lesionale psoriasis huid.
190 NEDERLANDSE SAMENVATTING
De cytokines IFN-α, IL-12 en IL-23 activeren de di erentiatie van CLA+ Th1/Th17 cellen in 
de lymfeklieren die naar de huid migreren. Deze γδ T cellen, Th1, Th17, neuropeptides en 
mogelijk de LL-37 speci eke T cellen en hun cytokines in de huid zorgen voor activatie 
en proliferatie van de keratinocyten. De toegenomen levels VIP en signalering via de 
opgereguleerde VPAC1 receptor in de epidermis en mogelijk op T cellen, resulteert in 
een aanhoudend in ammatoir Th17 pro el. De interactie tussen deze cellen en het 
pro-in ammatoire milieu resulteert in de productie van nog meer pro-in ammatoire 
mediatoren en meer AMP en neuropeptides, die niet alleen door T cellen worden 
geproduceerd, maar ook door macrofagen, mest cellen, neutro elen en  broblasten. 
Uiteindelijk leidt dit tot een vicieuze cirkel van in ammatie, die niet onderdrukt kan 
worden door het regulatoire systeem en dit leidt tot de klinisch zichtbare verdikking en 
schilfering van de huid.
Onze en andere recente studies laten mogelijke therapeutische targets zien voor de 
behandeling van psoriasis. Psoriasis ontsteking in de huid ontstaat door een gecom-
bineerde actie van verschillende factoren die de homeostase in de huid verstoren 
(Figuur 1).. De balans kan tijdelijk gereset worden door therapeutische interventies. 
Echter ondanks deze interventies kan psoriasis na het stoppen van behandeling, maar 
ook zelfs tijdens behandeling opvlammen. De gecombineerde interactie van genen, 
aangeboren en verworven immuniteit, neurogene in ammatie en psychologische 
Figuur 1. Factoren die een rol spelen in de pathogenese van psoriasis.
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factoren (huid-brein-as), kan leiden tot psoriasis. De meeste van deze factoren kunnen 
door behandeling worden aangepakt en toekomstig onderzoek dient zich dan ook op 
al deze aspecten te richten.
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ABL1  Abelson gene
AMP  antimicrobial peptide(s)
CGRP  calcitonin gene-related peptide
CLA  cutaneous lymphocyte-associated antigen
CNS  central nervous system
CRP  C-reactive protein
DC  dendritic cells
EC  epidermal cells
ESR  erythrocyte sedimentation rate
FAE  fumaric acid esters
HaCaT  spontaneously immortalized human skin keratinocytes
hBD-2  β-defensin-2
HO-1  heme oxygenase-1
ILC  innate lymphoid cells
IPA  Ingenuity Pathway Analysis
KC  keratinocytes
LC  Langerhans cells
NF-κB  nuclear factor of kappa light polypeptide gene enhancer
NGF  nerve growth factor
NN  normal healthy control skin
P75NTR  p75 neurotrophin receptor
PASI  psoriasis area severity index
PBMC   peripheral blood mononuclear cells
PNS  peripheral nervous system
PP  psoriatic plaque
S100A7  psoriasin
SP  substance P
TLR  Toll-like receptor
TrkA  tyrosine kinase A
VIP  vasoactive intestinal peptide
VPAC1,2  vasoactive intestinal peptide receptor 1 and 2
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Psoriasis is een chronische huidziekte, waaraan  
ongeveer 350.000 mensen in Nederland lijden.  
Hoewel psoriasis geen levensbedreigende ziekte is, 
heeft de ziekte wel een grote impact op de kwaliteit 
van leven van patiënten. 
Patiënten worden elke dag met hun ziekte  
geconfronteerd en door de omgeving wordt vaak 
onterecht gedacht dat de ziekte besmettelijk is. 
Onderzoek naar deze huidaandoening gericht op 
de immunopathogenese en het identificeren van 
verschillende subpopulaties binnen de heterogene 
groep van psoriasis patiënten zal uiteindelijk  
leiden tot betere behandelingen voor de patiënt. 
Dit proefschrift richt zich op verschillende  
facetten van psoriasis waaronder:
• de invloed van het zenuwstelsel  
en neuropeptides
• het werkingsmechanisme van fumaarzuur
• de werking van de biologic ustekinumab  
en het identificeren van responders en  
non-responders op ustekinumab op basis  
van cytokine profielen en
• het anti-inflammatoire mechanisme  
van interleukine-4 bij psoriasis
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